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Summary 
Ion channels are expressed in virtually all cell types in the human body and are involved 
in various physiological processes. Hence, it is not surprising that ion channels play an important 
role in modern drug discovery. Lead compounds are nowadays routinely tested against a panel of 
ion channels to evaluate selectivity and potential off-target activities.  
The human ether-à-go-go-related gene (hERG) channel, a voltage-gated potassium 
channel, is the currently most critical antitarget with respect to cardiac safety. Inhibition of the 
hERG channel can prolong the QT interval on the electrocardiogram (ECG) and, as a 
consequence, lead to life-threatening arrhythmia. Considering the daily intake of plant-derived 
foods and herbal products, surprisingly few natural products have been tested for hERG blocking 
properties. In the course of an interdisciplinary hERG project, a selection of widely used herbal 
drugs and dietary plants was screened by means of a two-microelectrode voltage-clamp assay 
with Xenopus oocytes. Moderate hERG block was observed for the traditional Chinese herbal 
drug Coptidis rhizoma and black pepper fruits, and successfully tracked by HPLC-based activity 
profiling to dihydroberberine and piperine, respectively. The hERG blocking activity of 
cinnamon, guarana, and nutmeg, in contrast, was attributed to tannins. Our screening data suggest 
that major European medicinal plants and frequently consumed food plants are associated with a 
low risk for hERG inhibition. However, the case of Coptidis rhizoma pointed towards a need for a 
more thorough assessment of herbal drugs of the traditional Chinese medicine (TCM). Subsequent 
screening of a plant-derived alkaloid library led to the identification of several potent hERG 
blockers. Further investigations are certainly warranted to assess the cardiac safety profile of these 
alkaloids.  
Dehydroevodiamine (DHE), a major bioactive constituent of the traditional Chinese herbal 
drug Evodiae fructus, has been previously shown to inhibit several cardiac ion currents in vitro. 
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For further evaluation of its in vivo pharmacological and toxicological properties, gram amounts 
of DHE were needed. Since DHE is not commercially available, we developed an efficient 
method for its gram-scale isolation from a crude Evodia extract. Our approach is based on a 
combination of cation-exchange chromatography and preparative RP-HPLC. Moreover, the DHE 
content in commercially available Evodia products was assessed by HPLC-PDA analysis. A daily 
intake of up to mg amounts of DHE was calculated from recommended doses of these products. 
We also devised a procedure for the production of DHE-depleted Evodia products, should DHE 
indeed turn out to be toxicologically relevant.  
The gamma-aminobutyric acid type A (GABAA) receptor, a ligand-gated chloride channel, 
mediates fast inhibitory neurotransmission in the central nervous system (CNS), and is thus a 
clinically important drug target. In the search for positive α1β2γ2S GABAA receptor modulators of 
plant origin, we investigated an extract of Curcuma kwangsiensis rhizomes. HPLC-based activity 
profiling was used in combination with a two-microelectrode voltage-clamp assay on Xenopus 
oocytes to identify the active constituents. Targeted isolation afforded a series of 11 structurally 
related labdane diterpenoids, including four new natural products. Structure elucidation was 
achieved by comprehensive analysis of HR-ESI-TOF-MS and NMR data. The absolute 
configuration of the compounds was assigned by electronic circular dichroism (ECD). The highest 
GABAA receptor modulating activity was observed for zerumin A.  
From a more general perspective, this study demonstrates that HPLC-based activity 
profiling is an effective strategy to characterize bioactive compounds in crude natural extracts.  
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Zusammenfassung 
Ionenkanäle werden in nahezu allen Zelltypen des menschlichen Körpers exprimiert und 
sind in verschiedene physiologische Prozesse involviert. Daher ist es nicht verwunderlich, dass 
Ionenkanäle eine wichtige Rolle in der modernen Arzneimittelforschung spielen. Um die 
Selektivität und mögliche Off-Target-Aktivitäten von Leitsubstanzen zu beurteilen, werden diese 
heutzutage routinemässig an einer Vielzahl von Ionenkanälen auf ihre Aktivität hin untersucht.  
Der hERG Kanal, ein spannungsgesteuerter Kaliumkanal, ist das derzeit bedeutenste 
Antitarget hinsichtlich der kardialen Sicherheit von Arzneistoffen. Eine Blockade des hERG 
Kanals kann zu einer Verlängerung des QT-Intervalls im Elektrokardiogramm (EKG) führen und 
infolgedessen lebensbedrohliche Herzrhythmusstörungen hervorrufen. Trotz der steigenden 
Popularität von Naturheilmitteln und des täglichen Verzehrs von pflanzlichen Nahrungsmitteln ist 
die Interaktion von Naturstoffen mit dem hERG Kanal bisher wenig erforscht. Im Rahmen eines 
interdisziplinären hERG Projektes wurden sowohl bedeutende Medizinalpflanzen als auch 
gebräuchliche Nahrungspflanzen in einem Zwei-Mikroelektroden-Spannungsklemm-Assay an 
Xenopus Oozyten getestet. Die chinesische Arzneidroge Coptidis Rhizoma und der schwarze 
Pfeffer riefen beide eine moderate, aber nennenswerte hERG Blockade hervor. Mittels  
HPLC-basiertem Aktivitätsprofiling konnten die entsprechenden aktiven Inhaltsstoffe als 
Dihydroberberine und Piperin identifiziert werden. Die hERG-blockierende Wirkung von Zimt, 
Guarana und Muskatnuss wurde hingegen auf Tannine zurückgeführt. Die Screeningergebnisse 
zeigen, dass die wichtigsten europäischen Heilpflanzen und pflanzlichen Nahrungsmittel ein 
geringes Risiko für eine Blockade des hERG Kanals aufweisen. Das Beispiel von Coptidis 
Rhizoma weist jedoch darauf hin, dass pflanzliche Arzneidrogen der traditionellen chinesischen 
Medizin (TCM) gründlich überprüft werden müssen. In einem zweiten Screening wurden 
ausgewählte pflanzliche Alkaloide getestet und einige potente hERG Blocker identifiziert. Um die 
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kardiale Sicherheit dieser Alkaloide beurteilen zu können, sind weitere Untersuchungen 
erforderlich.  
Dehydroevodiamine (DHE) ist ein pharmakologisch wirksames Hauptalkaloid aus der 
chinesischen Arzneidroge Evodiae Fructus. In einer früheren Arbeit wurde gezeigt, dass DHE 
mehrere kardiale Ionenströme hemmen kann. Die Substanz wird derzeit in verschiedenen 
Tiermodellen auf kardiotoxische Effekte hin untersucht. Für die Durchführung dieser Studien 
wurden Gramm-Mengen an DHE benötigt. Da DHE als Referenzsubstanz kommerziell nicht 
verfügbar ist, wurde die Verbindung aus einem Evodia-Extrakt isoliert. Unter Verwendung eines 
selektiven Kationaustauschers und präparativer RP-HPLC konnte DHE einfach und effizient 
aufgereinigt werden. Des Weiteren wurde mit Hilfe einer HPLC-UV Methode der DHE-Gehalt in 
kommerziell erhältlichen Evodia-Präparaten bestimmt. In den jeweiligen empfohlenen 
Tagesdosen dieser Produkte wurde DHE im Milligramm-Bereich nachgewiesen. Zusätzlich wurde 
ein Verfahren für die Abreicherung von DHE aus Evodia-Extrakten entwickelt, sollte DHE sich 
tatsächlich als toxikologisch relevant erweisen.  
Der Gamma-Aminobuttersäure Typ A (GABAA) Rezeptor, ein ligandengesteuerter 
Chloridkanal, ist der wichtigste inhibitorische Rezeptor im zentralen Nervensystem (ZNS). Viele 
Arzneistoffe, die die neuronale Reizleitung hemmen, binden an GABAA Rezeptoren und 
verstärken den GABA-induzierten Chloridstrom. Zudem ist bekannt, dass zahlreiche Naturstoffe 
die Aktivität des GABAA Rezeptors beeinflussen können. In einem breit angelegten Screening rief 
ein Extrakt aus den Rhizomen von Curcuma kwangsiensis einen positiv modulierenden Effekt an 
GABAA Rezeptoren des α1β2γ2S Subtyps hervor. Als Testsystem diente ein Zwei-
Mikroelektroden-Spannungsklemm-Assay an Xenopus Oozyten. Die aktiven Extraktkomponenten 
wurden mittels HPLC-basiertem Aktivitätsprofiling als Labdanditerpene identifiziert. Insgesamt 
wurden 11 strukturell verwandete Labdanditerpene im semipräparativen Maßstab aufgereinigt. 
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Anhand von NMR-Messungen und hochaufgelösten massenspektrometrischen Daten konnte 
deren Struktur eindeutig aufgeklärt werden. Die absolute Konfiguration einzelner Verbindungen 
wurde mittels Zirculardichroismus bestimmt. Darüber hinaus wurden vier der isolierten 
Substanzen als neue Naturstoffe identifiziert. Von den getesteten Labdanditerpenen verstärkte 
Zerumin A den GABA-induzierten Chloridstrom am stärksten. 
Bei der Suche nach biologisch aktiven Substanzen in komplexen Pflanzenextrakten erwies 
sich das HPLC-basierte Aktivitätsprofiling als erfolgreiche Strategie. 
14
  
 
 
 
 
 
 
1. Aim of the work 
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Medicinal plants and phytomedicines continue to increase in popularity all over the world. 
Many herbal remedies that are used as alternatives to conventional pharmacotherapy or as 
complementary medicines are available as over-the-counter (OTC) products. It is also widely 
accepted that a plant-based diet with high intakes of fruits and vegetables brings numerous health 
benefits. Various therapeutic properties and health claims have been attributed to particular plant 
secondary metabolites. However, one has to consider that any pharmacologically active 
compound may also possess undesirable properties or even direct toxicity. It has been estimated 
that the consumption of plant-derived foods and the use of medicinal herbs result in an intake of 
plant secondary metabolites that may reach up to several grams per day. This clearly warrants a 
critical assessment of frequently consumed botanicals for potential safety liabilities.  
The currently most important antitarget with respect to cardiac safety is the human  
ether-à-go-go-related gene (hERG) channel. Inhibition of hERG can delay the cardiac action 
potential repolarization and, as a consequence, lead to severe complications, such as ventricular 
tachyarrhythmia and sudden cardiac death. In contrast to synthetic drug substances which 
nowadays are routinely tested for hERG liability during preclinical development, very little is 
known about the hERG inhibitory potential of plant-derived natural products. Our goal was to 
evaluate whether widely used herbal medicines and edible plants are associated with a risk for 
hERG channel inhibition. The first step was to screen a focused plant extract library by means of a 
two-microelectrode voltage-clamp assay on Xenopus oocytes. A test concentration of 100 µg/mL 
was used, and extracts inhibiting the hERG current (IhERG) by ≥ 30% were considered as active. 
Next, the active principles had to be identified and characterized in more detail. The aim was to 
follow up the activity with the aid of an HPLC-based profiling approach, and to study the hERG 
channel blocking effects of purified compounds in vitro.  
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Cardiovascular safety concerns had been previously raised for the quaternary 
indoloquinazoline alkaloid dehydroevodiamine (DHE), a major constituent of the traditional 
Chinese herbal drug Evodiae fructus (Evodia rutaecarpa fruits). For example, the compound has 
been shown to inhibit several cardiac ion currents in vitro. In view of further risk assessment 
studies, gram amounts of highly pure DHE were needed. Since the compound is not commercially 
available, it had to be isolated from the herbal drug. Hence, a method for the efficient large-scale 
purification of DHE had to be developed. Quantitative data on the DHE intake are, however, 
essential to obtain an overall safety profile. An additional aim was, therefore, to determine the 
DHE content in commercially available Evodia products in order to calculate the DHE intake in 
recommended daily doses for these products. Also, we devised a procedure for the selective 
removal of DHE from Evodia extracts, should DHE indeed be a safety issue.  
The third part of this thesis aimed at the discovery of new plant-derived GABAA  
(gamma-aminobutyric acid type A) receptor modulators. The GABAA receptor mediates fast 
inhibitory neurotransmission in the central nervous system (CNS), and is thus a clinically 
important drug target. Over the last few years, our research group searched for new scaffolds for 
this target, and successfully identified numerous structurally diverse plant secondary metabolites 
with positive GABAA receptor modulating activity. In the course of this ongoing in vitro 
screening approach, an ethyl acetate extract of Curcuma kwangsiensis rhizomes showed moderate 
but significant activity, and was of sufficient interest for further investigation. The aim was to 
identify the main active extract constituents, to fully elucidate their structures, and to evaluate 
their individual GABAA receptor modulating properties in a functional Xenopus oocyte assay.  
17
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2. Introduction 
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2.1. The hERG channel  
The human ether-à-go-go-related gene (hERG, or KCNH2 in the new nomenclature) 
encodes the pore-forming α–subunit of a voltage-gated potassium channel which conducts the 
rapid component of the delayed rectifier potassium current (IKr). According to the International 
Union of Pharmacology, the fully assembled ion channel is referred to as hERG or Kv11.1 
channel [1]. The family name “ether-à-go-go” (eag) was coined in 1969 by Kaplan and Trout, 
who investigated the behavior of four neurological mutants of Drosophila melanogaster. All 
mutant flies showed an increased neuronal excitability following etherization and started to shake 
their legs vigorously [2]. One mutant phenotype was termed “ether-à-go-go” because its rapid 
leg-shaking resembled the action of go-go dancers in the 1960s at the nightclub “Whisky a Go 
Go” in West Hollywood (California, United States) [3]. Later, in 1994, Warmke and Ganetzky 
screened a human hippocampal cDNA library and looked as to whether an eag-like channel is 
expressed in human tissue. They found a corresponding human channel gene and named it human 
ether-à-go-go-related gene (hERG) [4]. 
 
Structure and gating of the hERG channel 
Functional hERG channels have a tetrameric structure and are formed by co-assembly of 
four identical α–subunits, each containing six transmembrane domains (denoted S1–S6). Each 
subunit comprises a voltage sensor domain (S1–S4) and a pore domain (S5‒S6). As the S4 
domain contains multiple basic amino acids, it is regarded as the “voltage sensor” which responds 
to changes in the membrane potential. The pore domain consists of an outer (S5), inner (S6), and 
an intervening pore loop, the later forming the pore helix and the selectivity filter (Figure 1) [5]. 
Sanguinetti et al. showed that hERG channels are highly selective for K+ ions over Na+ ions by a 
factor of > 100 [6]. In addition to the membrane-spanning helices, the hERG α–subunit contains 
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large intracellularly located COOH- and NH2-terminal domains (Figure 1). The C-terminus is 
known to have only small influence on the channel conductance, but seems to be important for the 
post-translational processing of the hERG channel. Deletion studies and point mutations revealed 
that the N-terminus plays a crucial role in the deactivation process [3,7].  
 
 
Figure 1. Topology and structure of the hERG channel. Schematic representations of the extracellular view 
(A) and intracellular view (B) of the tetrameric hERG channel. Transmembrane topology of two opposing hERG 
α-subunits (C). Color coding of the voltage sensor domain (S1–S4, green) and pore domain (S5–S6, yellow) is 
the same as in (A) and (B). P indicates the pore helix, and SF represents the selectivity filter. Adapted from 
Vandenberg et al., 2012 [3].  
 
 
The conformation of the hERG channel and, thus, the dimension of its central cavity 
changes voltage-dependently. Depending on the transmembrane potential, the hERG channel is 
either closed, open or inactivated. Characteristic for hERG channels are their unique gating 
kinetics, namely a slow transition between open and closed states, and a rapid transition between 
open and inactivated states (Figure 2). The hERG channel is closed at the resting membrane 
potential. Upon depolarization, channels slowly open and pass an outward K+ current (IKr). 
However, depolarization to voltages > 0 mV limits IKr due to rapid channel inactivation. 
Following repolarization inverts the transitions between these channel states. Rapid recovery from 
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inactivation elicits a huge tail current, which progressively decreases as the electrochemical 
gradient for K+ ions declines and channels slowly return to the closed state (Figure 3) [3,7].  
 
 
Figure 2. Conduction and kinetics of the hERG channel. The channel conformation and K+ ion conductance 
is controlled by the membrane potential. Key high-affinity drug-binding sites are the aromatic residues Y652 and 
F656 on the S6 helix. Only two of the four channel subunits are shown. Adapted from Raschi et al., 2008 [5]. 
 
 
Figure 3. Gating of hERG channels. Exemplary hERG current 
trace recorded from a transfected Xenopus oocyte (bottom) in 
response to a two-step voltage protocol (top). Transitions between 
the different states (c: closed, o: open, i: inactivated) are color-coded.  
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Localization and physiological role of the hERG current IKr 
In humans, hERG channels are expressed throughout the body in a wide range of tissues, 
but the physiological role is best characterized in the heart. Western blot analysis of human 
ventricular and atrial membrane proteins revealed that the expression of hERG channels is much 
higher in ventricles than in atria [8]. The unusual hERG channel gating properties make the 
underlying current particularly suitable for controlling the terminal repolarization phase of the 
cardiac action potential. As phase 3 repolarization starts, hERG channels recover from 
inactivation, hence passing more K+ ions and contributing to consecutive repolarization. Overall, 
IKr turned out as the most important potassium current for repolarization, and any change in hERG 
channel activity will consequently affect the action potential duration (APD) [3]. The cardiac 
action potential defines the electrical activity of the heart, which can be measured by means of the 
surface electrocardiogram (ECG). On the ECG, the ventricular APD is represented by the  
QT interval (Figure 4). The QT interval exhibits a high degree of intra-individual variability, 
which makes a definition of “normal” values difficult [9]. As the QT interval has an inverse 
relationship to heart rate, the measured QT interval is typically corrected for heart rate with the 
aid of mathematical functions, leading to comparable QTc values [10].  
 
Figure 4. Correlation between ventricular APD and QT interval. 
(A) Action potential of human ventricular myocytes with phases 0−4 
and major underlying ion currents. The K+ current IKr is part of an 
ensemble of ion currents that characterizes the morphology and 
duration of the ventricular action potential. (B) The QT interval on 
the surface ECG is a measure of the elapsed time between 
ventricular depolarization (QRS complex) and repolarization 
(T wave). Adapted from Fermini et al., 2003 [10]. 
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Apart from myocytes, hERG channels are also expressed in the central nervous system, 
gastrointestinal smooth muscles, and endocrine cells. However, the precise physiological role of 
hERG channels in these tissues is not as well characterized as in ventricular myocytes. Numerous 
studies suggested that IKr has an impact on the excitability of these cells by influencing the resting 
membrane potential. Moreover, hERG channels have been detected in various cancer cell lines, 
such as leukemia, neuroblastoma, and endometrial adenocarcinoma cells. Interestingly, highest 
expression levels were found in metastatic cancers, hence hERG channels have been implicated in 
the control of tumor cell invasion and angiogenesis [3,5,11]. 
 
Pharmacology of hERG channels 
Whether the hERG channel is regarded as a target or an antitarget depends on the intended 
therapeutic indication. In arrhythmology, the hERG channel is the molecular target of class III 
anti-arrhythmic drugs, such as amiodarone, sotalol, and dofetilide. These drugs inhibit IKr and 
reduce the net outflow of K+ ions. Delayed repolarization increases the effective refractory period 
and is thought to reduce the risk of re-entry arrhythmias. However, the therapeutic potential of 
class III anti-arrhythmic agents is limited due to the simultaneous propensity to be 
arrhythmogenic. Excessive QT prolongation (long QT syndrome [LQTS]) can induce a 
polymorphic ventricular tachycardia called torsades de pointes (TdP). TdP arrhythmia can result 
in palpitations, syncope or seizures, and is often self-limiting. Occasionally, it can also degenerate 
into life-threatening ventricular fibrillation and lead to sudden cardiac death [12].  
In clinical practice, an overwhelming number of non-cardiac drugs, belonging to different 
therapeutic classes and with distinct structural features, have been shown to prolong the  
QT interval (Figure 5) [13]. In this context it is important to note that inhibition of IKr accounts for 
the vast majority of drug-induced QT prolongation [14]. Drug-induced LQTS represents a major 
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safety issue for both the pharmaceutical industry and drug-regulatory agencies. Several  
non-cardiac drugs have been restricted in their use, or even withdrawn as a consequence of their 
arrhythmogenic liability, plus the availability of safer drug alternatives [5].  
 
 
Figure 5. Structures of hERG channel blocking drugs. Risk assessment studies provided substantial evidence 
that these drugs can induce TdP arrhythmia through QT prolongation. This potentially fatal side effect has led to 
several drug withdrawals (e.g., terfenadine, cisapride, and clobutinol), restrictions of use (e.g., thioridazine and 
moxifloxacin), or specific labelings (e.g., chloroquine). 
 
 
However, not every hERG channel blocker necessarily leads to QT prolongation. As 
numerous overlapping ion currents contribute to the morphology and duration of the ventricular 
action potential (Figure 4), effects on multiple ion channels may counteract the reduced hERG 
current flow. An excellent example is the hERG channel blocker verapamil. This drug also blocks 
L-type Ca2+ channels and is thus devoid of pro-arrhythmic properties [3,7]. Moreover,  
QT prolongation alone is not sufficient to trigger TdP arrhythmia in patients. Additional risk 
factors linked to an increased incidence of TdP arrhythmia include inherited LQTS, female 
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gender, electrolyte disorders (e.g., hypokalemia, hypomagnesemia), and pre-existing cardiac 
diseases (e.g., bradycardia, cardiomyopathy). Any concurrent medication, be it a prescription or 
over-the-counter medicine, is critical in the view of pharmacodynamic and pharmacokinetic  
drug-drug interactions. The risk assessment is further complicated in the presence of hepatic 
diseases and renal insufficiency as the extent of metabolism and excretion remarkably affects the 
plasma concentration of a drug. Hence, the severity of QT prolongation and the susceptibility to 
TdP arrhythmia vary from drug to drug, and from patient to patient [15].  
 
Drug-binding site 
Homology models suggest that, unlike other voltage-gated K+ channels, the hERG channel 
has a comparatively large inner cavity. Most of the drugs that reduce IKr directly bind within the 
central cavity, thereby blocking the outward flow of K+ ions. Typically, the drugs gain access to 
the channel pore from the intracellular side of the membrane, when the channel is in the open or 
inactivated state (Figure 2). Both site-directed mutagenesis studies and docking studies have 
identified several pore-lining residues which are crucial for the high-affinity binding of various 
hERG channel blockers. The aromatic residues Y652 and F656 located on the S6 domain are the 
most important drug-binding sites, whereas the contribution of polar pore helix residues (e.g., 
T623, S624, and V625) to drug binding appears compound-specific. Based on comprehensive 
docking simulations, it has been proposed that the aromatic side chain at position Y652 forms 
either cation-π or π-stacking interactions with the hERG channel blocker, whereas F656 is 
essential due to its hydrophobic properties [3,16]. Replacement of either Y652 or F656 with 
alanine drastically attenuates the potency of numerous hERG channel blocking drugs (e.g., 
terfenadine and cisapride) [17]. Similar findings have been observed among hERG channel 
blockers of plant origin (see Chapter 2.3). The potency of ajmaline is completely abolished in 
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Y652A and F656A mutant channels, indicating that ajmaline presumably interacts with those 
residues [18]. In contrast, the inhibitory effects of hesperetin and naringenin remain unaltered in 
Y652A mutant channels, but are significantly reduced in F656A mutant channels [19,20]. 
Interestingly, unique blocking characteristics have been identified for the pungent irritant 
capsaicin. The Y652A mutation increases the potency of capsaicin by approximately fourfold, 
whereas the F656A mutation does not significantly alter its affinity [21].  
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2.2. Preclinical strategies for assessing the cardiac safety profile 
Since inhibition of IKr is the most common mechanism that underlies acquired LQTS and 
TdP arrhythmia, the hERG channel is considered as a “promiscuous” target in basic research and 
safety pharmacology. Assessing the hERG liability of a test compound can be achieved using 
several different in vitro approaches. Non-electrophysiological screening techniques include, for 
example, binding competition (detecting radioligand displacement), rubidium efflux (measuring 
extracellular Rb+ ion concentration, based on the ability of Rb+ ions to permeate through hERG 
channels), and fluorescence-based assays (monitoring changes in fluorescence, based on  
voltage-sensitive dyes). These testing strategies are favorable for high-throughput 
experimentation, although it is important to note their inherent limitations [1-3]. A major 
drawback of these techniques is that the cell membrane potential cannot be controlled  
(e.g., clamped at a preset value). At present, only electrophysiological measurements allow a 
direct voltage control and, hence, are considered as “gold standard” to study the hERG channel 
function on a millisecond timescale. The mediated charge transfer across the cell membrane  
(K+ ion efflux) can thus be measured directly and quantitatively [4]. Electrophysiological 
recordings on native cardiomyocytes face some technical difficulties, like the existence of 
overlapping ion currents that need to be selectively excluded. Heterologous expression systems 
are, therefore, increasingly favored for primary electrophysiological screens. In this case, the 
hERG channel protein is either transiently or stably expressed in non-cardiac cell lines. The most 
common expression systems include human embryonic kidney cells (HEK293), Chinese hamster 
ovary cells (CHO), and Xenopus laevis oocytes [2,3]. 
Such electrophysiological measurements provide valuable information about a 
compound’s potential to reduce the hERG channel activity in vitro. However, these approaches 
alone are not sufficient to evaluate its cardiac safety profile [5]. To estimate the risk for delayed 
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ventricular repolarization and QT prolongation, the following data are needed: (i) effects on other 
cardiac ion currents, (ii) action potential parameters in isolated cardiac preparations, (iii) ECG 
parameters in conscious or anesthetized animals, and clinically most relevant, (iv) the 
arrhythmogenic potential in isolated cardiac preparations or animals. General considerations 
regarding appropriate test systems, and specific recommendations for an integrated risk 
assessment are described in the ICH (International Conference on Harmonization) safety 
guideline S7B [6]. In vitro effects on cardiac electrophysiology can be further studied with 
multicellular preparations, the most commonly used tissues being Purkinje fibers, papillary 
muscles, and intact hearts. Cardiac preparations from guinea pig, rabbit, and dog are generally 
considered as the most suitable ones, as the ionic mechanism of repolarization in these animal 
species is similar to that of humans [1,6]. However, only in vivo ECG recordings can ultimately 
detect pro-arrhythmic effects under physiological conditions and, thus, are a reliable measure of 
hERG-related safety liabilities. One important advantage of such in vivo studies is that numerous 
safety parameters (e.g., QTc interval, heart rate, and blood pressure) can be assessed 
simultaneously. Furthermore, blood samples can be collected for determination of plasma 
concentrations of the administered compound and its metabolites [1,6,7]. Advantages and 
disadvantages of the most widely used preclinical models have been reviewed in detail elsewhere 
[7,8]. Within the past decade, zebrafish (Danio rerio) have emerged as an attractive and 
promising in vivo model to study various aspects of cardiotoxicity [9]. Several studies showed that 
drugs known to induce QT prolongation in humans induced bradycardia or arrhythmia in  
three-day-old zebrafish embryos, and that similar effects were observed after knocking down the 
Zerg protein (the zebrafish ortholog of human KCNH2) [9-12].  
The key challenge in extrapolating in vitro/in vivo electrophysiological results to clinical 
settings is interpreting those data with regard to the pharmacokinetic profile of a compound. 
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Besides the peak free plasma concentration (cmax), properties like the apparent volume of 
distribution, protein binding, lipophilicity, and metabolic pathways should be considered. 
Especially if the compound has a large volume of distribution, myocardial binding and, hence, the 
effective cardiac tissue concentration becomes increasingly important [8,13]. In this context, the 
often-cited study from Redfern and colleagues appears quite noteworthy. They performed a 
comprehensive literature survey to evaluate the relationships between preclinical cardiac 
electrophysiology data, clinical QT prolongation and TdP arrhythmia for a broad range of drugs. 
Their dataset suggested that a 30-fold margin between the hERG in vitro IC50 value and cmax 
“would be adequate to ensure an acceptable degree of safety from arrhythmogenesis, with a low 
risk of obtaining false positives” [14]. This study clearly implicates that a thorough risk 
assessment should primarily focus on safety margins rather than absolute hERG channel blocking 
potencies. 
Comparatively little is known about the pharmacokinetics of plant secondary metabolites, 
especially with respect to their oral bioavailability. Numerous natural products mentioned in the 
next chapter displayed hERG in vitro IC50 values in the range of 5-100 µM. While these values do 
not point towards a high-affinity block, possible in vivo effects on ventricular repolarization 
cannot be ruled out. Even relatively weak hERG in vitro inhibitors can produce clinically relevant 
QT prolongation if plasma levels are sufficiently high [15]. This phenomenon, for example, has 
been observed with the fluoroquinolone sparfloxacin. Its average plasma levels (~1.8 µM) after 
therapeutic doses clearly approximate concentrations that diminish the hERG channel activity in 
vitro (studies in mammalian cells revealed IC50 values between 13.5 and 44.0 µM) [2,16].  
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2.3. Plant-derived natural products as hERG channel inhibitors 
Considering hERG channel inhibition as a major liability in safety pharmacology, data on 
plant-derived natural products and possible hERG-related effects are still scarce. This chapter 
provides an overview on plant secondary metabolites for which hERG in vitro 
electrophysiological data are available in accessible scientific literature. Depending on the study 
design, the underlying hERG current is termed IKr when referring to studies in native 
cardiomyocytes, or IhERG when referring to studies in heterologous expression systems. Most of 
the plant-derived compounds mentioned here showed hERG channel blocking effects, but one 
will also find reports on inactive natural products and hERG channel activators (Tables 1‒3). It is 
important to emphasize that all of those findings are highly valuable for an integrated risk 
assessment. Although representing relevant information, studies that have focused only on crude 
plant extracts or corresponding fractions were not considered. Additional data regarding in vitro 
and/or in vivo electrocardiographic effects (action potential parameters in isolated cardiac 
preparations and ECG parameters in animals) were also not included and are beyond the scope of 
this compilation.  
It is important to note that for some natural products the reported hERG channel blocking 
potencies vary remarkably. Most in vitro electrophysiological studies have been carried out in 
heterologous expression systems, primarily with Xenopus oocytes and mammalian cells (HEK293 
and CHO cells). In general, IC50 values obtained in Xenopus oocytes are considerably higher than 
those from mammalian cell lines. For instance, a nearly 100-fold difference in the sensitivity to 
papaverine could be found in the literature [1,2]. Such a decreased compound potency in Xenopus 
oocytes has been mainly attributed to the large amounts of lipophilic yolk. The yolk particles can 
adsorb molecules, and thus lower the effective intracellular free compound concentration [3]. 
However, even if the same expression system is used, IC50 values obtained in different 
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laboratories may still vary by more than one magnitude [4]. Papaverine, for example, blocks 
hERG currents in HEK293 cells with IC50 values ranging from 7.3 µM to 0.58 µM [1,5]. The 
degree of hERG channel inhibition could be further influenced by a variety of parameters, such as 
electrolyte concentrations, pulse protocol, and temperature. Based on comparative studies, the 
impact of these experimental parameters appears compound-specific [4,6]. Increasing the 
extracellular K+ concentration [K+]o has been shown to attenuate the hERG channel inhibitory 
potency of cisapride. Concentration-response experiments in the presence of 0, 5, and 135 mM 
[K+]o yielded IC50 values of 7.5, 24.1, and 108.8 nM, respectively [7]. In contrast, the hERG 
channel block of cocaine was independent of changes in [K+]o [8]. The applied pulse protocol, 
especially the duration and amplitude of the voltage steps, allows a direct control for how long the 
hERG channel stays in the open, inactivated, and closed state. Thus, the potency of particular 
hERG channel blockers may vary depending on their state-dependent binding. Moreover, the 
pulsing rate (stimulation frequency) can have an impact on the estimation of IC50 values [9]. 
Electrophysiological measurements on mammalian cells can be performed at both room  
(20–24°C) and near-physiological temperature (35–37°C). It has been demonstrated that hERG 
channel gating kinetics are markedly affected by changes in temperature, and that the rates of 
activation, inactivation, recovery from inactivation, and deactivation all show different 
temperature sensitivities [10,11]. In principle, it is also possible that an increased temperature 
affect the binding kinetics (association and dissociation rate constants) of hERG channel ligands, 
and, thus, the onset and degree of inhibition. In this context, it is worth mentioning that 
oxymatrine showed opposing in vitro effects on hERG channel gating when tested at different 
temperatures. In HEK293 cells, oxymatrine (100 µM) potentiated IhERG at 20°C (potentiation of 
IhERG by 50.1 ± 0.9%), but exhibited hERG channel blocking properties at 30°C (inhibition of 
IhERG by 31.6 ± 0.5%) [12].   
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Alkaloids tested for hERG channel inhibition  
Recently, the stereoselective inhibition of hERG channels has been reviewed for selected 
chiral drugs, such as bupivacaine, verapamil, and methadone [13]. Although numerous reports of 
chiral natural products inhibiting the hERG current could be found in the literature, virtually 
nothing is known about potential enantioselective effects. An historical and probably the most 
prominent example among hERG channel blockers of plant origin are the Cinchona alkaloids 
quinidine and quinine. Both alkaloids have opposite absolute configurations at two centers 
(Figure 6) and, thus, are diastereomers. Quinidine served as a class I anti-arrhythmic drug, 
whereas quinine is used for treating multidrug-resistant malaria. Interestingly, both alkaloids can 
block the cardiac Na+ current INa, and even though quinidine has a greater potency against some 
malarial strains, quinine is the preferred antimalarial drug. Moreover, severe in vivo cardiotoxicity 
(QT prolongation) has only been reported for quinidine [13-15]. Just 10 years ago, the two 
diastereomers were tested for their hERG liability by means of two-microelectrode voltage-clamp 
recordings in Xenopus oocytes. The in vitro results revealed that quinidine and quinine inhibited 
IhERG with IC50 values of 4.6 ± 1.2 µM and 57.0 ± 3.3 µM, respectively [16]. The distinct hERG 
channel inhibitory properties may explain why quinidine has a pronounced in vivo effect on 
ventricular repolarization. In this case, the stereoselective pharmacodynamic effects determined 
both the clinical indication and the cardiac 
safety profile of the two stereoisomers [13]. 
 
Figure 6. Structures of the stereoisomers quinine 
and quinidine. 
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Table 1. Alkaloids tested for hERG channel inhibition. 
Substance Source Bioassay  Observed Effect Reference 
Aconitine Aconitum anthora 
(Ranunculaceae) 
Whole-cell patch-clamp assay using CHO cells 
1) Conc.: 10 µM 
2) Screening of 23 structurally related diterpene alkaloids 
Conc.: 10 µM 
1) Inhibition of IhERG by 44.9 ± 7.4% 
2) Inhibition of IhERG ranged from 6.5% to 39.6% 
[17] 
 
 Whole-cell patch-clamp assay using HEK293 cells 
Screening of five structurally related diterpene alkaloids 
Conc.: 1, 10 µM 
No significant effect on IhERG  [18] 
 Patch-clamp assay IC50: 13.5 µM [19] 
 Two-microelectrode voltage-clamp assay using Xenopus oocytes IC50: 1.801 ± 0.332 µM [20] 
Ajmaline Rauvolfia serpentina 
(Apocynaceae)  
Whole-cell patch-clamp assay using HEK293 cells IC50: 1.0 ± 0.1 µM [21] 
 Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Concentration-response experiment 
2) Conc.: 300 µM 
3) Mutation study (hERG F656A, conc.: 300 µM) 
4) Mutation study (hERG Y652A, conc.: 300 µM) 
1) IC50: 42.3 ± 11.9 µM 
2) Reduction of IhERG to 10.7 ± 3.0% 
3) No significant effect on IhERG 
4) No significant effect on IhERG 
[21] 
  HERG-Lite® assay  
Conc.: 10 µM 
Classified as hERG blocker [5] 
Allocryptopine Corydalis cava 
(Fumariaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 49.65 µM [22] 
Arecoline Areca catechu 
(Arecaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 9.55 µM [23] 
Benzoylecgonine Erythroxylum coca 
(Erythroxylaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 20, 1000 µM 
Inhibition of IhERG by 6 ± 2% (20 µM), 15 ± 8% 
(1000 µM) 
[24] 
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Substance Source Bioassay  Observed Effect Reference 
Berberine Coptis chinesis 
(Ranunculaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 3.1 ± 0.5 µM [25]  
  Two-microelectrode voltage-clamp assay using Xenopus oocytes IC50: 75 ± 12 µM [26] 
  Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Concentration-response experiment 
2) Mutation study (hERG F656T, conc.: 300 µM) 
3) Mutation study (hERG Y652A, conc.: 300 µM) 
1) IC50: 80 ± 5 µM 
2) No significant effect on IhERG 
3) No significant effect on IhERG 
[25]  
 Guinea pig ventricular myocytes – IKr 
Conc.: 30 µM 
No effect on IKr [27] 
Caffeine Coffea arabica 
(Rubiaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 5, 20 mM 
Reduction of IhERG to 61.1 ± 2.2% (5 mM), 12.7 ± 1.1% 
(20 mM) 
[28] 
  Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Conc.: 5 mM 
2) Mutation study (hERG F656A, conc.: 5 mM) 
3) Mutation study (hERG Y652A, conc.: 5 mM) 
1) Reduction of IhERG to 77.8 ± 2.4% 
2) Reduction of IhERG to 93.6 ± 1.4% 
3) Reduction of IhERG to 92.6 ± 1.4% 
[28] 
Capsaicin Capsicum frutescens 
(Solanaceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Concentration-response experiment 
2) Conc.: 5, 10 µM 
3) Mutation study (hERG F656A) 
4) Mutation study (hERG Y652A, conc.: 5, 10 µM) 
1) IC50: 17.45 ± 2.63 µM 
2) Inhibition of IhERG by 18.9 ± 3.5% (5 µM), 
34.7 ± 4.8% (10 µM) 
3) No significant difference to hERG WT, compound 
potency was not altered  
4) Inhibition of IhERG by 53.9 ± 6.0% (5 µM), 
73.4 ± 6.1% (10 µM); IC50: 4.11 ± 0.96 µM 
[29] 
Changrolin Dichroa febrifuga 
(Hydrangeaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 18.23 µM [30] 
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Substance Source Bioassay  Observed Effect Reference 
Chelerythrine  Chelidonium majus 
(Papaveraceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 0.11 ± 0.01 µM [31] 
 Canine ventricular myocytes – IKr 
Conc.: 1, 10 µM 
Inhibition of IKr  by 87.2% (1 µM), 100% (10 µM) [31] 
Cocaine Erythroxylum coca 
(Erythroxylaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 7.2 µM [32] 
 Whole-cell patch-clamp assay using HEK293 cells IC50: 4.4 ± 1.1 µM [24]  
  Whole-cell patch-clamp assay using HEK293 cells 
1) Concentration-response experiment 
2) Mutation study (hERG F656W, hERG F656Y, hERG 
F656V, hERG F656T) 
3) Mutation study (hERG Y652A) 
1) IC50: 8.7 ± 1.6 µM 
2) IC50: 8.4 ± 0.8 µM (hERG F656W), 12.2 ± 1.6 µM 
(hERG F656Y), 88.9 ± 11.8 µM (hERG F656V), 
161.8 ± 24.2 µM (hERG F656T) 
3) IC50: 309.6 ± 49.0 µM 
[8]  
 Whole-cell patch-clamp assay using tsA201 cells‡ IC50: 5.6 ± 0.4 µM [33] 
  Guinea pig ventricular myocytes – IKr 
1) Concentration-response experiment 
2) Conc.: 3, 10, 30 µM 
1) IC50: 4 µM 
2) Inhibition of IKr  by 39.7 ± 11.3% (3 µM), 
66.7 ± 7.2% (10 µM), 81.4 ± 4.6% (30 µM) 
[34] 
Codeine Papaver somniferum 
(Papaveraceae) 
Whole-cell patch-clamp assay using CHO cells IC50: 97 ± 5 µM [35] 
 Whole-cell patch-clamp assay using HEK293 cells IC50: > 300 µM [36] 
Cyclovirobuxine D Buxus microphylla 
(Buxaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
1) Concentration-response experiment 
2) Conc.: 1, 10, 30, 100 µM 
1) IC50: 19.7 µM 
2) Inhibition of IhERG by 12.3 ± 4.7% (1 µM), 
21.7 ± 16.1% (10 µM), 57.7 ± 7.5% (30 µM), 
71.2 ± 5.1% (100 µM) 
[37] 
Dauricine Menispermum dauricum 
(Menispermaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 3.5 µM [38] 
Guinea pig ventricular myocytes – IKr  IC50: 16 µM [39] 
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Substance Source Bioassay  Observed Effect Reference 
Daurisoline Menispermum dauricum 
(Menispermaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
1) Concentration-response experiment 
2) Conc.: 1, 3, 10, 30 µM 
1) IC50: 9.6 µM 
2) Inhibition of IhERG by 16.7 ± 5.8% (1 µM), 
31.1 ± 4.5% (3 µM), 55.1 ± 7.2% (10 µM), 
81.2 ± 7.0% (30 µM) 
[40] 
Ephedrine / 
Pseudoephedrine  
Ephedra sinica 
(Ephedraceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 10 µM 
No effect on IhERG [5] 
HERG-Lite® assay  
Conc.: 100 µM 
Classified as non-hERG blockers [5] 
Galanthamine Galanthus nivalis 
(Amaryllidaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 760.2 µM [41] 
Guanfu base A Aconitum coreanum 
(Ranunculaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 1.64 mM [42] 
  Whole-cell patch-clamp assay using HEK293 cells 
1) Conc.: 0.025, 0.1, 0.4, 1.0, 2.5 mM 
2) Mutation study (hERG F656C, conc.: 0.4, 1 mM) 
1) Inhibition of IhERG by 1.5% (0.025 mM), 13.6% 
(0.1 mM), -5.9% (0.4 mM), 30.1% (1.0 mM), 
38.5% (2.5 mM) 
2) Inhibition of IhERG by 12.2% (0.4 mM), 23.4% 
(1 mM) 
[43] 
Guanfu base G Aconitum coreanum 
(Ranunculaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 17.9 µM [42] 
Liensinine  Nelumbo nucifera 
(Nelumbonaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
1) Conc.: 1, 3, 10, 30, 100, 300 µM 
2) Mutation study (hERG F656V, conc.: 100, 300 µM) 
3) Mutation study (hERG Y652A, conc.: 100, 300 µM) 
1) Concentration-dependent inhibition of IhERG 
2) Inhibition of IhERG is attenuated 
3) Inhibition of IhERG is attenuated  
[44] 
Lobeline Lobelia inflata 
(Campanulaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 0.34 µM [45] 
Matrine Sophora flavescens 
(Fabaceae) 
Whole-cell patch-clamp assay using CHO cells IC50: 411 ± 23 µM [46] 
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Substance Source Bioassay  Observed Effect Reference 
Matrine       
(continued) 
 Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 1, 10, 100 µM 
Potentiation of IhERG at 1 and 10 µM, inhibition of IhERG 
at 100 µM 
[47] 
Methylecgonine Erythroxylum coca 
(Erythroxylaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 20, 1000 µM 
Inhibition of IhERG by 12 ± 3% (20 µM), 21 ± 4% 
(1000 µM) 
[24] 
Morphine Papaver somniferum 
(Papaveraceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: > 1 mM [36] 
Neferine Nelumbo nucifera 
(Nelumbonaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
1) Concentration-response experiment 
2) Conc.: 1, 3, 10, 30 µM 
1) IC50: 7.419 ± 1.162 µM 
2) Inhibition of IhERG by 21.8 ± 6.1% (1 µM), 
39.8 ± 5.1% (3 µM), 56.6 ± 2.7% (10 µM), 
65.8 ± 2.6% (30 µM) 
[48] 
  Whole-cell patch-clamp assay using HEK293 cells 
1) Conc.: 1, 3, 10, 30, 100, 300 µM 
2) Mutation study (hERG F656V, conc.: 100, 300 µM) 
3) Mutation study (hERG Y652A, conc.: 100, 300 µM) 
1) Concentration-dependent inhibition of IhERG 
2) Inhibition of IhERG is attenuated 
3) Inhibition of IhERG is attenuated  
[44] 
Nicotine Nicotiana tabacum 
(Solanaceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes IC50: 16.8 ± 2.2 µM # [49] 
 Canine ventricular myocytes – IKr IC50: 1.3 ± 0.5 µM # [50] 
  Guinea pig ventricular myocytes – IKr 
Conc.: 10, 30, 100 µM 
Inhibition of IKr by 36.7 ± 1.3% (10 µM), 75.1 ± 3.6% 
(30 µM), 87.8 ± 2.9% (100 µM) 
[51] 
Oxymatrine Sophora flavescens 
(Fabaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Impact of temperature on compound potency was studied 
1) Concentration-response experiment, temp.: 30°C 
2) Conc.: 1, 10, 100, 300 µM; temp.: 30°C 
3) Conc.: 1, 10, 100, 300 µM; temp.: 20°C 
1) IC50: 665.0 ± 1.3 µM 
2) Inhibition of IhERG by 6.9 ± 0.2% (1 µM), 
19.0 ± 0.2% (10 µM), 31.6 ± 0.5% (100 µM), 
43.2 ± 0.3% (300 µM) 
3) Potentiation of IhERG by 29.5 ± 1.8% (1 µM), 
40.0 ± 0.6% (10 µM), 50.1 ± 0.9% (100 µM); 
inhibition of IhERG by 36.5 ± 0.4% (300 µM) 
[12] 
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Substance Source Bioassay  Observed Effect Reference 
Papaverine Papaver somniferum 
(Papaveraceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 7.3 µM [5] 
 Whole-cell patch-clamp assay using HEK293 cells IC50: 0.58 µM [1] 
 Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Concentration-response experiment 
2) Mutation study (hERG F656A, conc.: 50 µM) 
3) Mutation study (hERG Y652A, conc.: 50 µM) 
1) IC50: 30.0 ± 1.8 µM 
2) No significant effect on IhERG  
3) Inhibition of IhERG is attenuated  
[1] 
 Two-microelectrode voltage-clamp assay using Xenopus oocytes IC50: 71.03 ± 4.75 µM [2] 
 HERG-Lite® assay  
Conc.: 10 µM 
Classified as hERG blocker [5] 
Quinidine§  Cinchona officinalis 
(Rubiaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 0.41 ± 0.04 µM [52] 
 Whole-cell patch-clamp assay using CHO cells IC50: 3.2 ± 0.3 µM [53] 
 Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Concentration-response experiment 
2) Mutation study (hERG F656A) 
3) Mutation study (hERG Y652A) 
1) IC50: 4.6 ± 1.2 µM 
2) 125-fold reduction of compound potency 
3) IC50: 16.0 ± 1.7 µM 
[16] 
  Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Conc.: 10 µM 
2) Mutation study (hERG Y652F, conc.: 10 µM) 
1) Inhibition of IhERG by 59.7 ± 2.7% 
2) No significant difference to hERG WT, compound 
potency was not altered  
[54] 
Quinine Cinchona officinalis 
(Rubiaceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes IC50: 57.0 ± 3.3 µM [16] 
Rhynchophylline  Uncaria rhynchophylla 
(Rubiaceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Concentration-response experiment 
2) Conc.: 10, 100, 1000 µM 
1) IC50: 773.4 ± 42.5 µM 
2) Inhibition of IhERG by 9.5 ± 7.5% (10 µM), 
16.2 ± 5.9% (100 µM), 72.6 ± 2.3% (1000 µM) 
[55] 
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Reserpine Rauvolfia serpentina 
(Apocynaceae) 
FluxOR thallium influx assay using U-2 OS cells∆ IC50: 4.9 ± 1.7 µM  [56] 
 Whole-cell patch-clamp assay using CHO-K1 cells₸ IC50: 1.9 µM [56] 
Sophocarpine Sophora flavescens 
(Fabaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 10, 30, 100, 300 µM 
Inhibition of IhERG by 1.1 ± 3.0% (10 µM), 17.1 ± 3.3% 
(30 µM), 32.7 ± 1.9% (100 µM), 56.0 ± 2.4% (300 µM) 
[57] 
 Whole-cell patch-clamp assay using HEK293 cells 
Conc: 10, 30, 100, 300 µM 
Inhibition of IhERG by 0.5 ± 3.0% (10 µM), 16.5 ± 1.9% 
(30 µM), 37.0 ± 1.7% (100 µM), 60.9 ± 1.4% (300 µM) 
[58] 
Sophoridine  Sophora flavescens 
(Fabaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc: 10, 30, 100, 300 µM 
Inhibition of IhERG by 5.4 ± 2.3% (10 µM), 16.3 ± 2.6% 
(30 µM), 29.3 ± 2.1% (100 µM), 41.9 ± 2.0% (300 µM) 
[58] 
Theobromine Theobroma cacao 
(Sterculiaceae) 
Whole-cell patch-clamp assay using CHO cells 
Conc.: 100 µM 
No significant effect on IhERG  [35] 
Theophylline Camellia sinensis 
(Theaceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes 
Conc.: 500 µM 
No effect on IhERG [2] 
‡ tsA201 cells: cells derived from HEK293 cells by stable transfection with SV40 temperature-sensitive T antigen.  
# Decreases in step current amplitudes were taken as a measure of hERG channel inhibition.  
§ Representative in vitro data are listed. The available reports in the literature are by far higher. 
∆ U-2 OS cells: human osteosarcoma cells. 
₸ CHO-K1 cells: subclone from the parental CHO cell line. 
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Flavonoids tested for hERG channel inhibition  
The effects of flavonoids on heterologously expressed hERG channels have been first 
studied by Zitron et al., who screened a focused library of flavonoids and coumarin derivatives 
(Figure 7). The flavanone naringenin showed the highest activity among the compounds tested, 
and its hERG channel blocking properties were later on studied in more detail, both in vitro and  
in vivo [59-62]. 
 
Figure 7. Blockade of hERG 
channels by selected flavonoids 
and coumarin derivatives. 
Compounds were tested at a 
concentration of 1 mM by means 
of a two-microelectrode voltage-
clamp assay on Xenopus laevis 
oocytes. Relative hERG currents 
are given as mean ± SEM. 
Significant difference from control 
(DMSO, left column) is indicated 
by a darker color. Figure by Zitron 
et al., 2005 [59]. 
 
 
 
 
 
Naringenin is the main flavonoid in grapefruits and naturally occurs in glycosylated forms, 
with naringin being the most prominent glycoside. Quantitative data revealed that fresh 
grapefruits contain high amounts of naringin in the albedo tissue, where concentrations of up to 
3.15 mg/g have been detected. Significantly lower concentrations were found in the flavedo layer 
and in the pulp, whereas the seeds showed the lowest naringin content [63]. It is well known that 
the naringin content in both commercially available and freshly prepared grapefruit juices can 
vary considerably. Regarding its concentration in commercial juices, ranges of 174-1492 µM, 
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82-2062 µM, and 309-1182 µM have been reported in literature [63-65]. Marked variations have 
been observed among different brands, and even among various batches of the same brand 
product. If the juice is prepared from fresh grapefruits, the squeezing procedure will have a major 
impact on the naringin level. Hand-squeezed juices typically show lower amounts of naringin 
compared to juices prepared with a squeezer or blender. Juices prepared by blending the whole 
fruits (with peel) will undoubtedly exhibit the highest naringin content. A notable finding from 
these studies was that the aglycone naringenin was either not detectable or only present in very 
low concentrations [63-65]. 
It has been shown that the consumption of 1 L of freshly squeezed pink grapefruit juice 
leads to a mild prolongation of the QTc interval in both young healthy volunteers and 
cardiomyopathy patients [59,62]. The observed effect is presumably attributable to naringenin, but 
synergistic effects with other grapefruit constituents cannot be ruled out. As mentioned in the 
previous chapter, an integrated risk assessment should always include information about the 
pharmacokinetic profile of the particular hERG channel blocker. Naringenin is comparatively well 
characterized in terms of human plasma concentrations after a single intake of grapefruit juice. 
The aglycone is formed in the distal parts of the small intestine and/or in the colon by hydrolysis 
of its native glycosides. There are, however, quite high interindividual variations with respect to 
its bioavailability [62,66]. For example, a mean peak plasma concentration of 6.0 ± 5.4 µM was 
found in healthy volunteers after consumption of a defined volume of grapefruit juice (8 mL/kg 
body weight, 349 mg/L naringenin1) [66]. 
 
 
 
 
1 The concentration of naringenin in the grapefruit juice was determined after enzymatic hydrolysis of its 
naturally occurring glycosides.   
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Table 2. Flavonoids tested for hERG channel inhibition. 
Substance Source Bioassay  Observed Effect Reference 
Acacetin  Saussurea tridactyla 
(Asteraceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 32.4 µM [67] 
Epigallocatechin-3-
gallate (EGCG) 
Camellia sinensis 
(Theaceae) 
Whole-cell patch-clamp assay using CHO cells 
Conc.: 30, 100 µM 
Inhibition of IhERG by 1.3 ± 2.4% (30 µM), 22.7 ± 6.6% 
(100 µM) 
[68] 
Whole-cell patch-clamp assay using HEK293 cells  IC50: 6.0 µM [69] 
Two-microelectrode voltage-clamp assay using Xenopus oocytes  
1) Concentration-response experiment Conc.: 20 µM 
2) Conc.: 20 µM 
1) IC50: 20.5 µM 
2) Inhibition of IhERG by 40.7 ± 4.4% 
 
[69] 
Hesperetin  Citrus sinensis 
(Rutaceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes  IC50: 288.8 µM [59] 
 Two-microelectrode voltage-clamp assay using Xenopus oocytes 
4) Concentration-response experiment 
5) Conc.: 1 mM 
6) Mutation study (hERG F656A, conc.: 1 mM) 
7) Mutation study (hERG Y652A, conc.: 1 mM) 
1) IC50: 267.4 ± 26.5 µM 
2) Reduction of IhERG to 13.7 ± 5.3% 
3) Reduction of IhERG to 51.8 ± 5.1%  
4) No significant difference to hERG WT, compound 
potency was not altered  
[70] 
Morin  Morus alba     
(Moraceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes  IC50: 111.4 µM [59] 
Naringenin  Citrus paradisi 
(Rutaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
1) Concentration-response experiment 
2) Conc.: 1 µM 
1) IC50: 36.5 µM 
2) Inhibition of IhERG by 13.8 ± 2.4% 
[59] 
 
  Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Concentration-response experiment 
2) Mutation study (hERG F656A, conc.: 1 mM) 
3) Mutation study (hERG Y652A, conc.: 1 mM) 
1) IC50: 102.6 µM 
2) Inhibition of IhERG is attenuated  
3) No significant difference to hERG WT, compound 
potency was not altered 
[60] 
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Substance Source Bioassay  Observed Effect Reference 
Naringenin 
(continued) 
 Two-microelectrode voltage-clamp assay using Xenopus oocytes  IC50: 102.3 µM [59] 
 Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) Concentration-response experiment 
2) Conc.: 10, 100, 1000 µM 
3) Conc.: 100 µM, co-administration of a hERG channel 
blocking drug (1 µM: quinidine, azimilide, dofetilide, 
amiodarone) 
4) Conc.: 100 µM, co-administration of a hERG channel 
blocking drug (10 µM: quinidine, azimilide, dofetilide, 
amiodarone) 
1) IC50: 173.3 ± 3.1 µM 
2) Inhibition of IhERG by 15 ± 5% (10 µM), 31 ± 6% 
(100 µM), 75 ± 5% (1000 µM) 
3) Increased inhibition of IhERG during co-application 
4) Increased inhibition of IhERG during co-application 
[61] 
Taxifolin-3-O-β-D-
glycopyranoside 
Rhododendron 
mucronulatum 
(Ericaceae) 
Whole-cell patch-clamp assay using CHO cells 
Conc.: 5, 10, 30, 50, 100 µM 
Inhibition of IhERG by 12.0 ± 2.5% (5 µM), 18.1 ± 4.7% 
(10 µM), 26.3 ± 4.5% (30 µM), 35.4 ± 5.6% (50 µM), 
36.9 ± 3.0% (100 µM) 
[71] 
5,7,4`-Trimethyl-
apigenin  
Citrus sinensis 
(Rutaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 18.4 ± 1.2 µM [72]  
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Miscellaneous structural classes tested for hERG channel inhibition 
The naturally occurring triterpenoid celastrol has been shown to impair the hERG channel 
function by a dual mode of action. When tested at 10 µM in HEK293 cells, celastrol acutely 
inhibits IhERG by 63 ± 10%. As revealed by Western blot analysis, celastrol also reduces the cell 
surface expression of the mature, fully glycosylated hERG channel protein after overnight 
incubation, with approximately 30% inhibition observed at a concentration of 200 nM [73]. Both 
mechanisms occur over different time and concentration scales, but the effect can appear additive 
following long-term exposure. From a clinical perspective, disrupting the hERG channel 
trafficking has been associated with a delayed onset of LQTS [74]. The cardiac glycoside 
digitoxin, for example, displays no direct hERG channel block but clearly reduces the cell surface 
expression of hERG channels at clinically relevant concentrations. However, digitoxin has 
typically not been associated with QT prolongation and TdP arrhythmia. As discussed by the 
authors, the observed hERG trafficking inhibition may contribute to the complex 
electrocardiographic changes seen with digitoxin in the clinic [75]. 
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Table 3. Miscellaneous structural classes tested for hERG channel inhibition.  
Substance Source Bioassay  Observed Effect Reference 
Celastrol Celastrus scandens 
(Celastraceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 10 µM 
Inhibition of IhERG by 63 ± 10% [73] 
Curcumin Curcuma zedoaria 
(Zingiberaceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 5.55 µM [76] 
 Whole-cell patch-clamp assay using HEK293 cells IC50: 4.9 µM [77]  
 Whole-cell patch-clamp assay using HEK293 cells 
1) Conc.: 10 µM 
2) Mutation study (hERG F656A, conc.: 10 µM) 
3) Mutation study (hERG Y652A, conc.: 10 µM) 
1) Reduction of IhERG to 14.9% 
2) Reduction of IhERG to 41.5% 
3) Reduction of IhERG to 25.3% 
[78] 
  Whole-cell patch-clamp assay using CHO-K1 cells₸ IC50: 22 µM [56] 
Digitoxin Digitalis purpurea 
(Plantaginaceae)  
Guinea pig ventricular myocytes – IKr 
Conc.: 500 nM 
No effect on IKr [75] 
Digoxin Digitalis lanata 
(Plantaginaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 500 nM 
No significant effect on IhERG [75] 
  Guinea pig ventricular myocytes – IKr 
Conc.: 1 µM 
No significant effect on IKr [79] 
Digoxigenin Digitalis lanata 
(Plantaginaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 1 µM 
No significant effect on IhERG [75] 
Dihydroartemisinin Artemisia annua 
(Asteraceae) 
Whole-cell patch-clamp assay using HEK293 cells IC50: 9.6 ± 1.0 µM (IC50: 7.7 ± 0.9 µM in a second set 
of experiments) 
[80] 
Ginsenoside Re Panax ginseng 
(Araliaceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes 
Conc.: 1 µM 
No significant effect on IhERG 
 
[81] 
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Ginsenoside Re 
(continued) 
 Guinea pig ventricular myocytes – IKr 
Conc.: 3 µM 
Inhibition of IKr [82] 
Ginsenoside Rg3 Panax ginseng 
(Araliaceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes 
Screening of 7 ginsenosides and 2 ginsenoside aglycons 
Conc.: 1 µM 
Potentiation of IhERG – Rg3 showed highest activity 
(potentiation of IhERG by 18.8 ± 4.8%) 
[81] 
Glycyrrhetinic acid Glycyrrhiza glabra 
(Fabaceae) 
Two-microelectrode voltage-clamp assay using Xenopus oocytes 
1) 18α- Glycyrrhetic acid, conc.: 100 µM 
2) 18β- Glycyrrhetic acid, conc.: 100 µM  
1) No significant effect on IhERG 
2) No significant effect on IhERG 
[83] 
Hirsutenone  Alnus japonica 
(Betulaceae) 
Whole-cell patch-clamp assay using CHO cells 
1) Concentration-response experiment 
2) Conc.: 5, 10, 20, 30, 50 µM 
3) IC50: 14.9 ± 2.0 µM 
4) Inhibition of IhERG by 13.3 ± 3.1% (5 µM), 
29.5 ± 2.9% (10 µM), 42.2 ± 10.2% (20 µM), 
55.9 ± 8.8% (30 µM), 83.7 ± 10.8% (50 µM) 
[84] 
Mallotoxin Mallotus philippensis 
(Euphorbiaceae) 
Whole-cell patch-clamp assay using CHO cells 
Conc.: 0.1, 0.5, 2.5, 10 µM 
Concentration-dependent potentiation of IhERG 
 
[85] 
Ouabain Strophanthus gratus 
(Apocynaceae) 
Patch-clamp assay 
Conc.: ≥ 100 µM 
No effect on IhERG [19] 
Oxypeucedanin Angelica dahurica 
(Apiaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 1 µM 
No effect on IhERG [86] 
Paeoniflorin Paeonia lactiflora 
(Paeoniaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 100 µM 
No effect on IhERG [87] 
Phorbol-12-myristate-
13-acetate 
Croton tiglium 
(Euphorbiaceae) 
Guinea pig ventricular myocytes – IKr 
Conc.: 1, 10, 100 nM 
Inhibition of IKr  by 2.7 ± 8.7% (1 nM), 20.0 ± 7.3% 
(10 nM), 44.0 ± 7.4% (100 nM) 
[88] 
Resveratrol Phytoalexin in red wine Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 1, 10, 100 µM 
Concentration-dependent inhibition of IhERG  [89] 
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Substance Source Bioassay  Observed Effect Reference 
Resveratrol 
(continued) 
 Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 10 µM 
No effect on IhERG [5] 
  Guinea pig ventricular myocytes – IKr 
Conc.: 100 µM 
No significant effect on IKr [90] 
  HERG-Lite® assay  
Conc.: 100 µM 
Classified as non-hERG blocker [5] 
Tanshinone IIA Salvia miltiorrhiza 
(Lamiaceae) 
Whole-cell patch-clamp assay using HEK293 cells 
Conc.: 100 µM 
No significant effect on IhERG [91] 
₸ CHO-K1 cells: subclone from the parental CHO cell line. 
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2.4. Identification of ion channel ligands from plant extracts  
Ion channels are pore-forming membrane proteins that permit the passive flow of ions 
down their electrochemical gradients. Key features are the gating properties, and ion channels are 
typically classified into multiple classes based on how their opening and closure is regulated. 
Modulation of gating can occur, for example, in response to chemical stimuli (intracellular or 
extracellular ligands), changes in transmembrane potential, changes in temperature, or mechanical 
forces. Ion channels are expressed in virtually all cell types in the human body and are involved in 
various physiological processes, including nerve and muscle excitation, hormone secretion, salt 
and water balance, learning and memory, fertilization, and sensory transduction. Defects in ion 
channel function have been associated with a wide range of diseases; hence, it is not surprising 
that ion channels are attractive targets in current and future drug discovery [1-3]. Moreover, 
profiling of putative lead compounds against a panel of ion channels is nowadays routinely 
performed to evaluate selectivity within a family of related ion channels as well as potential safety 
liabilities (so-called off-target activities) [4].  
Natural product-based drug discovery has been a historically successful approach for the 
discovery of new lead compounds. They can either be used as such or serve as inspiration for 
synthetic efforts [5]. A recent review on new chemical entities (NCEs) approved as drugs over a 
30-year time frame (January 1, 1981 to December 31, 2010) highlighted that approximately 34% 
of all small molecules directly derived from natural products [6]. We currently pursue an 
interdisciplinary screening approach aiming at the identification of ion channel ligands in plant 
extracts. Special emphasis has been placed on a screening for hERG channel inhibition 
(representing the most critical ion channel for cardiac safety) and the discovery of new scaffolds 
for positive GABAA receptor modulators (representing a primary drug target in the central 
nervous system). One of the principle challenges in studying ion channels and their ligands is to 
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obtain detailed information regarding the nature of interactions, especially whether a test 
compound has agonistic or antagonistic effects, or a preference for a particular channel subtype 
[7]. Electrophysiology has a solid and undisputed position in the analysis of ion channels, 
although this methodology is in general labor-intensive, time-consuming, and has a low 
throughput [8,9]. Recent advances have focused on increasing the throughput by automating 
certain process steps, thus allowing parallel recordings from several cells [7,9]. Automated  
patch-clamp platforms usually require stably transfected cell lines, which makes the system less 
flexible when working with multiple ion channels. Two-electrode voltage-clamp (TEVC) 
recordings from Xenopus oocytes are an equally useful means for the functional characterization 
of heterologously expressed ion channels. Several properties make the Xenopus oocyte system 
particularly suitable for such studies: (i) oocytes are robust cells, easy to handle (up to 1.2 mm in 
diameter), and can be obtained in large numbers; (ii) they are easily maintained in inorganic 
buffer solution; (iii) exogenous membrane proteins are expressed at relatively high levels; (iv) the 
Xenopus oocyte expression system is highly flexible with respect to the targets, meaning that 
different mutant channels (e.g., hERG Y652A and hERG F656A) or certain channel subtypes 
(e.g., GABAA receptors composed of α1β2γ2S subunits) can be investigated; (v) only few ion 
channels are endogenously expressed in Xenopus oocytes, allowing the ion channel of interest to 
be studied in virtual isolation [9,10]. In the search for new plant-derived hERG channel inhibitors 
and positive α1β2γ2S GABAA receptor modulators, we employed a medium-throughput  
two-microelectrode voltage-clamp assay with Xenopus oocytes which transiently expressed the 
desired ion channel. The principle of this approach is shown in Figure 8. 
Herbal extracts are highly complex mixtures and usually contain several hundreds of 
constituents. Among the wealth of plant secondary metabolites, probably only one or just a few 
are responsible for a particular pharmacological effect. Tracking bioactive compounds in such 
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 Figure 8. Schematic workflow of TEVC recordings from Xenopus oocytes. The oocytes are surgically 
removed from Xenopus laevis and defolliculated by enzymatic treatment. Stage V‒VI oocytes are injected with 
the desired cRNA and incubated to ensure expression of functional ion channels. TEVC recordings allow a direct 
measurement of ion channel activity by quantifying the ion flux across the oocyte membrane. Standardized 
solution applications to the oocytes and a medium sample throughput can be achieved by means of an automated 
fast perfusion system (for details, see [11]). Adapted from Kvist et al., 2011 [9]. 
 
 
matrices is like “searching for the needle in the haystack” and, thus, a highly challenging task. 
The judicious interfacing of biological data with chemo-analytical information remains a 
cornerstone to match the timelines and the workflow of modern natural product-based drug 
discovery. Numerous innovative approaches have emerged over the past two decades and opened 
new possibilities for the rapid localization and characterization of bioactive compounds in crude 
extracts. The unbroken trend towards miniaturization, automation, and multi-hyphenated systems 
has also considerably increased the potential of bioactivity screening [12-14]. High-performance 
liquid chromatography (HPLC) has undoubtedly become the most versatile technique for the 
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efficient separation of extract constituents prior to their detection. An overview of the detection 
methods used in natural product analysis, as well as their potential and limitations can be found in 
a dedicated review [15]. 
For the discovery of plant-derived ion channel ligands, we have used an HPLC-based 
activity profiling approach which combines HPLC microfractionation with on-line and off-line 
spectroscopy, and bioactivity testing of each fraction (Figure 9) [13,14]. This strategy enables the 
activity to be assigned to chromatographic peaks, and to be correlated with on-line HPLC-UV-MS 
data. Measuring the UV-Vis absorbance is particularly useful for the detection of natural products 
with characteristic chromophores, whereas MS detection provides important information on the 
structure of the analytes, such as molecular weight, molecular formula, and diagnostic ion
 
 
Figure 9. Principle of HPLC-based activity profiling. An extract is separated by gradient HPLC, and collected 
microfractions are tested in the particular bioassay. Simultaneously, on-line (UV and MS) and off-line 
(microprobe NMR) spectroscopic data are recorded. Spectral data are evaluated in combination with 
chemotaxonomic information and physicochemical data provided by natural product databases. Note that the 
characterization of bioactive compounds in crude extracts is already possible with minute sample amounts. 
Adapted from Potterat and Hamburger, 2013 [14]. 
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fragments. Compound dereplication and identification, however, often requires additional 
structural information (e.g., NMR data) to distinguish between already known constituents and 
new metabolites. Determining the absolute configuration of chiral natural products is also of great 
importance to understand stereoselective pharmacological effects and to establish reliable 
structure-activity relationships. A targeted preparative isolation is carried out if the active 
principles are of sufficient interest for further pharmacological evaluation, or in the case of 
compounds possessing novel spectroscopic features for complete structure elucidation.  
 
References 
 
1 Ashcroft FM. From molecule to malady. Nature 2006; 440: 440-447 
2 Bagal SK, Brown AD, Cox PJ, Omoto K, Owen RM, Pryde DC, Sidders B, Skerratt SE, Stevens EB, 
Storer RI, Swain NA. Ion channels as therapeutic targets: A drug discovery perspective. J Med Chem 
2013; 56: 593-624 
3 Restrepo-Angulo I, De Vizcaya-Ruiz A, Camacho J. Ion channels in toxicology. J Appl Toxicol 2010; 
30: 497-512 
4 Kaczorowski GJ, Garcia ML, Bode J, Hess SD, Patel UA. The importance of being profiled: Improving 
drug candidate safety and efficacy using ion channel profiling. Front Pharmacol 2011; 2: 78 
5 Potterat O, Hamburger M. Drug discovery and development with plant-derived compounds. In: 
Petersen F, Amstutz R, editors. Progress in Drug Research, Volume 65: Natural compounds as drugs 
(I). Basel/Boston/Berlin: Birkhäuser Verlag AG; 2008: 45-118 
6 Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 
2010. J Nat Prod 2012; 75: 311-335 
7 Priest BT, Bell IM, Garcia ML. Role of hERG potassium channel assays in drug development. Channels 
2008; 2: 87-93 
8 Grewer C, Gameiro A, Mager T, Fendler K. Electrophysiological characterization of membrane 
transport proteins. Annu Rev Biophys 2013; 42: 95-120 
9 Kvist T, Hansen KB, Bräuner-Osborne H. The use of Xenopus oocytes in drug screening. Expert Opin 
Drug Dis 2011; 6: 141-153 
10 Kapur A, Derry JMC, Hansen RS. Expression and study of ligand-gated ion channels in Xenopus laevis 
oocytes. In: Lajtha A, Baker G, Dunn S, Holt A, editors. Handbook of neurochemistry and molecular 
neurobiology: Practical neurochemistry methods. New York: Springer Science+Business Media, LLC; 
2007: 323-340 
11 Baburin I, Beyl S, Hering S. Automated fast perfusion of Xenopus oocytes for drug screening. Pflug 
Arch Eur J Phy 2006; 453: 117-123 
12 Potterat O. Targeted approaches in natural product lead discovery. Chimia 2006; 60: 19-22 
13 Potterat O, Hamburger M. Natural products in drug discovery: Concepts and approaches for tracking 
bioactivity. Curr Org Chem 2006; 10: 899-920 
14 Potterat O, Hamburger M. Concepts and technologies for tracking bioactive compounds in natural 
product extracts: Generation of libraries, and hyphenation of analytical processes with bioassays. Nat 
Prod Rep 2013; 30: 546-564 
15 Wolfender JL. HPLC in natural product analysis: The detection issue. Planta Med 2009; 75: 719-734 
 
 
60
  
 
 
 
 
 
 
3. Results and discussion 
 
61
3.1. Natural products as potential hERG channel inhibitors ‒ Outcomes 
from a screening of widely used herbal medicines and edible plants 
 
Schramm A, Jähne EA, Baburin I, Hering S, Hamburger M. 
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Extracts obtained from widely used herbal drugs and edible plants were screened for  
in vitro hERG channel inhibition by means of a functional Xenopus oocyte assay. The 
hERG channel blocking properties of selected extracts were tracked by HPLC-based 
activity profiling to tannins and alkaloids. Major European medicinal plants and frequently 
consumed vegetables, fruits, and spices were found to be associated with a low risk for 
hERG toxicity. 
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Abstract 
Inhibition of the hERG channel is the single most important risk factor leading to 
acquired long QT syndrome. Drug-induced QT prolongation can cause severe cardiac 
complications including arrhythmia, and is thus a liability in drug development. Considering 
the importance of hERG as an antitarget and the daily intake of plant-derived foods and 
herbal products, surprisingly few natural products have been tested for hERG channel 
blocking properties. In an assessment of possible hERG liabilities, a selection of widely used 
herbal medicines and edible plants (vegetables, fruits, and spices) was screened by means of a 
functional two-microelectrode voltage-clamp assay with Xenopus oocytes. The hERG channel 
blocking activity of selected extracts was investigated with the aid of an HPLC-based 
profiling approach, and attributed to tannins and alkaloids. Major European medicinal plants 
and frequently consumed food plants were found to have a low risk for hERG toxicity. 
 
Keywords: herbal drugs, dietary plants, hERG channel inhibition, Xenopus oocyte assay, 
HPLC-based activity profiling, alkaloids 
 
Abbreviations:  
LQTS  long QT syndrome 
hERG  human ether-a-go-go-related gene 
WHO  World Health Organization 
QTc  corrected QT interval 
PLE  pressurized liquid extraction  
SPE  solid phase extraction 
TCM  traditional Chinese medicine   
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Introduction  
A growing number of non-antiarrhythmic drugs have been shown to exhibit side 
effects associated with QT prolongation [1]. Drug-induced long QT syndrome (LQTS) can 
cause ventricular tachyarrhythmia (torsades de pointes arrhythmia) and sudden cardiac death. 
Due to this potentially fatal side effect, drugs such as terfenadine and cisapride had to be 
withdrawn from the market. The most important determinant of acquired LQTS is inhibition 
of IKr (IhERG), the rapidly activating component of the delayed rectifier potassium current that 
is mediated by the hERG (human ether-a-go-go-related gene) channel. Reduction of IhERG can 
delay the repolarization phase of the cardiac action potential and, as a consequence, lead to 
prolongation of the QT interval [2]. Hence, hERG channel blockage is nowadays considered 
as a major safety liability in preclinical drug development and clinical practice.  
Medicinal plants and phytomedicines are used worldwide, either as alternatives to 
conventional pharmacotherapy, or as complementary medicines. For example, preparations 
containing ginkgo, garlic, echinacea, saw palmetto, or St. John`s wort belong to the  
top-selling herbal products in the United States [3]. An increased understanding of the impact 
of nutrition on human health led to specific dietary recommendations aimed at lowering the 
incidence of certain diseases. Dietary phytochemicals such as flavonoids and organosulfur 
compounds are believed to possess preventive effects in chronic diseases, e.g., cancer and 
cardiovascular diseases [4-6]. The WHO (World Health Organization) dietary guideline 
recommends a daily intake of at least 400 g of fruits and vegetables [7]. Consumption of 
plant-derived foods (vegetables, fruits, and spices) and the use of medicinal 
herbs/phytomedicines result in a remarkable intake of total plant secondary metabolites. It has 
been estimated that the human dietary intake of phytochemicals may reach up to several 
grams per day [8,9]. Plant-derived compounds possess a spectrum of beneficial properties, but 
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they may also show adverse effects and/or interactions with prescription and OTC drugs 
[10,11].  
Considering the importance of hERG as an antitarget, surprisingly few natural 
products have been tested for hERG channel blocking properties. A number of structurally 
diverse natural products have been shown to diminish hERG channel activity in vitro, e.g., 
naringenin, trimethyl-apigenin, curcumin, lobeline, chelerythrine, papaverine, and capsaicin 
[12-18]. It has been shown that the consumption of 1 L of freshly squeezed pink grapefruit 
juice (containing the hERG channel blocking flavanone naringenin) leads to a mild 
prolongation of the QTc interval in both young healthy volunteers and patients suffering from 
cardiomyopathy [12,19]. The fact that not only synthetic drug substances but also widely 
occurring natural products, such as flavonoids and alkaloids, block IhERG warrants an 
assessment of widely used medicinal and dietary plants for their potential to inhibit IhERG. 
Also, the concomitant use of QT-prolonging medications along with hERG channel blocking 
natural products may lead to clinically relevant drug interactions and may be a concern with 
respect to consumer safety.  
In the present study, we wanted to address the following questions: (i) Do herbal 
medicines and plant-derived foods contain hERG channel blocking constituents and, if so, (ii) 
do their in vitro activity, daily intake in diet and/or herbal medicines point towards possible 
risks that would warrant an investigation in animal models for cardiac arrhythmia? For this 
purpose, we prepared a focused library of plant extracts from herbal drugs widely used in 
Europe, US, and China, and from frequently consumed spices, vegetables, and fruits. Food 
plants were selected according to consumption pattern in Central Europe, taxonomic 
considerations (in order to cover a broad range of chemically diverse secondary metabolites), 
and seasonal availability. The hERG channel inhibition was assessed by means of a two-
microelectrode voltage-clamp assay with transfected Xenopus laevis oocytes.   
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Results and Discussion 
A total of 79 plant samples were successively extracted with solvents of increasing 
polarities to afford a library of 187 extracts. This library was tested in a functional assay with 
transfected Xenopus laevis oocytes expressing hERG channels (Table 1S–3S, Supporting 
Information). An initial test concentration of 100 µg/mL was used, and extracts inhibiting the 
hERG current (IhERG) by ≥ 30% were selected for further investigation. Of the extracts tested, 
six were found to be active, including methanolic extracts from cinnamon (Cinnamomum 
zeylanicum Nees, Lauraceae), guarana (Paullinia cupana Kunth, Sapindaceae), nutmeg 
(Myristica fragrans L., Myristicaceae), and Coptidis rhizoma (Coptis chinensis Franch., 
Ranunculaceae), and ethyl acetate and methanolic extracts from fruits of black pepper (Piper 
nigrum L., Piperaceae).  
The active extracts were submitted to HPLC-based activity profiling in order to 
identify and characterize hERG channel blocking constituents [20]. Prior to 
microfractionation, they were analyzed by LC-PDA-ESI-MS to obtain a qualitative 
phytochemical fingerprint, and HPLC-based activity profiling was then carried out after 
optimization of separation. Aliquots of each extract (5 mg) were separated by semi-
preparative RP-HPLC, and microfractions of 90 s each were collected and tested in the oocyte 
assay. 
The methanolic extracts of cinnamon (Cinnamomum zeylanicum), guarana (Paullinia 
cupana), and nutmeg (Myristica fragrans) were among the most active extracts in our 
screening (inhibition of IhERG by 64.5 ± 5.7%, 45.3 ± 10.2%, and 42.3 ± 1.0%, respectively). 
However, the chromatograms all showed broad humps in the region of activity (Fig. 1, left 
column), indicative of a possible presence of tannins in the extract. Therefore, tannins were 
selectively removed from the extracts by solid phase extraction on polyamide columns [21]. 
Comparison of HPLC profiles before and after polyamide filtration confirmed the 
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effectiveness of tannin removal, without significant alterations of the HPLC chromatograms 
(Fig. 1, right column). The hERG inhibitory activity of tannin-depleted extracts was 
significantly lower (see insets in Fig. 1), and we concluded that tannins were responsible for 
the in vitro hERG channel blocking properties of these extracts. Given the negligible oral 
bioavailability of tannins [22,23], one can reasonably assume that no in vivo effects are to be 
expected. Moreover, gallic acid (1), ellagic acid (2), and (+)-catechin (3) (Fig. 3), which can 
be formed by the intestinal microflora as breakdown products of tannins and are known to be 
resorbed [22,23], were devoid of hERG inhibitory activity when tested at 100 µM in the 
oocyte assay. We conclude that the activity of tannins in our in vitro assay was likely due to 
non-specific interactions [20,21]. High levels of tannins are present in nuts, fruits, and some 
widely used spices (e.g., bay leaves, cinnamon, star anise, nutmeg, allspice, and juniper), 
whereas most vegetables lack them completely [24-26]. 
Ethyl acetate and methanolic extracts from fruits of black pepper (Piper nigrum) 
reduced IhERG by 32.4 ± 0.5% and 36.9 ± 9.1%, respectively. For both extracts, the activity 
profiles showed that the activity peak correlated with the major peak in the HPLC 
chromatogram (Fig. 2A-B). By analysis of LC-PDA-ESI-MS data and comparison with 
literature data, this peak was readily identified as piperine (4) (Fig. 3) [27]. The hERG 
inhibitory activity of the alkaloid was determined in the oocyte assay. Piperine (4) inhibited 
IhERG by 15.3 ± 1.1% and 35.7 ± 2.5% when tested at 100 µM and 300 µM concentrations, 
respectively (Fig. 2C-D). With an IC50 value > 300 µM, piperine (4) was a weak hERG 
channel blocker. The pronounced activity peak observed in the EtOAc extract (microfraction 
ten inhibited IhERG by 64.3 ± 7.3%) was due to the high piperine content in the extract [28]. 
Piperine (4) has been previously identified as a promising scaffold for novel GABAA receptor 
modulators with anticonvulsant and anxiolytic activity [27,29].  
68
The methanolic extract of the TCM (traditional Chinese medicine) herbal drug 
Coptidis rhizoma (Coptis chinensis) reduced IhERG by 31.7 ± 2.0%. By means of HPLC-based 
activity profiling of the crude extract, the hERG channel blocking constituents were tracked to 
known protoberberine alkaloids. Dihydroberberine was most active, as it reduced IhERG at 
100 µM by 30.1 ± 10.1%, while berberine at the same concentration was less active 
(inhibition of IhERG by 16.3 ± 2.0%) [30]. While these values do not point towards a high-
affinity block, possible effects on ventricular repolarization cannot be ruled out. Even 
relatively weak hERG in vitro inhibitors can produce clinically relevant QT prolongation if 
plasma levels are sufficiently high [31]. Moreover, if the metabolites are more lipophilic than 
the administered compound, they could accumulate in the systemic compartment more 
efficiently. This has been recently demonstrated for berberine and its main metabolite 
berberrubine formed by O-demethylation [32]. Also, biodistribution, metabolism, and 
accumulation in target organs may differ between single-dose and chronic administration.  
To our knowledge, this is the first screening study evaluating the potential of herbal 
drugs and plant-derived foods for in vitro hERG channel inhibition. Our data suggest that 
widely used European medicinal plants, frequently consumed spices, vegetables, and fruits 
are associated with a low risk for hERG toxicity. However, the case of Coptidis rhizoma 
emphasizes the need for a more extensive assessment of herbal remedies from other 
traditional health systems (e.g., TCM, Ayurveda, Kampo, and Unani) that are increasingly 
used worldwide for therapeutic purposes and/or as nutritional supplements.  
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Materials and Methods 
General experimental procedures 
Analytical and semi-preparative HPLC separations were carried out with SunFire C18 
columns (3 × 150 mm i.d., 3.5 µm; 10 × 150 mm i.d., 5 µm). ESI-MS data were recorded on 
an Esquire 3000 plus ion trap mass spectrometer (Bruker Daltonics) coupled via a T-splitter 
(split ratio 1:5) to an Agilent 1100 system consisting of an autosampler, degasser, binary 
pump, column oven, and PDA detector. Semi-preparative HPLC separations were performed 
on an Agilent 1100 system consisting of an autosampler, quaternary pump with degasser 
module, column thermostat, and PDA detector. Unless otherwise stated, H2O (solvent A) and 
MeCN (solvent B) were used as mobile phase. The flow rate was 0.5 mL/min for LC-PDA-
ESI-MS, and 4 mL/min for semi-preparative HPLC. Detection was at 254 nm, while PDA 
spectra were measured from 210 to 400 nm. Data acquisition and analysis were performed 
using HyStar 3.2 software. 
 
Solvents and Chemicals 
Solvents used for extraction and polyamide filtration were of analytical grade, whereas 
HPLC-grade solvents were used for HPLC separations. HPLC-grade water was obtained by 
an EASY-pure II water purification system. Formic acid (98.0–100.0%) and HPLC-grade 
MeCN were from Scharlau. Ellagic acid dihydrate (≥ 97% by HPLC), (+)-catechin (≥ 98% by 
HPLC), gallic acid (≥ 98.5% by GC), and piperine (≥ 97% by TLC) were purchased from 
Sigma-Aldrich.   
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Plant material  
The origin of plant species used in this study is listed in Tables 1S–3S of the 
Supporting Information. Fresh plant material and freshly squeezed grapefruit juice were shock 
frozen and lyophilized. Voucher specimens are preserved at the Division of Pharmaceutical 
Biology, University of Basel, Switzerland.  
 
Extraction 
Prior to extraction, the dried plant material was ground in a ZM 1 ultracentrifugal mill 
(sieve size 2.0 mm; Retsch). Unless otherwise stated, plant extracts were prepared by 
pressurized liquid extraction (PLE) using an ASE 200 instrument connected to a solvent 
controller (all Dionex). Ground plant material was packed into steel cartridges (11 mL; 
Dionex) and consecutively extracted with solvents of increasing polarity (petroleum ether 
[PE], EtOAc, and MeOH). Extraction temperature was at 70°C, and the pressure was set at 
120 bar. Duration of a static extraction cycle was 5 min, and 3 extraction cycles were used for 
each solvent to obtain exhaustive extraction [33,34]. Plant-derived foods containing high 
amounts of sugars, proteins, or triglycerides were extracted by percolation at room 
temperature, using the same solvents as for PLE. The following edible plants were extracted 
by percolation: Brassica nigra, Citrus paradisi, Coffea arabica, Euterpe oleracea, Ficus 
carica, Glycine max, Lycium barbarum, Malus domestica, Morinda citrifolia, Myristica 
fragrans, Opuntia ficus-indica, Phaseolus vulgaris, Rheum rhabarbarum, Sinapis alba, 
Theobroma cacao, and Vaccinium macrocarpon. Extracts were dried under reduced pressure, 
and stored at 4°C until use.  
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HPLC-based activity profiling  
A validated HPLC-based profiling protocol for the identification of hERG channel 
inhibitors in herbal extracts was used [30]. Briefly, an aliquot (5 mg) of crude extract (100 µL 
of 50 mg/mL in DMSO) was separated by semi-preparative RP-HPLC using H2O (solvent A) 
and MeCN (solvent B) as mobile phase, unless otherwise stated. The gradient profiles were as 
follows: MeOH extract of Paullinia cupana: 10–70% B in 20 min, hold 70% B for 5 min 
(Fig. 1B); MeOH extract of Myristica fragrans: 20–100% B in 30 min, hold 100% B for 
5 min (Fig. 1C); EtOAc extract of Piper nigrum: 30–100% B in 30 min, hold 100% B for 
10 min (Fig. 2A); MeOH extract of Piper nigrum: 20–100% B in 30 min, hold 100% B for 
10 min (Fig. 2B). The MeOH extract of Cinnamomum zeylanicum was separated with 0.1% 
aqueous formic acid (solvent C) and MeCN containing 0.1% formic acid (solvent D) using 
the following gradient: 5–70% D in 30 min, hold 70% D for 5 min (Fig. 1A). Time-based 
microfractions of 90 s each were manually collected into glass tubes. Evaporation of 
microfractions was achieved with an EZ-2 Plus vacuum evaporator (Genevac). Prior to testing 
for hERG channel inhibition, residues were re-dissolved in 30 µL of DMSO and diluted with 
2.97 mL of bath solution.  
 
Polyamide solid phase extraction  
To remove tannins from methanolic extracts of cinnamon, guarana, and nutmeg, the 
crude extracts were subjected to solid phase extraction (SPE) on polyamide. Polyamide  
(0.05–0.16 mm, Carl Roth GmbH) was conditioned in MeOH for 24 h, and packed into glass 
columns of 1.7 cm diameter to give bed heights of approximately 6 cm. A portion (100 mg) of 
each extract was dissolved in MeOH (50 mL), applied to the column, and eluted at a flow rate 
of 1 mL/min. Columns were washed with 300 mL of MeOH. For crude cinnamon extract, 
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polyamide filtration was also performed using MeOH/H2O 7:3 (v/v) as eluent. The tannin-
depleted effluents were collected, evaporated to dryness, and analyzed along with the 
untreated extracts.  
 
Electrophysiological bioassay: expression of hERG channels in Xenopus oocytes and voltage-
clamp experiments 
Oocyte preparation 
Oocytes from the South African clawed frog, Xenopus laevis, were prepared as 
follows: After 15 min exposure of female Xenopus laevis to the anesthetic (0.2% solution of 
MS-222; the methane sulfonate salt of 3-aminobenzoic acid ethyl ester; Sigma-Aldrich), parts 
of the ovary tissue were surgically removed. Defolliculation was achieved by enzymatical 
treatment with 2 mg/mL collagenase type 1A (Sigma-Aldrich). Stage V–VI oocytes were 
selected and injected with the hERG-encoding cRNA. Injected oocytes were stored at 18°C in 
ND96 bath solution containing 1% penicillin-streptomycin solution (Sigma-Aldrich). ND96 
bath solution contained 96 mM NaCl, 2 mM KCl, 1 mM MgCl2 × 6H2O, 1.8 mM 
CaCl2 × 2H2O, and 5 mM HEPES (pH 7.4).  
 
Automated two-microelectrode voltage-clamp studies 
Currents through hERG channels were studied with the two-microelectrode voltage-
clamp technique using a TURBO TEC-03X amplifier (npi electronic GmbH). 
Electrophysiological experiments were performed one to three days after cRNA injection. 
Voltage-recording and current-injecting microelectrodes (Harvard Apparatus) were filled with 
3 M KCl and had resistances between 0.5 and 2 MΩ. Oocytes with maximal current 
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amplitudes > 3 µA were discarded to avoid voltage-clamp errors. The following voltage 
protocol was used: From a holding potential of -80 mV, the cell membrane was initially 
depolarized to +20 mV (300 ms) in order to achieve channel activation and subsequent rapid 
inactivation. During following repolarization to -50 mV (300 ms) channels recover from 
inactivation and elicit the hERG current (IhERG). A final step to the holding potential ensured 
that channels returned to the closed state. The protocol was applied either in 3-s intervals 
(extract screening) or in 1-s intervals (bioactivity studies on fractions and pure compounds). 
Measurements were started after the initial current ʻrun upʼ (slow increase of hERG current 
amplitudes during repetitive pulsing) reached a steady baseline. The automated fast perfusion 
system ScreeningTool (npi electronic GmbH, see [35] for details) was used to apply the test 
solutions to the oocyte. Sample stock solutions (prepared in DMSO) were freshly diluted 
every day with ND96 bath solution. Steady-state block of IhERG was evaluated at ambient 
temperature (20–24°C). Decreases in tail current amplitudes were taken as a measure of block 
development during repetitive pulsing. The final maximum DMSO concentration (1%) in test 
solutions did not affect hERG currents (data not shown). Cisapride (Sigma-Aldrich; purity 
≥ 98%) was used as positive control. The IC50 value for hERG current inhibition at 0.3 Hz 
pulse frequency was 1.6 ± 0.4 µM (n = 3, Fig. 1S of the Supporting Information, see also [36] 
for comparison). Data acquisition and processing were performed using pCLAMP 10.0 
software and Clampfit 10.2 software, respectively.  
 
Data analysis  
Inhibition of the hERG potassium current (IhERG) was defined as  
[1 – I(hERG,drug)/I(hERG,ctrl)] * 100, where I(hERG,drug) is the current amplitude in the presence of 
the indicated test material (extract, fraction, or pure compound) and I(hERG,ctrl) is the control 
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current amplitude. Data were analyzed using Origin software 7.0 (OriginLab Corporation). 
Data points represent the mean ± S.E. from at least two oocytes and two oocyte batches. 
 
 
Supporting Information 
Data on the hERG channel inhibitory activity of 18 European medicinal plants (Table 1S),  
5 traditional Chinese herbal drugs (Table 2S), and 56 food plants and spices (Table 3S) are 
available as Supporting Information. 
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Figure Legends 
Figure 1: HPLC-PDA analysis of A cinnamon (Cinnamomum zeylanicum) MeOH extract, B 
guarana (Paullinia cupana) MeOH extract, and C nutmeg (Myristica fragrans) MeOH 
extract. Activity profiling of crude extracts (left column), with HPLC chromatograms and 
corresponding activity profiles (% inhibition of IhERG) of time-based microfractions. HPLC 
fingerprints of tannin-depleted extracts (right column) are shown for comparison purposes. 
Inhibition of IhERG by crude extracts and tannin-depleted extracts (100 µg/mL) is indicated on 
the upper right side of each chromatogram. UV traces were recorded at 254 nm.  
Figure 2: HPLC-based activity profiling of black pepper (Piper nigrum) fruits extracts. A 
EtOAc extract. B MeOH extract. HPLC chromatograms (254 nm) and corresponding activity 
profiles (% inhibition of IhERG) of time-based microfractions are shown. C, D Concentration-
dependent inhibition of IhERG by piperine (4). The control current is superimposed with the 
current traces recorded during a 1 Hz pulse train (15 pulses) in the presence of piperine 
(100 µM and 300 µM). 
Figure 3: Structures of compounds 1–4 tested for hERG channel inhibitory activity. 
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Figure 3 
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Fig. 1S. Concentration-response relationship for the inhibition of IhERG by cisapride. The IC50 value 
for hERG current inhibition at 0.3 Hz pulse frequency was 1.6 ± 0.4 µM (n = 3).  
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Table 1S. In vitro inhibition of the hERG potassium current (IhERG) in Xenopus oocytes by 
medicinal plants widely used in Europe and in the United States.  
 
Common name Scientific namea Sourceb 
(Lot no.) 
Extract  Inhibition of IhERG 
(%) at 100 µg/mL 
Garlic Allii sativi bulbus  A 
(3457001) 
PE 
EtOAc 
MeOH 
12.1 ± 4.7 
0.0 ± 0.0 
0.0 ± 0.0 
Black cohosh Cimicifugae rhizoma B 
(K07.06.1999) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Cinnamon Cinnamomi cortex A 
(3206401) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
64.5 ± 5.7 
Hawthorn  Crataegi folium cum flore A 
(3510503) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Javanese Turmeric  Curcumae xanthorrhizae rhizoma A 
(3759702) 
PE 
EtOAc 
MeOH 
7.3 ± 3.9 
9.2 ± 2.2 
6.2 ± 2.7 
Echinacea / Purple coneflower Echinaceae purpureae radix   A 
(3584101) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
14.7 ± 6.5 
Ginkgo  Ginkgo folium  A 
(3460602) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Ginseng Ginseng radix A 
 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
8.6 ± 2.4 
St. John`s wort Hyperici herba A 
(3142502) 
PE 
EtOAc 
MeOH 
6.8 ± 3.6 
0.0 ± 0.0 
22.7 ± 6.9 
Licorice  Liquiritiae radix A 
(3400601) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
10.5 ± 4.3 
11.4 ± 5.6 
Hop strobile  Lupuli flos  C 
(2008.12.0312) 
PE 
EtOAc 
MeOH 
9.2 ± 4.4 
0.0 ± 0.0 
7.5 ± 3.6 
Chamomile Matricariae flos  A 
(3535701) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Indian Frankincense  Olibanum indicum (gum resin) D 
(3.002.007) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Kava kava  Piperis methystici rhizoma A 
(6106802) 
PE 
EtOAc 
MeOH 
8.7 ± 2.8 
12.4 ± 6.6 
8.3 ± 1.7 
Senna Sennae folium  A 
(3474604) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
23.8 ± 6.2 
0.0 ± 0.0 
Saw palmetto  Sabal fructus  A 
(3081202) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Milk thistle Silybi mariani fructus  A 
(1899605) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
21.3 ± 7.5 
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Common name Scientific namea Sourceb 
(Lot no.) 
Extract  Inhibition of IhERG 
(%) at 100 µg/mL 
Valerian Valerianae radix  A 
(3031802) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
7.3 ± 5.2 
a Scientific names can be found in the corresponding ESCOP monographs [1,2].  
b A: Dixa AG (St. Gallen, Switzerland); B: sinoMed GmbH & Co. (Bad Kötzting, Germany); C: Hänseler AG (Herisau, Switzerland); 
D: Rigoni Relax Center (Bretzwil, Switzerland). 
 
 
 
 
 
 
 
Table 2S. In vitro inhibition of the hERG potassium current (IhERG) in Xenopus oocytes by 
medicinal plants widely used in traditional Chinese medicine (TCM).  
 
Common name (Chinese pinyin 
name)a 
Scientific namea Sourceb 
(Lot no.) 
Extract  Inhibition of IhERG 
(%) at 100 µg/mL 
Chuanxinlian  Andrographis herba A 
(P690672A) 
PE 
EtOAc 
MeOH 
8.3 ± 5.8 
9.2 ± 2.6 
0.0 ± 0.0 
Baizhi  Angelicae dahuricae radix B 
(0610402) 
PE 
EtOAc 
MeOH 
13.2 ± 2.6 
0.0 ± 0.0 
0.0 ± 0.0 
Chaihu  Bupleuri radix B 
(0901503) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
5.4 ± 2.5 
Huanglian Coptidis rhizoma  B 
(0901503) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
31.7 ± 2.0 
Danshen Salviae miltiorrhizae radix et rhizoma B 
(0110202) 
PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
a Pinyin names and scientific names can be found in the corresponding monographs of the Chinese Pharmacopoeia 2010 [3].  
b A: Lian Chinaherb AG (Wollerau, Switzerland); B: Yong Quan GmbH (Ennepetal, Germany).  
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Table 3S. In vitro inhibition of the hERG potassium current (IhERG) in Xenopus oocytes by  
plant-derived foods (vegetables, fruits, and spices).  
 
Common name Scientific plant namea Sourceb 
(Lot no.) 
Extract  Inhibition of 
IhERG (%) at 
100 µg/mL 
Onion  Allium cepa L.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Leek Allium porrum L.  A EtOAc 
MeOH 
0.0 ± 0.0 
4.5 ± 1.6 
Dill Anethum graveolens L.  A EtOAc 
MeOH 
5.5 ± 3.9 
7.4 ± 2.9 
Celery stalks Apium graveolens L. var. dulce A EtOAc 
MeOH 
4.9 ± 2.2 
3.8 ± 0.2 
Celery root Apium graveolens L. var. rapaceum A EtOAc 
MeOH 
5.9 ± 1.1 
4.3 ± 2.2 
Horseradish Armoracia rusticana P.Gaertn., Mey. & 
Scherb. 
A EtOAc 
MeOH 
3.4 ± 4.5 
6.7 ± 2.6 
Wormwood Artemisia absinthium L.  B 
(3518004) 
EtOAc 
MeOH 
2.9 ± 1.3 
5.4 ± 2.9 
Tarragon Artemisia dracunculus L.  C 
(1602) 
EtOAc 
MeOH 
4.4 ± 5.7 
1.1 ± 1.1 
Rooibos tea  Aspalathus linearis (Burm.f.) Dahlg.  A 
 
EtOAc 
MeOH 
1.8 ± 1.8 
1.6 ± 2.2 
Asparagus Asparagus officinalis L.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Beetroot Beta vulgaris L. var. esculenta L.  A EtOAc 
MeOH 
-0.5 ± 2.2 
1.8 ± 1.8 
Black mustard  Brassica nigra (L.) Koch C 
(5218) 
EtOAc 
MeOH 
6.7 ± 4.1 
3.7 ± 2.6 
Broccoli  Brassica oleracea L. var. italica Plenck  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Chilli  Capsicum frutescens L.  B 
(2037101) 
EtOAc 
MeOH 
1.4 ± 2.1 
8.1 ± 2.8 
Lime Citrus aurantiifolia (Christm.) Swingle A EtOAc 
MeOH 
27.1 ± 3.2 
9.4 ± 0.2 
Lemon Citrus limon (L.) Burm.f.  A EtOAc 
MeOH 
18.1 ± 5.5 
9.1 ± 1.7 
Grapefruit juice Citrus paradisi Macfad.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Coffee  Coffea arabica L.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Coriander (fruits) Coriandrum sativum L. C 
(7335) 
EtOAc 
MeOH 
8.4 ± 1.5 
0.2 ± 2.0 
Coriander (leaves) Coriandrum sativum L. A EtOAc 
MeOH 
4.4 ± 0.8 
13.5 ± 2.4 
Zucchini Cucurbita pepo ssp. pepo convar. 
giromontiina   
A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Artichoke Cynara scolymus L. A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Cardamom Elettaria cardamomum (L.) Maton D 
(2005.07.0866) 
EtOAc 
MeOH 
1.7 ± 3.8 
1.7 ± 2.9 
Rocket Eruca sativa Mill. A EtOAc 
MeOH 
1.6 ± 1.6 
4.4 ± 1.3 
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Common name Scientific plant namea Sourceb 
(Lot no.) 
Extract  Inhibition of 
IhERG (%) at 
100 µg/mL 
Acai  Euterpe oleracea Mart.  E PE 
EtOAc 
MeOH 
0.0 ± 0.0 
4.2 ± 2.4 
6.4 ± 4.2 
Fig Ficus carica L.  A EtOAc 
MeOH 
-6.0 ± 3.3 
0.2 ± 0.2 
Fennel Foeniculum vulgare Mill. var. azoricum A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Mangosteen Garcinia mangostana L.  A PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Soybean Glycine max (L.) Merr.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Mate Ilex paraguariensis A. St.-Hil.  B 
(1544201) 
EtOAc 
MeOH 
-5.4 ± 1.7 
0.0 ± 0.0 
Star anise Illicium verum Hook.f. C 
(5901) 
EtOAc 
MeOH 
2.5 ± 2.1 
6.8 ± 2.6 
Bay Laurus nobilis L.  B 
(3143300) 
EtOAc 
MeOH 
3.6 ± 0.3 
8.4 ± 3.6 
Lovage Levisticum officinale Koch A EtOAc 
MeOH 
3.4 ± 2.0 
0.3 ± 2.5 
Goji Lycium barbarum L.  F PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Tomato Lycopersicon esculentum Mill.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Apple Malus domestica Borkh.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Noni  Morinda citrifolia L.  G PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
8.2 ± 4.3 
Nutmeg Myristica fragrans L.  C 
(0524) 
EtOAc 
MeOH 
6.2 ± 3.8 
42.3 ± 1.0 
Prickly pear (fruits) Opuntia ficus-indica (L.) Mill.  H PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Prickly pear (leaves) Opuntia ficus-indica (L.) Mill.  H PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Oregano Origanum vulgare L.  C 
(0403) 
EtOAc 
MeOH 
8.7 ± 1.7 
0.2 ± 3.5 
Guarana Paullinia cupana Kunth B 
(3759605) 
EtOAc 
MeOH 
5.9 ± 2.9 
45.3 ± 10.2 
Parsley Petroselinum crispum (Mill.) A.W. Hill A EtOAc 
MeOH 
4.4 ± 2.2 
4.4 ± 3.3 
Common bean Phaseolus vulgaris L. A EtOAc 
MeOH 
3.3 ± 1.9 
0.4 ± 2.8 
Black pepper Piper nigrum L.  B 
(3604607) 
EtOAc 
MeOH 
32.4 ± 0.5 
36.9 ± 9.1 
Rhubarb Rheum rhabarbarum L.  A EtOAc 
MeOH 
2.6 ± 3.7 
0.1 ± 2.3 
Rosemary Rosmarinus officinalis L. C 
(6702) 
EtOAc 
MeOH 
8.8 ± 1.4 
1.3 ± 1.7 
Sage Salvia officinalis L.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
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Common name Scientific plant namea Sourceb 
(Lot no.) 
Extract  Inhibition of 
IhERG (%) at 
100 µg/mL 
White mustard Sinapis alba L.  B 
(2038801) 
EtOAc 
MeOH 
6.4 ± 0.9 
4.0 ± 1.0 
Spinach Spinacea oleracea L.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Clove Syzygium aromaticum (L.) Merr. & Perry B 
(2076901) 
EtOAc 
MeOH 
3.8 ± 3.8 
5.0 ± 3.3 
Cacao bean Theobroma cacao L.  I MeOH 0.0 ± 0.0 
Garden thyme Thymus vulgaris L.  B 
(4047704) 
EtOAc 
MeOH 
0.0 ± 0.0 
0.6 ± 0.6 
Cranberry  Vaccinium macrocarpon Aiton A PE 
EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
Corn salad Valerianella locusta (L.) Laterr.  A EtOAc 
MeOH 
0.0 ± 0.0 
0.0 ± 0.0 
Ginger Zingiber officinale Rosc. A EtOAc 
MeOH 
16.1 ± 1.2 
0.0 ± 0.0 
a Scientific plant names can be found in [4].  
b A: Fresh plant material from local markets (Basel, Switzerland); B: Dixa AG (St. Gallen, Switzerland); C: Drogerie 
zum Chrüterhüsli AG (Basel, Switzerland); D: Hänseler AG (Herisau, Switzerland); E: Brasilfruits (Bern, Switzerland); F: Shanghai 
Institute of Materia Medica (China); G: Nature's Sunshine Products (Spanish Fork, UT, US); H: Instituto Tecnológico y de Estudios 
Superiores de Monterrey (Mexico); I : Confiserie Sprüngli AG (Zurich, Switzerland). 
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3.2. hERG channel inhibitors in extracts of Coptidis rhizoma 
 
Schramm A, Baburin I, Hering S, Hamburger M. 
Planta Med 2011; 77: 692–697 
 
 
 
HPLC-based activity profiling was used in combination with a functional assay on Xenopus 
oocytes to localize and identify hERG channel blockers in Coptis chinensis rhizomes. Five 
quaternary protoberberines were purified, and structurally characterized by high-resolution 
mass spectrometry and microprobe NMR. Quaternary alkaloids, as well as di- and 
tetrahydroberberine were tested for their ability to reduce the hERG current. Berberine and 
dihydroberberine showed the highest hERG inhibitory activity.  
 
 
 
 
 
 
 
 
 
 
Extraction of plant material, HPLC microfractionation, isolation of compounds, recording 
and interpretation of analytical data for structure elucidation (LC-PDA-ESI-TOF-MS, 
microprobe NMR), writing the draft of the manuscript, and preparation of figures (Fig. 
2A‒B, 3, 4, and 5A) were my contributions to this publication.  
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Abstract
!
Inhibition of the hERG channel delays repolariza-
tion and prolongs the QT interval and cardiac ac-
tion potential which can lead to sudden death.
Several drugs have been withdrawn from the
market due to hERG channel inhibition. In the
search of hERG channel inhibitors of natural ori-
gin, we established an HPLC-based profiling ap-
proach which combines HPLC-microfractionation
and bioactivity testing on Xenopus laevis oocytes.
The methanolic extract of the TCM herbal drug
Coptidis rhizoma (Coptis chinensis Franch., Ra-
nunculaceae) reduced the peak tail hERG current
by 31.7 ± 2.0% at 100 µg/mL. HPLC-based activity
profiling pointed towards berberine as the active
constituent. However, hERG inhibition by 100 µM
of a reference sample of berberine (16.3 ± 1.6%)
was less pronounced than previously reported.
Subsequent LC‑PDA‑MS analysis showed that ber-
berine collected by microfractionation of the Cop-
tis extract had been, in part, transformed to active
dihydroberberine. Formic acid added to the HPLC
mobile phase to reduce peak tailing of protober-
berine alkaloids acted as a reducing reagent ac-
cording to the mechanism of the Leuckart-Wal-
lach reaction. Among other structurally related
protoberberines tested, dihydroberberine
(30.1 ± 10.1% at 100 µM) was the most potent
hERG inhibitor.
Abbreviations
!
hERG: human ether-a-go-go-related gene
ECG: electrocardiogram
TdP: torsades de pointes
TCM: traditional Chinese medicine
ASE: accelerated solvent extraction
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!
In the myocardium, the hERG (human ether-a-go-
go-related gene) channel conducts the rapid de-
layed rectifier K+ current (IKr) which accelerates
the repolarization of the action potential. Channel
inhibition leads to delayed repolarization and,
consequently, to a prolonged action potential visi-
ble as an extended QT interval on the electrocar-
diogram (ECG) [1]. Class III anti-arrhythmic
agents block IKr. Thus, hERG channel inhibition
may be associated with pro-arrhythmic and anti-
arrhythmic effects. Drug-induced QT prolonga-
tion is a risk factor for the development of tor-
sades de pointes (TdP), a potentially life-threaten-
ing arrhythmia. This has led to several drug with-
drawals, restrictions of use, warnings, and rela-* The authors contributed equally to this work.
itors… Planta Med 2011; 77: 692–697 91bellings [2]. One of the most recent withdrawals
due to an arrhythmogenic risk has been the anti-
tussive drug clobutinol in 2007 [3]. Since both car-
diac and noncardiac drugs have the potential to
inhibit the repolarizing current IKr, screening for
hERG channel inhibition is routinely performed
in the pharmaceutical industry as part of the early
pharmacological profiling of leads [4]. In contrast,
virtually nothing is known about hERG channel
blockers of natural origin. Naringenin is probably
the best studied natural product, both in vitro and
in vivo. Intake of naringenin via grapefruit juice
has been shown to lead to QT prolongation in
healthy humans [5–7].
To assess the risk of hERG channel inhibition by
medicinal plants, we screened a library of 91
herbal extracts derived frommajor officinal herb-
al drugs of the European and Chinese Pharmaco-
poeias. Extracts were tested by means of an auto-
mated two-microelectrode voltage-clamp assay
Fig. 1 Inhibition of potassium currents through hERG channels expressed
in Xenopus oocytes by Coptidis rhizoma extract (MeOH, 100 µg/mL).
A A mean current inhibition by 31.7 ± 2.0% (n = 6) was observed. B A cur-
rent trace recorded in the absence (control) of the drug is superimposed
with the current traces recorded in the presence of Coptidis rhizoma
(MeOH; 100 µg/mL) during a 1 Hz pulse train (15 pulses) applied from
−80mV. The voltage protocol is shown above the current traces.
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l.on Xenopus laevis oocytes [8], at a concentration of 100 µg/mL.
This concentration has been previously found to be appropriate
for screening of herbal extracts in the oocyte model with other
ion channel-type targets such as GABAA receptors [9,10]. Among
the extracts tested, the methanolic extract of Coptidis rhizoma
(Coptis chinensis Franch., Ranunculaceae) induced 31.7 ± 2.0%
(n = 6) inhibition of the peak tail hERG current (l" Fig. 1). Coptidis
rhizoma (Huanglian) is a well-known herbal drug in traditional
Chinese medicine (TCM). According to the Chinese Pharmaco-
poeia, it is used as an antipyretic, antimicrobial, and anti-inflam-
matory remedy for treating fever, gastrointestinal disorders (e.g.,
dysentery, vomiting, and icterus), insomnia, nose bleeding, and
toothache [11,12]. Quaternary protoberberine alkaloids repre-
sent the main constituents and are regarded as pharmacologi-
cally active principles of the herbal drug [12,13]. On the other
hand, the alkaloids are mainly responsible for the acute toxicity
of Coptidis rhizoma extract. Berberine, the most abundant alka-
loid [14], also showed the strongest cytotoxicity in different cell
lines [13]. The broad public considers herbal drugs to be gener-
ally safe. However, it is known that some herbs cause drug inter-
actions or may display unwanted effects [15]. In the case of Cop-
tidis rhizoma, respiratory failure, liver function injury, and severe
arrhythmia have been reported [13]. Here, we describe the local-
ization of hERG channel inhibitory activity of Coptidis rhizoma
extract with the aid of an HPLC-based profiling protocol. HPLC-
based activity profiling enables rapid identification of pharmaco-
logically active natural products in extracts with only milligram-
amounts of extracts [16].D
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General experimental procedures
Analytical HPLC separations were performed with an Agilent
1100 system consisting of an autosampler, degasser, binary
pump, column oven, and diode array detector. The HPLC condi-
tions were: SunFire C18 (3.5 µm, 3.0 × 150mm) column (Waters),
water + 0.1% formic acid (solvent A), methanol + 0.1% formic acid
(solvent B), gradient profile: 20%→ 35% B (0–25min), 35%→
100% B (25–26min), 100% B (26–30min), flow rate: 0.4mL/min,
DAD 254 nm. For LC‑PDA‑MS analysis, the HPLC was coupled to a
micrOTOF ESI‑MS system (Bruker Daltonics). Mass calibration
was performed with a solution of formic acid 0.1% in 2-propa-
nol/water (1 :1) containing 5mM NaOH. Mass spectra were re-
corded in the positive ion mode. Data acquisition and analysis
were performed using HyStar 3.2 software. NMR spectra (1H,
COSY, HSQC, HMBC, NOESY, NOE) were recorded on a Bruker
Avance III 500MHz spectrometer (Bruker Daltonics) operating at
500.13MHz for 1H. The instrument was equipped with a 1-mm
TXI microprobe. All measurements were carried out at 291.15 K.
Topspin 2.1 was used to process and analyse the spectra.
Solvents and chemicals
Formic acid (98.0–100.0%), dimethylsulfoxide (DMSO), and
HPLC-grade methanol were from Scharlau. Trifluoroacetic acid
(≥ 98%) was purchased from Sigma-Aldrich. Solvents for the ex-
traction and isolation process were of analytical grade whereas
HPLC-grade solvents were used for HPLC separations. Berberine
chloride hydrate (~ 95%), dihydroberberine (≥ 91% by HPLC), and
(R,S)-tetrahydroberberine (≥ 95% by TLC andMS) were purchased
from Fluka, Phytolab, and Latoxan, respectively.92Plant material
The drug Coptidis rhizoma (Huanglian) (batch no. 0901503) was
purchased from Yong Quan GmbH. A voucher sample (num-
ber 00197) is preserved at the Division of Pharmaceutical Biol-
ogy, University of Basel, Switzerland. Prior to extraction, the
plant material was frozen with liquid nitrogen and powdered
with a ZM 1 ultracentrifugal mill (sieve size 2.0mm) (Retsch).
Extraction
The extract for the initial screening and the HPLC-based activity
profiling was prepared by accelerated solvent extraction (ASE)
using a Dionex ASE 200 extractor with solvent controller (Dio-
nex). Extraction was carried out in 11mL cartridges with the fol-
lowing conditions: preheat time, 1min; static extraction cycle,
5min; purge, 120 s with nitrogen; temperature, 70°C; pressure,
120 bar. Extraction was successively done with petroleum ether,
ethyl acetate, and methanol (3 cycles per each solvent). For isola-
tion, the ground rhizomes (375 g) were extracted exhaustively
with methanol by percolation at room temperature. After evapo-
ration of the solvent under reduced pressure, a viscous extract
(60.8 g) was obtained. All samples, including the extracts, were
stored at 4°C until use.
Microfractionation and activity profiling
Microfractionation for HPLC-based activity profiling was carried
out on an Agilent 1100 system consisting of an autosampler, de-
gasser, quaternary pump, column oven, and diode array detector.
We separated 2.5mg of the extract by semipreparative RP-HPLC
into 42 one-minute microfractions. Separationwas achieved on a
SunFire Prep C18 (5 µm, 10 × 150mm) column (Waters) with
water + 0.1% formic acid (solvent A) and methanol + 0.1% formic
acid (solvent B) using the following gradient profile: 15%→ 35%
B (0–35min), 35%→ 100% B (35–36min), 100% B (36–42min).
The flow rate was 4mL/min, and detection was at 254 nm. 50 µL
of a stock solution of the extract (50mg/mL in DMSO) was in-
jected. Fractions were collected into glass tubes. After solvent re-
moval (Genevac EZ-2 Plus evaporator), the dried films were re-
dissolved in methanol, transferred to 4-mL glass vials, and dried
again under N2 gas prior to dissolution in DMSO for bioassay.Schramm A et al. hERG Channel Inhibitors… Planta Med 2011; 77: 692–697
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l.Isolation of protoberberines 1–5
For isolation of alkaloids, a portion (12.1 g) of the extract was sep-
arated by column chromatography on silica gel 60 column (63–
200 µm, 9 × 31 cm i.d.). The mobile phase was a mixture of pro-
panol, methanol, water, and formic acid (64:30:5 :1 v/v/v/v). To
elute the alkaloids, the polarity of the solvent system was in-
creased gradually (64 :30:5:1, 59:30 :10:1, 54:30:15:1,
49:30:20:1, 39:40:20:1, 29:50:20:1; 2 L each). Fractions of
200mL were collected and combined after TLC analysis (silica
gel 60 F254 precoated Al sheets, propanol-methanol-water-formic
acid 64:30:5:1 v/v/v/v, detection at UV366 nm) into 16 fractions.
Final purification of quaternary protoberberines was achieved on
a prep HPLC system consisting of a LC-8A preparative pump, SCL-
10AVP system controller, and SPD-M10A VP PDA detector and
controlled by class-VP V6.14 SP2A software (all Shimadzu). Pre-
parative HPLC separations were performed on a SunFire Prep
C18 OBD (5 µm, 30 × 150mm) column (Waters) using
water + 0.025% TFA (solvent A) and methanol + 0.025% TFA (sol-
vent B) as eluents. The flow rate was 20mL/min, and chromato-
grams were recorded at 254 nm. Separation of fraction 10 af-
forded 1 (tR 11.1min) and 5 (tR 13.6min) with the following gra-
dient: 30% B (0–3min), 30%→ 55% B (3–18min), 55%→ 100% B
(18–19min), 100% B (19–23min). Purification of fraction 5
yielded 3 (tR 14.1min) and 4 (tR 15.4min), while compound 2 (tR
12.4min) was isolated from fraction 16. The gradient was as fol-
lows: 30% B (0–4min), 30%→ 55% B (4–24min), 55%→ 100% B
(24–26min), 100% B (26–30min). Compound purity was ≥ 95%
by 1H‑NMR.
Expression of hERG channels and voltage clamp studies
Preparation of stage V–VI oocytes from Xenopus laevis (NASCO),
synthesis of capped run-off complementary RNA (cRNA) tran-
scripts from linearized complementary DNA (cDNA) templates,
and injection of cRNA were described previously [17]. Currents
through hERG channels were studied 1–4 days after microin-
jection of the cRNA with the two-microelectrode voltage clamp
methodmaking use of a TURBO TEC-03X amplifier (npi electronic
GmbH). The bath solution contained: 96mM 2-(N-morpho-
lino)ethanesulphonic acid sodium salt, 2mM 2-(N-morpho-Schramm A et al. hERG Channel Inhibitors… Planta Med 2011; 77: 692–697 9lino)ethanesulphonic acid potassium salt, 1mM CaCl2, 5mM
HEPES, and 1mM MgCl2 adjusted to pH 7.6 with methanesul-
phonic acid. Voltage-recording and current-injecting micro-
electrodes were filled with 3mM KCl and pulled to have resis-
tances between 0.3 and 2MΩ. Oocytes withmaximal current am-
plitudes > 2 µA were discarded to exclude voltage clamp errors.
The pClamp software package version 10.0 (Molecular Devices,
Inc.) was used for data acquisition.
Voltage protocol
The voltage protocol (see insets in l" Figs. 1B, 2C–D, and l" 5B)
was designed to simulate voltage changes during a cardiac action
potential with a 300ms depolarization to + 20mV (analogous to
plateau phase), a repolarization for 300ms to − 40mV (inducing a
tail current) and a final step to the holding potential. The + 20mV
depolarization rapidly inactivates hERG channels, thereby limit-
ing the amount of outward current. During the repolarization to
− 40mV, the previously activated channels open due to rapid re-
covery from inactivation. The decreases in the resulting tail cur-
rent amplitudes were taken as a measure of block development
during a pulse train.
Drug application and analysis
Drugs were applied by means of a fast ScreeningTool perfusion
technique (npi electronic GmbH) [8]. ORIGIN software version
7.0 (OriginLab Corporation) was used for data analysis. Data are
given asmean ± S.E. of at least two oocytes and ≥ 2 oocytebatches.Results and Discussion
!
In the search for hERG channel inhibitors of natural origin, we
adapted a previously developed protocol for discovery of GABAA
receptor modulators [9]. For this purpose, we separated 2.5mg
of the methanolic extract of Coptidis rhizoma by semipreparative
RP-HPLC into 42 one-minutemicrofractions whichwere tested in
the functional bioassay. l" Fig. 2 shows the HPLC chromatogram
recorded at 254 nm and the corresponding activity profile. hERG
inhibition was studied during 1Hz pulse trains applied from aFig. 2 Activity profiling of Coptidis rhizoma ex-
tract (MeOH) for inhibition of the hERG channel.
B HPLC chromatogram (254 nm) of a semiprepara-
tive separation of 2.5mg extract and (A) inhibition
(in %) of hERG currents by 42 one-minute fractions
are shown. C, D The control current (recorded in
the absence of drug) is superimposed with the
hERG currents recorded during a 1 Hz pulse train
(15 pulses) in the presence of the two most active
fractions (24 and 25). Same voltage protocol as in
l" Fig. 1.
D
3
695Rapid Communications
d 
by
: U
ni
ve
rs
itä
t B
as
el
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.holding potential of − 80mV (seeMethods for details on the pulse
protocol). Main activity was identified in microfractions 24 and
25 (peak tail hERG current inhibition by 63.3 ± 16.7% [n = 2] and
59.5 ± 20.9% [n = 2], respectively) which corresponded to the
dominant HPLC peak. With the aid of on-line (LC‑PDA‑MS) and
off-line (1mmmicroprobe NMR of collected peak) spectroscopic
data, the main peak was identified as berberine (4) (l" Fig. 3), a
previously reported hERG channel blocker of natural origin [18,
19]. However, inhibition of the hERG current by 100 µM of a ref-
erence sample of berberine was, in our hands, less pronounced
than previously reported (16.3 ± 1.6%, n = 3, but see [18,19]).
However, subsequent LC‑PDA‑MS analysis showed that berberine
(4) collected bymicrofractionation of the Coptis extract had been,
in part, transformed to active dihydroberberine (6). This could be
explained by the mechanism of the Leuckart-Wallach reaction
[20], whereby formic acid added to the mobile phase to reduce
peak tailing of quaternary alkaloids, acted as a reducing reagent
(l" Fig. 4E). The iminium ion structure of protoberberines is sen-
sitive to a nucleophilic attack by the hydride ion delivered by for-
mic acid. Traces of formic acid remaining in the microfractions
after evaporation of the mobile phase were apparently sufficient
for the partial reduction of quaternary protoberberines at room
temperature. The reaction occurred in the aprotic solvent DMSO,
which is used to dissolve the fractions for bioassay, but not in the
protic solvent methanol. This differential behaviour can be best
explained by the solvent capability to solvate ions rather than by
the solvent polarity [21]. The formation of dihydroberberine (6)
was confirmed by comparative off-line microprobe NMR and
on-line LC‑PDA‑MS analysis in DMSO and methanol of active mi-
crofraction 24 (l" Fig. 4A–D). However, dihydroprotoberberines
are also known to auto-oxidize back to the quaternary alkaloids,
especially under the influence of light [22]. Given the initial
profiling protocol and the findings described above, microfrac-
tions 24 and 25 in the profiling consisted of a mixture of berber-
ine (4) and dihydroberberine (6). When tested at 100 µM, dihy-
droberberine (6) reduced the peak tail hERG current more effi-94ciently (30.1 ± 10.1% [n = 3, l" Fig. 5]) than the same concentra-
tion of the reference sample of berberine (16.3 ± 1.6%). We report
here on the hERG channel inhibitory property of dihydroberber-
ine for the first time.
Despite the fact that the activity profile revealed no notable ac-
tivity for other peaks in the chromatogram, we isolated structur-
ally related quaternary protoberberines for the purpose of pre-
liminary information on structure activity relationships for this
compound class. Compounds 1–5 (l" Fig. 3) were purified by
means of open column chromatography on silica gel and prepar-
ative RP-HPLC. To avoid the above described conversion into di-
hydro derivatives in samples used for activity testing, trifluoro-
acetic acid (TFA) was used as the mobile phase additive for RP-
HPLC. Quaternary alkaloids 1–5, as well as dihydroberberine (6)
and (R,S)-tetrahydroberberine (7), were tested at 100 µM for
their ability to block the human hERG channel (l" Fig. 5). Quater-
nary protoberberines were marginally active, and substitution
pattern at positions C(2), C(3), C(9), and C(10) had moderate in-
fluence on activity. Among berberine (4) and its derivatives 6 and
7, dihydroberberine (6) showed the highest activity (peak tail
hERG current inhibition by 30.1 ± 10.1%, n = 3). Berberine (4) dis-
played an inhibition (14.9 ± 1.7%, n = 3) similar to that obtained
with the reference sample of berberine (see above), while tetra-
hydroberberine (7) had almost no effect (6.6 ± 5.4%, n = 3,
l" Fig. 5A). These observations suggest that the double bond be-
tween C(13) and C(13a) and the resulting extended conjugated
π-electron system are of importance for the inhibitory effect.
Although berberine prolongs the action potential duration, the
underlying molecular mechanism remains elusive [23]. The less
pronounced hERG inhibition by berberine, in our hands, may be
explained by reduced channel inhibition during the shorter con-
ditioning pre-pulses applied in our study (300ms vs. 4 s in [18,
19]). Future studies will show if the different voltage protocols
applied induce different state-dependent hERG inhibition [17].
Coptidis rhizoma preparations are mostly used internally and,
therefore, the oral bioavailability of the main alkaloid, berberine,Fig. 3 Structures of the isolated protoberberine
alkaloids 1–5 and the two berberine derivatives di-
hydroberberine (6) and (R,S)-tetrahydroberberine
(7).
Schramm A et al. hERG Channel Inhibitors… Planta Med 2011; 77: 692–697
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Fig. 4 Formation of dihydroberberine (6) from berberine (4) in active frac-
tion 24 (l" Fig. 1). 1H‑NMR spectrum recorded in MeOH‑d4 (A) and in
DMSO‑d6 (B). HPLC‑PDA analysis of sample dissolved in methanol (C) and
DMSO (D), with UV spectra of peaks shown as insets. (E) The proposed reac-
tion mechanism for reduction of berberine (4) in the presence of formic acid
and DMSO.
Fig. 5 Inhibition of hERG currents (in %) by com-
pounds 1–7 at 100 µM.A Amean current inhibition
by 4.2 ± 0.8% (n = 2) for coptisine, 2.4 ± 2.4% (n = 2)
for epiberberine, 2.0 ± 2.0% (n = 2) for jatrorrhizine,
14.9 ± 1.7% (n = 3) for berberine, 2.5 ± 0.8% (n = 2)
for palmatine, 30.1 ± 10.1% (n = 3) for dihydrober-
berine, and 6.6 ± 5.4% (n = 2) for tetrahydrober-
berine was observed. B The current trace recorded
in the absence of the drug (control) is superimposed
with the currents recorded during the 1 Hz pulse
train (15 pulses) in the presence of 100 µM dihydro-
berberine. Same pulse protocol as inl" Fig. 1.
696 Rapid Communications
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
itä
t B
as
el
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.is relevant in view of an assessment of possible undesirable ef-
fects. Daily recommended doses of Coptidis rhizoma vary from
1.5 to 9 g [24], which corresponds to a daily intake of 60 to
900mg berberine [14]. Also, berberine, dihydroberberine, and
some derivatives are currently being studied as drug candidates
for treating type 2 diabetes and various neurological diseases
[25,26]. Several studies, conducted in animals and humans, dem-
onstrated poor bioavailability of berberine after oral administra-
tion [26–28]. In human volunteers, plasma concentrations (Cmax)
after a single dose of 300mg of berberine reached 0.39 µg/mL
[26]. The comparatively high concentrations of phase I and II me-Schramm A et al. hERG Channel Inhibitors… Planta Med 2011; 77: 692–697 9tabolites in human urine indicated extensive biotransformation
after absorption [29,30]. Upon intravenous administration in
rats, berberine showed fast distribution into the liver and biliar
excretion [31]. Oral bioavailability of dihydroberberine was high-
er than that of berberine, albeit also limited by the fact that the
compound is prone to acidic-catalyzed aromatisation in the
stomach, and the bioavailable amount of dihydroberberine is
converted to berberine in the plasma [25,32].
Identification of other hERG channel blockers in herbal drugs and
means to selectively remove such compounds from herbal ex-
tracts will be reported in due course.5
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3.3. Natural products as potential human ether-a-go-go-related gene 
channel inhibitors – Screening of plant-derived alkaloids 
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Planta Med 2014; 80: 740–746 
 
 
 
A focused plant-derived alkaloid library was screened for hERG inhibitory activity by 
means of a functional Xenopus oocyte assay. Compounds that reduced the hERG current at 
100 µM by more than 50% were selected for evaluation of their concentration-response 
relationships. Pronounced in vitro hERG block was observed for some widely occurring 
alkaloids, such as protopine. 
 
 
 
 
 
 
 
 
 
 
Semi-synthesis of 8-oxoberberine and 8-oxocoptisine (including spectral characterization 
by HR-ESI-TOF-MS and microprobe NMR), initial screening of 27 compounds 
(preparation of Xenopus oocytes, two-microelectrode voltage-clamp measurements, data 
analysis), writing the draft of the manuscript, and preparation of Fig. 1 were my 
contributions to this publication.  
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Abstract
!
Inhibition of the cardiac human ether-a-go-go-
related gene channel is a problematic off-target
pharmacological activity and, hence, a major
safety liability in clinical practice. Several non-
cardiac drugs have been restricted in their use, or
even removed from the market due to this poten-
tially fatal adverse effect. Comparatively little is
known about the human ether-a-go-go-related
gene inhibitory potential of plant-derived com-
pounds. In the course of an ongoing human
ether-a-go-go-related gene in vitro study, a total
of 32 structurally diverse alkaloids of plant origin
as well as two semi-synthetically obtained proto-
berberine derivatives were screened by means of
an automated Xenopus oocyte assay. Protopine,
(+)-bulbocapnine, (+)-N-methyllaurotetanine,
(+)-boldine, (+)-chelidonine, (+)-corynoline, re-
serpine, and yohimbine reduced the human
ether-a-go-go-related gene current by ≥ 50% at
100 µM, and were submitted to concentration-re-
sponse experiments. Our data show that some
widely occurring plant-derived alkaloids carry a
potential risk for human ether-a-go-go-related
gene toxicity.
Abbreviations
!
ECG: electrocardiogram
hERG: human ether-a-go-go-related gene
IhERG: hERG potassium current
TCM: traditional Chinese medicine
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l.Introduction
!
Cardiotoxicity is among the most frequent rea-
sons for the discontinuation of preclinical/clinical
drug discovery programs, for serious adverse
drug effects, and for withdrawal of already mar-
keted drugs [1]. A promiscuous target with re-
spect to cardiac safety is the hERG channel. The
underlying IhERG plays a pivotal role during ven-
tricular repolarization and is, hence, an important
determinant of the cardiac action potential dura-
tion. Inhibition of IKr can prolong the QT interval
on the ECG and, as a consequence, may cause se-
vere side effects, such as ventricular tachyar-
rhythmia (torsades de pointes arrhythmia) and
sudden cardiac death [2]. Synthetic drug candi-
dates are, therefore, routinely evaluated for hERG* These authors contributed equally to this work.
… Planta Med 2014; 80: 740–746 98channel blocking properties in the early stage of
lead development [3].
Natural products of plant origin exhibit a wealth
of beneficial pharmacological activities, but may
also have a potential for adverse drug reactions.
Side effects may arise from various mechanisms,
e.g., direct toxicities and/or pharmacological in-
teractions with concomitantly administered
drugs. Given that hERG block is a potential safety
liability, surprisingly little is known about the
hERG inhibitory potential of plant-derived com-
pounds. So far, a number of flavonoids (e.g., aca-
cetin, naringenin, and trimethyl-apigenin) and al-
kaloids (e.g., changrolin, dauricine, and lobeline)
have been identified as hERG blockers in vitro
[4–9]. These examples illustrate the need for a
more comprehensive evaluation of the hERG li-
ability of widely occurring plant secondary me-
tabolites. We recently screened a selection of
widely used herbal drugs and dietary plants by
means of a functional Xenopus oocyte assay for
741Original Paperstheir ability to reduce IhERG. Moderate hERG inhibitory activity
was observed for the TCM herbal drug Huanglian (rhizomes of
Coptis chinensis Franch., Ranunculaceae) and black pepper fruits
(Piper nigrum L., Piperaceae), and successfully tracked to dihy-
droberberine and piperine, respectively [10,11]. Given the im-
portance of both alkaloids, in particular of piperine as a major
constituent in pepper fruits and as a starting point for the devel-
opment of promising GABAA receptor modulators [12], we com-
plemented our in vitro screening for hERG blockers with the eval-
uation of a focused alkaloid library. Compounds were selected to
include structurally diverse and pharmacologically important al-
kaloid scaffolds, and compounds with known and relevant phar-
macological activities, such as tryptanthrin, emetine, yohimbine,
reserpine, and galanthamine. Their effect on hERG channel func-
tion was assessed in an automated two-microelectrode voltage-
clamp assay with Xenopus oocytes.D
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l.Results and Discussion
!
A series of 32 plant-derived alkaloids and two semi-synthetic
protoberberine derivatives were tested for hERG inhibitory activ-
ity in vitro. Alkaloids 1–34 (l" Fig. 1) were screened in a function-
al Xenopus oocyte assay during 1 Hz pulse trains. The initial test
concentration was 100 µM (l" Table 1). Of the alkaloids tested,
protopine (16), (+)-bulbocapnine (18), (+)-N-methyllauroteta-
nine (19), (+)-boldine (20), (+)-corynoline (24), and reserpine
(31) reduced IhERG by more than 60% (inhibition of IhERG by
88.4 ± 1.9%, 72.0 ± 1.6%, 81.4 ± 2.9%, 65.8 ± 5.3%, 72.6 ± 2.4%, and
66.9 ± 0.3%, respectively). (+)-Chelidonine (23) and yohimbine
(30) were somewhat less active (inhibition of IhERG by 56.8 ±
8.2% and 52.6 ± 3.0%, respectively). Given the structural diversity
of the alkaloids included in this study, deriving structural fea-
tures critical for hERG inhibition was not possible. However, it
seems that alkaloids with an aporphine (17–20) or benzophe-
nanthridine (21–24) scaffold are particularly prone to hERG
block.
For comparative purposes, we also evaluated four alkaloids for
which in vitro data have been already published. For papaverine
(6), we observed a mean hERG current inhibition by 33.6 ± 3.4%
at a test concentration of 100 µM (l" Table 1). Reported IC50 val-
ues obtained with Xenopus oocytes range from 30.0 to 71.0 µM,
whereas those from HEK293 cells vary between 0.58 and 7.3 µM
[13–15]. Discrepancies between published data and our results
are most likely due to differences in assay conditions, e.g., the
use of different pulse protocols. Also, electrophysiological studies
performed with Xenopus oocytes typically produce IC50 values
that are significantly higher than those obtained in mammalian
cell lines. The difference is mainly due to the large amount of lip-
ophilic yolk in oocytes, which may adsorb lipophilic drug sub-
stances, thus lowering the effective intracellular free compound
concentration [16]. Another known hERG blocker of plant origin
is reserpine (31). Its hERG liability was previously detected in a
cell-based high-throughput fluorescence assay (FluxOR thallium
influx assay), and subsequently confirmed with an automated
whole-cell patch-clamp assay in CHO‑K1 cells (IC50: 1.9 µM)
[17]. In the Xenopus oocyte assay, the alkaloid reduced IhERG by
66.9 ± 0.3% (test concentration of 100 µM) (l" Table 1). Also, the
hERG inhibitory activity of galanthamine (32) and ephedrine
had been previously reported. When assayed in HEK293 cells,
galanthamine (32) had been classified as weak hERG blocker
(IC50: 760.2 µM) [18], whereas ephedrine showed no hERG block99at 10 µM [15]. (−)-Ephedrine (7) and (−)-galanthamine (32) were,
therefore, used as negative controls in our study and indeed in-
duced no hERG inhibition in the oocyte assay (l" Table 1).
As a next step, we studied the concentration-response relation-
ships for alkaloids that reduced IhERG by ≥ 50% in the initial library
screening. The hERG blocking effects of 16, 18–20, 23, 24, 30, and
31 were determined at concentrations ranging from 0.1 to
300 µM. Increasing compound concentrations were cumulatively
applied to the oocytes, and steady-state values of hERG inhibition
were assessed during 0.3 Hz pulse trains. All selected alkaloids
reduced IhERG in a concentration-dependent manner, albeit to
varying degrees (l" Fig. 2, Table 2). Protopine (16) and (+)-cory-
noline (24) were among the most potent alkaloids, with IC50 val-
ues of 4.1 ± 0.4 µM and 7.1 ± 0.4 µM, respectively. Representative
currents illustrating concentration-dependent inhibition of IhERG
by 16 and 24 are shown in l" Fig. 3. Interestingly, several com-
pounds induced a much stronger hERG block during high fre-
quency stimulation (1 Hz) than during lower frequency pulses
(0.3 Hz) when comparing the data at 100 µM (l" Table 1, Fig. 2).
This was evident for (+)-bulbocapnine (18) (72.0 ± 1.6% block at
1 Hz vs. 40.5 ± 2.1% at 0.3 Hz), (+)-N-methyllaurotetanine (19)
(81.4 ± 2.9% block at 1 Hz vs. 57.1 ± 3.3% at 0.3 Hz), and reserpine
(31) (66.9 ± 0.3% block at 1 Hz vs. 47.0 ± 3.8% at 0.3 Hz). Moreover,
hERG inhibition by these alkaloids was incomplete at 0.3 Hz, even
at high concentrations (300 µM). These findings indicate that the
hERG inhibitory activity of 18, 19, and 31 crucially depends on
the pulsing rate. Recovery from block between pulses at the low-
er frequency of 0.3 Hz reduces the steady-state block for some of
the compounds. Such a behavior is well established for hERG and
other voltage-gated ion channels. Our study highlights that hERG
channel inhibition by natural products can be substantially aug-
mented by frequent pulsing and that the frequency of membrane
depolarization may thus affect the estimation of IC50 values (see
also [19] where a stronger steady-state block at higher pulse fre-
quencies was observed for amiodarone and cisapride, while the
action of other hERG blocking drugs was less dependent on the
pulsing rate).
The pronounced in vitro hERG blocking activity of some widely
occurring alkaloids could represent a risk for cardiotoxicity. Fur-
ther studies are warranted to assess potential hERG-related
safety aspects, and to explore the clinical relevance of our find-
ings. For example, protopine (16) is a major constituent of Cali-
fornia poppy (Eschscholzia californica; Papaveraceae), a well-
known medicinal plant from North America. In folk medicine,
the herb has been used as an analgesic and sedative remedy
[20]. Protopine (16) has been reported to inhibit multiple cardiac
ion currents (e.g., INa, ICa,L, IK1, and IK) in isolated guinea pig ven-
tricular myocytes. Moreover, the alkaloid has been shown to
shorten the ventricular action potential duration [21]. It is, to
the best of our knowledge, still unclear whether the intake of
protopine with Eschscholzia-containing herbal preparations is
toxicologically relevant. Further studies are certainly needed to
evaluate its cardiac safety profile. The same applies for other
hERG blocking alkaloids identified in this study. The cardiac
safety of these alkaloids will depend on their oral bioavailability,
clinically achieved free plasma concentrations, and the hERG
blocking potency of their metabolites. Future pharmacodynam-
ic/pharmacokinetic studies should, however, not only be per-
formed with the hERG blocking alkaloids, but also with their cor-
responding herbal extracts, in order to evaluate a possible influ-
ence of other extract constituents.Schramm A et al. Natural Products as… Planta Med 2014; 80: 740–746
Fig. 1 Structures of alkaloids 1–34 tested for human ether-a-go-go-
related gene inhibitory activity.
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Table 1 Alkaloid library screening for human ether-a-go-go-related gene in
vitro inhibition (in %). The hERG inhibitory potential of alkaloids 1–34 was as-
sessed at 100 µM in a functional assay with Xenopus oocytes. Inhibition of IhERG
was determined during 1 Hz pulse trains applied from − 80mV.
Compound IhERG inhibition (%)
at 100 µM
(−)-Argemonine (1) 10.0 ± 0.8
(−)-Eschscholtzine (2) 14.6 ± 2.0
(−)-Neocaryachine (3) 9.8 ± 0.4
(−)-Californidine (4) 0.0 ± 0.0
(+)-Reticuline (5) 28.1 ± 2.0
Papaverine (6) 33.6 ± 3.4
(−)-Ephedrine (7) 0.0 ± 0.0
Indirubin (8) 0.0 ± 0.0
(−)-Sparteine (9) 0.0 ± 0.0
Harmine (10) 27.5 ± 3.1
Vasicine (11) 2.2 ± 0.3
Vasicinone (12) 0.0 ± 0.0
Tryptanthrin (13) 0.0 ± 0.0
8-Oxoberberine (14) 3.7 ± 1.9
8-Oxocoptisine (15) 0.9 ± 0.9
Protopine (16) 88.4 ± 1.9
(−)-Remerine (17) 42.7 ± 7.3
(+)-Bulbocapnine (18) 72.0 ± 1.6
(+)-N-methyllaurotetanine (19) 81.4 ± 2.9
(+)-Boldine (20) 65.8 ± 5.3
Sanguinarine (21) 34.8 ± 12.1
Dihydrosanguinarine (22) 22.5 ± 4.3
(+)-Chelidonine (23) 56.8 ± 8.2
(+)-Corynoline (24) 72.6 ± 2.4
(+)-Haemanthamine (25) 0.0 ± 0.0
(+)-Hippeastidine (26) 28.2 ± 1.1
(−)-Galanthine (27) 1.3 ± 0.3
Noscapine (28) 6.8 ± 3.0
Emetine (29) 3.3 ± 1.9
Yohimbine (30) 52.6 ± 3.0
Reserpine (31) 66.9 ± 0.3
(−)-Galanthamine (32) 0.7 ± 0.5
(+)-Salutaridine (33) 22.4 ± 1.6
(+)-Tazettine (34) 3.6 ± 1.1
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Chemicals
Noscapine (98% by TLC) and (−)-remerine hydrochloride (95% by
TLC) were purchased from Latoxan. (+)-Boldine (ROTICHROM®
~CHR) was from Carl Roth GmbH. (+)-Chelidonine monohydrate
(≥ 95% by 1H NMR), harmine (98% by TLC), sanguinarine chloride
(≥ 98% by HPLC), and tryptanthrin (≥ 95% by 1H NMR) were pur-
chased from Sigma-Aldrich.
Emetine dihydrochloride, (−)-ephedrine hydrochloride, papaver-
ine hydrochloride, reserpine, (−)-sparteine sulfate, and yohim-
bine hydrochloride were from the Institute of Pharmaceutical Bi-
ology, University of Jena (purities ≥ 95% by 1H NMR).
Vasicine (> 95% by 1H NMR) and vasicinone (> 95% by 1H NMR)
were isolated from leaves and twigs of Peganum harmala (Zygo-
phyllaceae) [22] (Supporting Information).
(−)-Argemonine, (−)-californidine iodide, (−)-eschscholtzine,
(−)-neocaryachine, (+)-N-methyllaurotetanine, protopine, (+)-re-
ticuline, and (+)-salutaridine were isolated from aerial parts and
roots of E. californica [23]. (+)-Bulbocapnine and (+)-corynoline
were isolated from tubers of Corydalis cava (Fumariaceae) [24].
(−)-Galanthamine, (−)-galanthine, (+)-haemanthamine, (+)-hip-101peastidine, and (+)-tazettine were isolated from the bulbs of
Zephyranthes robusta (Amaryllidaceae) [25]. Dihydrosanguinar-
ine was isolated from a commercial extract of Macleaya cordata
(Papaveraceae) (Supporting Information). Purities of isolated
compounds were ≥ 95% (TLC).
Indirubin (≥ 95% by 1H NMR) had been previously synthesized ac-
cording to published procedures [26,27].
8-Oxoberberine (≥ 95% by 1H NMR) and 8-oxocoptisine (≥ 95% by
1H NMR) were prepared according to an established procedure
[28], with minor modifications (Supporting Information).
Electrophysiological bioassay: expression of human
ether-a-go-go-related gene channels in Xenopus oocytes
and voltage-clamp experiments
Oocyte preparation: Oocytes from the South African clawed frog,
Xenopus laevis, were prepared as follows: After 15min exposure
of female Xenopus laevis to the anesthetic (0.2% solution of MS-
222; Sigma-Aldrich), parts of the ovary tissue were surgically re-
moved. Defolliculation was achieved by enzymatical treatment
with 2mg/mL collagenase type 1A (Sigma-Aldrich). Stage V–VI
oocytes were selected and injected with the hERG-encoding
cRNA. Injected oocytes were stored at 18°C in ND96 bath solu-
tion containing 1% penicillin-streptomycin solution (Sigma-Al-
drich). ND96 bath solution contained 96mM NaCl, 2mM KCl,
1mM MgCl2 × 6H2O, 1.8mM CaCl2 × 2H2O, and 5mM HEPES
(pH 7.4).
Automated two-microelectrode voltage-clamp studies: Currents
through hERG channels were studied with the two-microelec-
trode voltage-clamp technique using a Turbo TEC-03X amplifier
(npi electronic GmbH). Electrophysiological experiments were
performed one to three days after cRNA injection. Voltage-re-
cording and current-injecting microelectrodes (Harvard Appara-
tus) were filledwith 3MKCl and had resistances between 0.5 and
2MΩ. Oocytes with maximal current amplitudes > 4 µAwere dis-
carded to avoid voltage-clamp errors. For the initial compound
screening, the following voltage protocol was used: From a hold-
ing potential of − 80mV, the cell membrane was initially depolar-
ized to + 20mV (300ms) in order to achieve channel activation
and subsequent rapid inactivation. During following repolariza-
tion to − 50mV (300ms), channels recover from inactivation and
elicit IhERG. A final step to the holding potential ensured that
channels returned to the closed state. The protocol was applied
in 1-s intervals (1 Hz pulse frequency). Cumulative concentra-
tion-response experiments were performed with the same volt-
age protocol as described above, with minor modifications: the
holding potential was − 100mV, and pulse frequency was 0.3 Hz.
Measurements were started after the initial current “run up”
(slow increase of hERG current amplitudes during repetitive
pulsing) reached a steady baseline. The automated fast perfusion
system ScreeningTool (npi electronic GmbH, see [29] for details)
was used to apply the test solutions to the oocyte. Sample stock
solutions (prepared in DMSO) were freshly diluted every day
with ND96 bath solution. Steady-state block of IhERG was eval-
uated at ambient temperature (20–24°C). Decreases in tail cur-
rent amplitudes were taken as a measure of block development
during repetitive pulsing. The final maximum DMSO concentra-
tion (1%) in test solutions did not affect hERG currents (data not
shown). Cisapride (Sigma-Aldrich; purity ≥ 98%) was used as pos-
itive control. The IC50 value for hERG current inhibition at 0.3 Hz
pulse frequency was 1.6 ± 0.4 µM (n = 3, l" Table 2, see also [19]
for comparison). Data acquisition and processing were per-Schramm A et al. Natural Products as… Planta Med 2014; 80: 740–746
Fig. 2 Concentration-response relationships for
the inhibitory effects of selected alkaloids on hu-
man ether-a-go-go-related gene potassium current
in transfected Xenopus oocytes. Steady-state inhibi-
tion of IhERG at the indicated concentrations was es-
timated during 0.3 Hz pulse trains applied from
− 100mV.
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respectively.
Data analysis
Data were analyzed using Origin software 7.0 (OriginLab Corpo-
ration). Data from cumulative concentration-response experi-
ments were fitted using the Hill equation
I(hERG,comp)/I(hERG,ctrl) = (100 – A)/(1 + [C/IC50]nH) + A
where I(hERG,comp) is the current amplitude in the presence of a
given compound, I(hERG,ctrl) is the control current amplitude, IC50
is the concentration at which hERG current inhibition is half-
maximal, C is the applied compound concentration, A is the frac-
tion of hERG current that is not blocked, and nH is the Hill coeffi-Schramm A et al. Natural Products as… Planta Med 2014; 80: 740–746 10cient. Each data point represents the mean ± SE from at least
three oocytes and two oocyte batches.
Supporting information
Protocols for the isolation of vasicine and dihydrosanguinarine,
as well as details on the semi-synthesis and spectral character-
ization of 8-oxoberberine and 8-oxocoptisine are available as
Supporting Information.Acknowledgments
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Fig. 3 Representative currents illustrating concentration-dependent inhi-
bition of human ether-a-go-go-related gene potassium current by (A) pro-
topine (16) and (B) (+)-corynoline (24). Superimposed current traces re-
corded in the absence (control) and after attaining steady-state block with
increasing concentrations of 16 and 24 are shown. Steady-state inhibition
of IhERG was studied during 0.3 Hz pulse trains applied from − 100mV.
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Experimental details 
 
General experimental procedures: 
HR-TOF-ESI-MS data were obtained on a micrOTOF ESI-MS spectrometer (Bruker 
Daltonics). A solution of 0.1% formic acid in 2-propanol/water (1:1 v/v) containing 5 mM 
NaOH was used for mass calibration. Data acquisition and analysis were performed using 
HyStar 3.2 software. NMR spectra were recorded at 291.15 K on a Bruker Avance III 
spectrometer (Bruker Daltonics) operating at 500.13 MHz for 1H. A 1 mm TXI microprobe 
was used for 1D and 2D NMR experiments (1H, COSY, HSQC, HMBC). Topspin 2.1 
software was used for spectra analysis and processing. 
 
Isolation of vasicine: 
Vasicine was isolated from the CH2Cl2 extract of Peganum harmala L. (Zygophyllaceae). 
Briefly, a portion of the crude extract (2.0 g) was suspended in CH2Cl2 and partitioned with 
0.25 M H2SO4. Alkalinization of the aqueous phase to pH 12 with 26% NH4OH and 
subsequent extraction with CH2Cl2 yielded an alkaloid-enriched fraction. Final purification by 
semi-preparative HPLC (Agilent 1100 system, SunFire C18 column [10 × 150 mm i.d., 
5 µm], flow rate 4 mL/min, PDA 254 nm) with a gradient of 5–35% MeCN in aqueous 0.5% 
formic acid in 20 min afforded vasicine (11.1 mg). Vasicine was identified by ESI-MS 
(Esquire 3000 plus ion trap mass spectrometer, Bruker Daltonics), 1D and 2D NMR 
spectroscopy, and comparison with literature data [1]. Purity was  95% (1H NMR).  
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Isolation of dihydrosanguinarine: 
Dihydrosanguinarine was isolated from a commercial extract of Macleaya cordata (Macleaya 
cordata extract 60%; Organic Herb Inc., China). The alkaloidal extract (10 g) was dissolved 
in MeOH and filtered over 10 g of aluminum oxide. The effluent was collected, evaporated to 
dryness, and tested for alkaloids by means of TLC analysis (silica gel 60 F254 pre-coated Al 
sheets [Merck], toluene/Et2NH [95:5 v/v], Dragendorffʼs reagent). The concentrated 
alkaloidal extract (8.5 g) was fractionated by open column chromatography on aluminum 
oxide. Elution was done with a step gradient of petroleum ether/CHCl3 (9:1, 8:2, 7:3, 6:4, 1:1, 
4:6, 3:7, 2:8, 1:9; 500 mL each), followed by a step gradient of CHCl3/EtOH (1:1, 1:2, 1:3, 
1:4, 1:5; 500 mL each). Fractions of 150 mL were collected and combined after TLC analysis. 
Six subfractions were obtained (I‒VI). Dihydrosanguinarine (53 mg) was recrystallized in 
EtOH from subfraction I (95 mg). 
 
Synthesis of protoberberine derivatives: 
8-Oxoberberine was synthesized according to a published procedure [2], with minor 
modifications. To a solution of berberine chloride hydrate (~ 95%, Fluka; 50.7 mg dissolved 
in 4 mL of hot water), a 30% aqueous solution of NaOH (4 mL) was added dropwise under 
stirring. The mixture was heated under reflux for 3 h. After cooling to ambient temperature, 
the collected precipitate was washed with water and treated with 3% hydrochloric acid 
(25 mL) by heating the mixture on the water bath for 10 min. The precipitate was filtered off 
and washed with hot 3% hydrochloric acid. Crystallization from EtOH afforded 7.1 mg of 
yellow crystals of 8-oxoberberine (HR-ESI-TOF-MS m/z 374.1004 M+Na+, calcd. for 
C20H17NNaO5: 374.0999; 1H and 13C NMR data, see Table 1S).  
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8-Oxocoptisine was obtained as described above. Coptisine (50.6 mg) was isolated from 
rhizomes of Coptis chinensis Franch. (Ranunculaceae) [3]. Crystallization from EtOH yielded 
9.6 mg of orange crystals of 8-oxocoptisine (HR-ESI-TOF-MS m/z 358.0679 M+Na+, calcd. 
for C19H13NNaO5: 358.0686; 1H and 13C NMR data, see Table 2S). Purity of both products 
was ≥ 95% (1H NMR). 
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Table 1S NMR spectroscopic data for 8-oxoberberine (CDCl3, 500 MHz, δ in ppm).  
 
Position δH (J in Hz) δCa 
1 7.22, s 104.6 
2  147.5 
3  148.5 
4 6.70, s 107.8 
4a  130.1 
5 2.90, t (6.1)   28.6 
6 4.30, t (6.1)   39.3 
7   
8  159.9 
8a  119.4 
9  149.8 
10  151.5 
11 7.32, d (8.7) 119.3 
12 7.26, d (8.7) 122.0 
12a  132.5 
13 6.71, s 101.1 
13a  135.6 
13b  123.5 
2,3-OCH2O 6.00, s 101.2 
9-OCH3 4.03, s   61.5 
10-OCH3 3.95, s   57.0 
a 13C shifts deduced from HSQC and HMBC experiments.  
δH reference data measured in CDCl3 can be found in [2].  
δH and δC reference data measured in DMSO-d6 can be found in [4].  
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Table 2S NMR spectroscopic data for 8-oxocoptisine (CDCl3, 500 MHz, δ in ppm).  
 
Position δH (J in Hz) δCa 
1 7.17, s 104.7 
2  147.6 
3  148.1 
4 6.67, s 107.8 
4a  129.9 
5 2.86, t (6.2)   28.6 
6 4.25, t (6.2)   39.1 
7   
8  159.5 
8a  110.6 
9  146.5 
10  146.2 
11 7.12, d (8.2) 113.6 
12 7.00, d (8.2) 119.0 
12a  131.8 
13 6.70, s 101.9 
13a  135.2 
13b  123.8 
2,3-OCH2O 5.97, s 101.0 
9,10-OCH2O 6.18, s 102.3 
a 13C shifts deduced from HSQC and HMBC experiments.  
δH and δC reference data measured in DMSO-d6 can be found in [4]. 
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3.4. Gram-scale purification of dehydroevodiamine from Evodia rutaecarpa 
fruits, and a procedure for selective removal of quaternary 
indoloquinazoline alkaloids from Evodia extracts 
 
Schramm A, Hamburger M. 
Fitoterapia 2014; 94: 127–133 
 
 
 
A two-step procedure for the gram-scale isolation of dehydroevodiamine (DHE) from 
Evodia rutaecarpa fruits was developed. DHE was selectively enriched by cation-exchange 
solid phase extraction, and further purified by preparative RP-HPLC. A method for the 
selective removal of quaternary indoloquinazoline alkaloids from Evodia extracts was 
developed. The DHE content in commercially available Evodia products was assessed by 
HPLC-PDA analysis.  
 
 
 
 
 
 
 
Selective removal of quaternary indoloquinazoline alkaloids from Evodia extracts, 
developing a protocol for the gram-scale purification of dehydroevodiamine, quantitative 
analysis of dehydroevodiamine in commercially available Evodia products, writing the 
draft of the manuscript, and preparation of figures were my contributions to this 
publication.  
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throughput [2]. Gram-scale purification protocols have
developed for a broad range of rare natural products
triterpenoid esters from marigold [3], catechins from gre
[4], the iridoid glycoside geniposide from Gardenia jasmi
[5,6], the phenolic acid salvianolic acid B from Salvia miltio
[7], the coumarin scoparone from Artemisia scoparia [8
flavonolignans from milk thistle [9].
Evodiae fructus (Wu zhu yu) consists of the nearly
dried fruit of Evodia rutaecarpa (Juss.) Benth. (Ruta
and is among the most popular herbal drugs in tradi
Chinese medicine (TCM). It is widely used as an anal
anti-emetic, and astringent remedy for the treatme
headaches, gastrointestinal disorders, andmenstrual comp
and also for treating mouth ulcers [10,11]. Indoloquina
and quinolone alkaloids, flavonoids, and limonoids have
identified in the drug [11–15]. The quaternary indoloquina
.
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alkaloid dehydroevodiamine (DHE, 1) (Fig. 1) is a major
constituent that has been intensively studied from a pharma-
cological point of view. DHE has been shown to exhibit
pronounced anti-amnesic effects in vivo [16], and moderate
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hypotensive, bradycardiac, and vasorelaxant effects
been reported [18,19]. Electrophysiological studies i
lated guinea pig cardiomyocytes revealed that DHE inh
several cardiac ion currents (e.g., INa, ICa,L, and IK) and prol
duration of the atrial and ventricular action potential [20].
Cardiovascular safety liabilities are, however, of u
importance in drug discovery, drug development, and c
practice [21]. Similar considerations also have to be appl
herbal products containing potent active constituents. H
an assessment of the cardiac safety and pharmacok
properties of DHE is needed. As DHE is not comme
available, a simple, robust, and scalable procedure for pu
tion of DHE at the gram-scale was required. In parallel, w
devised a procedure for the selective removal of DHE
Evodia extracts, for the case that cardiac liabilities of
should be substantiated.
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formic acid [69:30:1 v/v/v], detection at 366 nm). Ana
HPLC separations were carried out on a SunFire C18 co
(3 × 150 mm i.d., 3.5 μm). LC-PDA analyses were perfo
with aWaters Alliance 2695 separationmodule equipped
996 PDA detector. Data acquisition and analysis were perfo
using Empower Pro 2 software. NMR spectra were rec
in methanol-d4 on a Bruker Avance III spectrometer (B
Daltonics) operating at 500 MHz and 125 MHz for 1H an
respectively. A 1 mm TXI microprobe was used for 1D a
NMR experiments (1H, NOE difference, COSY, HSQC, HMBCB for
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2.2. Solvents and chemicals
Methanol used for extraction and cation-exchange
matography was of technical grade, whereas HPLC-
solvents were used for HPLC separations. HPLC-grade
was obtained by an EASY-pure II water purification sy
HPLC-grade methanol and HPLC-grade acetonitrile
from Scharlau (Barcelona, Spain). Formic acid (98.0–10
dimethylsulfoxide (DMSO), and trifluoroacetic acid (TFA, ≥
were purchased from Sigma-Aldrich. Dehydroevodiamine
ride (purity N 95% by 1H NMR and HPLC) had been prev
synthesized at the Department of Pharmaceutical/Med
Chemistry, University of Jena, Germany. Lewatit® c
exchange resins were kindly provided by Chemia Bru
(Brugg, Switzerland).
2.3. Plant material
Evodiae fructus (fruits of E. rutaecarpa) (batc
70588813) were purchased from Yong Quan GmbH (Enn
Germany). A voucher specimen (number 00 465) has
deposited at the Division of Pharmaceutical Biology, Univer
Basel, Switzerland.
2.4. Extraction
Dried fruits were ground in a ZM 1 ultracentrifuga
(sieve size of 2.0 mm; Retsch, Haan, Germany) under co
with liquid nitrogen. The powdered fruits (526 g)
exhaustively percolated at room temperature with m
nol. Solvent evaporation under reduced pressure affor
dark brown viscous residue (108.8 g).
2.5. LC-PDA analysis
Analyses were carried out on an Alliance 2695 instru
(Waters). Separations were achieved with 0.1% aq
formic acid (solvent A) and acetonitrile containing
formic acid (solvent B). The gradient profile was as fo
5% B to 30% B in 25 min, 30% B to 100% B in 5 min, 100%
6 min. The flow rate was 0.5 mL/min, and the inj
volume was 10 μL. The samples were dissolved in DMS
concentration of 7.5 mg/mL for extracts (crude E. rutae
extract and alkaloid-depleted extracts), and 1 mg/mL f
alkaloid-enriched fraction. Detection was at 365 nm,
PDA spectra were recorded from 210 to 400 nm.
2.6. LC-PDA-ESI-TOF-MS analyses
HR-ESI-TOF-MS data were recorded on a micrOTOF E
spectrometer (Bruker Daltonics) coupled via a 1:10 spli
an Agilent 1100 system consisting of an autosampler, deg
binary pump, column oven, and PDA detector. Data acqu
and analysis were performed using HyStar 3.2 softw
solution of formic acid 0.1% in 2-propanol/water (1:
containing 5 mM NaOH was used for mass calibr114
Separation conditions were identical as those described in
Section 2.5. Typical mass accuracy was ±2 ppm.
2.7. Cation-exchange solid phase extraction
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2.9. Quantitative determination of DHE in Evodia-containing
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Three strongly acidic resins (Lewatit® MonoPlus SP 1
1221, and S 100 G1) and three weakly acidic resins (Lew
CNP 80, CNP 80WS, and S 8528) were tested for their abi
selectively retain the quaternary alkaloids. For this pu
the resins (suspended in methanol) were packed into
columns of 1.7 cm diameter to give bed heights of ap
mately 10 cm. Columns were washed with methanol un
effluent appeared colorless. A portion (0.5 g) of meth
E. rutaecarpa extract was dissolved in methanol (50
applied to the column, and allowed to percolate with a
rate of 1 mL/min. Columns were then washed with 30
of methanol. The alkaloid-depleted effluents were coll
evaporated to dryness, and submitted to LC-PDA analysi
2.7.2. Process optimization
The strong exchange resin Lewatit®MonoPlus SP 11
selected for further work. Conditions were optimized
respect to sample loading and sample elution. Alk
retention and breakthrough were monitored by mea
TLC analysis of collected fractions. The extract was dissol
methanol at a concentration of 10 mg/mL, and the max
loading ratio was 20% (1 g of crude extract with 5 g of r
The flow rate was 1 mL/min. Upon completion of sa
introduction, the column was washed with methanol un
effluent appeared colorless. For recovery of alkaloids, the
was transferred to a vessel and extracted under stirring w
solution of sodium chloride 5% in methanol/water (1:1
Exhaustive alkaloid recovery was achieved by repeatin
washing step until the supernatant was colorless. The
bined supernatants were evaporated to dryness under re
pressure. The residue was suspended in water and exhau
ly partitioned with chloroform. The alkaloidal fraction
obtained by evaporation of the organic phase on a
evaporator.
2.8. Preparative HPLC
Preparative HPLC separation was performed with a s
consisting of two LC-8A preparative pumps, a SCL-1
system controller, and SPD-M10A VP PDA detecto
Shimadzu). A 1 mL loopwas used for injection. Data acqu
and analysis were performed using class-VP V6.14
software. Separation was carried out on a Waters Su
Prep C18 OBD (30 × 150 mm i.d., 5 μm) column. The m
phase consisted of water containing 0.025% TFA (solve
and methanol containing 0.025% TFA (solvent D). The
rate was 20 mL/min. Detection was at 365 and 42
Separation of alkaloids was carried out in isocratic mode
C, 27% D) over 36 min. A stock solution of the alkaloidal fr
was prepared (40 mg/mL in DMSO/methanol [9:1 v/v]
repeatedly injected. The injection volume was 1 mL. Fra
corresponding to peaks of DHE and hortiamine were col
and evaporated with a Multivapor P-12 evaporator equ
with a vacuum pump V-700 and a vacuum controller
(all Büchi).,
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2695 instrument (Waters). The mobile phase consist
water containing 0.025% TFA (solvent E) and aceto
containing 0.025% TFA (solvent F). The gradient profile w
follows: 10% F to 40% F in 20 min, 40% F to 100% F in 2
100% F for 8 min. The flow rate was 0.5 mL/min, and det
was at 365 nm. The injection volume was 10 μL, u
otherwise stated. A stock solution of dehydroevodia
chloride (reference compound) was prepared in D
(1 mg/mL). Calibration solutions covering a concent
range of 10 to 200 μg/mL were prepared from the
solution by dilution with DMSO. A linear calibration
(y = 8.12 ∗ 107 x + 5.59 ∗ 104; R2 = 0.9999) was obt
Limit of detection (LOD; S/N ratio ≥ 3), and limit of qu
cation (LOQ; S/N ratio ≥ 10) were determined by
dilution of the stock solution. The LOD and LOQ (amou
compound injected) were 0.8 ng and 2 ng, respectively.
range of 10 to 200 μg/mL, intra-day precision (repeata
and inter-day precision (between-day precision) were ass
in the course of the analysis with calibration samples, q
control samples, and two Evodia extract samples demonst
that the method is precise (for details, see Supporting Inf
tion). Analyses were performed in triplicate, and at am
temperature (20–24 °C).
2.9.1. Unprocessed E. rutaecarpa fruits
Dried E. rutaecarpa fruits were purchased from
Quan GmbH (Ennepetal, Germany) (Lot no. 70588813)
Chinaherb AG (Wollerau, Switzerland) (Lot no. Y4103
and Complemedis AG (Trimbach, Switzerland) (Lot no.
Voucher specimens (number 00 465, 00 611, and 00
respectively) have been deposited at the Division of
maceutical Biology, University of Basel, Switzerland
macroscopic characteristics of E. rutaecarpa fruits
confirmed with the aid of the corresponding monogra
the Chinese Pharmacopeia and other literature [22,23].
anolic extracts were prepared by pressurized liquid extr
(PLE) using a Dionex ASE 200 instrument connected to a so
controller (Dionex). Ground plant material (ZM 1 ultrace
ugal mill, Retsch; sieve size 2.0 mm) was packed into
cartridges (11 mL; Dionex) and consecutively extracted
solvents of increasing polarity (petroleum ether, ethyl ac
and methanol). Extraction temperature was at 70 °C, an
pressure was set at 120 bar. Duration of a static extraction
was 5 min, and 3 extraction cycleswere used for each solv
obtain exhaustive extraction [24,25]. Extracts were dried
reduced pressure, and dissolved in DMSO at a concentrat
3.5 mg/mL.
2.9.2. Commercial Evodia-containing TCM products
The following five TCM products were purchased
analyzed: “Wu zhu yu” (Guangdong Yifang Pharmace
Co., Ltd., China), “Wu zhu yu zhi” (Plantasia, Obern
Austria), “Wuzhu yu tang” (Euroherbs BV, EZWestervoor
Netherlands), “Wen jing tang” (Euroherbs BV, EZ Wester
The Netherlands), and “Si shen wan” (Eagle Herbs,
Monica, CA, USA). Powdered granules were macerated ex
tively with methanol at room temperature. Pooled ex115
were filtered through a standard laboratory filter, concentrated
under reduced pressure, and lyophilized. Dried extracts were
dissolved in DMSO at a concentration of 10 mg/mL. The
injection volume was 10 μL, except for “Si shen wan” (25 μL).
ts) o
e and
roach
was clearly not applicable for purification at the gram-scale (data
not shown). Isolation of the structurally related minor alkaloid
hortiamine (2) (Fig. 1), e.g., for pharmacological and toxicolog-
ical studies, also required an efficient large-scale purification
loids,
hange
loids,
efore,
atit®
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Small-scale preparative purification (multi-mg amoun
DHE was achieved by a combination of normal-phas
reverse-phase column chromatography. However, this appFig. 2. LC-PDA fingerprints of crude E. rutaecarpa methanolic extract (A) an
column) acidic resins were tested for their potential of selective alkaloid retef
procedure.
Since DHE and hortiamine are both quaternary alka
enrichment of an alkaloidal fraction on a cation-exc
resin, followed by an HPLC separation of the alka
seemed to be an efficient two-stage approach. Ther
we first tested various strongly and weakly acidic Lewd alkaloid-depleted extracts (B). Three strongly (left column) and three weakly (right
ntion. Peak numbering denotes alkaloids 1 and 2. HPLC traces were recorded at 365 nm.
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resins for their ability to selectively retain the quaternary
alkaloids. LC-PDA analysis of the alkaloid-containing metha-
nolic extract, and alkaloid-depleted extracts revealed that
alkaloid retention (i) was successful with all resins and,
ever
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ing o
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t flow
rates (0.5, 1.0, and 2.0 mL/min) for elution of the column was
investigated. Flow rates up to 1.0 mL/min gave good retention
of alkaloids, and a flow rate of 1 mL/min was thus selected for
achieving highest possible throughput. Quaternary alkaloids
asing
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Fig. 3. Analytical HPLC chromatogram (365 nm) of the alkaloidal fraction obtained by enrichment on Lewatit® MonoPlus SP 112 resin. Peak numbering denotes
alkaloids 1 and 2, with UV spectra of peaks shown as insets.
131A. Schramm, M. Hamburger / Fitoterapia 94 (2014) 127–133(ii) was not influencedby the counterion of the resin.How
significant differences in the chromatographic fingerpri
the alkaloid-depleted extracts were observed. Represen
HPLC chromatograms are shown in Fig. 2. The strong exc
resin Lewatit® MonoPlus SP 112 showed the best selec
with respect to alkaloid retention, without significant m
cation of the non-alkaloidal fraction. Hence, this resin
selected for further work. Next, conditions for sample lo
and sample elution were optimized. With respect to al
extraction, removal via a packed column was more eff
than batch extraction in a resin suspension under stirring
not shown). The extract could be dissolved in metha
a maximum concentration of 10 mg/mL, as higher sa
concentrations (15 and 25 mg/mL) led to insoluble res
For further process optimization, the capacity of the resi
determined by serial sample loading and parallel monitor
breakthrough. Satisfactory alkaloid retention with mi
bleeding was achieved with a loading ratio up to 20% (
extract on 5 g of resin). Moreover, the effect of differenFig. 4. Preparative HPLC chromatogram of the alkaloidal fraction. HPLC tr
collected fractions.,
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were eluted from the cation-exchange resin by incre
the ionic strength with the aid of a solution of so
chloride 5% in methanol/water (1:1 v/v). The alka
fractionwas readily desalted by solvent partitioning, and fu
characterized by LC-PDA analysis and 1H NMR spectrosco
summary, cation-exchange solid phase extraction affor
highly enriched alkaloidal fraction composed of DHE (1
the accompanying minor alkaloid hortiamine (2) in a ra
91:9 (1H NMR and HPLC). A representative analytical
chromatogram of the alkaloidal fraction is shown in Fig.
The optimized cation-exchange solid phase extra
procedure was then upscaled for gram-scale purificat
DHE. A linear scale up was done, and the alkaloid enrich
was reproducible at preparative scale, as an alkaloidal fr
with 91% of DHE (1H NMR and HPLC) was obtained. S
attempts to separate DHE (1) and hortiamine (2) by cr
lization failed. Purification of alkaloids 1 and 2 was f
achieved by isocratic preparative RP-HPLC. Conditions
optimized with respect to sample loading, resolutionaces of a separation of 40 mg of alkaloidal fraction are shown. Dashed lines denote
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separation time. Increasing both sample volume and sampl
concentration caused a noticeable column overload and led
to peak broadening and saturation of the detector signa
However, amounts of up to 40 mg of alkaloidal fraction could
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Fig. 5. Procedure for the large-scale purification of DHE (1) from crude E
rutaecarpa extract.
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132 A. Schramm, M. Hamburger / Fitoterapia 94 (2014) 127–133be separated in a single HPLC run, without significant l
separation performance (Fig. 4). Repeated injections com
with automated solvent evaporation of collected fra
afforded200 mgofDHEper day. The structurally related al
hortiamine was isolated for the first time from E. ruta
fruits. The identity of compounds was confirmed by co
hensive analysis of on-line (LC-PDA-ESI-TOF-MS) and o
(microprobe 1D and 2D NMR) spectroscopic data, and co
ison with published literature [26–28]. Hortiamine has
previously reported from Hortia arborea Engl. and
brasiliana Vand. ex DC., but no NMR spectral data were rec
at that time [28,29]. The 1H and 13C NMR spectroscopic d
hortiamine are listed in Table S2 of the Supplementary
Final purities of alkaloids 1 and 2 were ≥95%, as determin
LC-PDA analysis and 1H NMR spectroscopy (for 1H NMR s
see Supplementary data).
The purification strategy used for the gram-scale isolat
DHE from themethanolic Evodia extract is summarized in
The procedure involved two steps, namely cation-exc
solid phase extraction and RP-HPLC. Due to the ionic nat
the target compounds, an enrichment of the alkaloidal fr
was readily achieved with a cation-exchange resin. C
selection of an appropriate cation-exchange resin was c
for a selective enrichment of the alkaloidal fraction
minimal non-alkaloidal contaminants. Given the purity
Table 1
Content of DHE in commercial Evodia products1.
Supplier of crude Evodiae fructus DHE content in RDD2 (1.5–4.5Lian Chinaherb AG 12.0–36.0 mg
Complemedis AG 12.4–37.3 mg
Yong Quan GmbH 14.4–43.2 mg
nd: not determined (no RDD given by the supplier).
1 Contents are expressed as dehydroevodiamine chloride and represent
2 RDD: recommended daily dose.
3 For details on the composition of the investigated preparations, see Sue
l.
f
s
a
-
e
-
a
f
.
y
a
f
.
e
f
l
l
e
resins can be easily regenerated and are amenable to rep
use. There is, however, room for further optimization
purification procedure, e.g., unattended operation of the
by an automated MS-triggered fractionation. Also, chlor
could be replaced as the organic phase in the partitionin
by a more eco-friendly solvent.
Postharvest processing of herbs is a unique feature of
and is believed to enhance the efficacy and/or reduc
toxicity of crude herbal drugs [30]. According to Bensky
unprocessed Evodia fruits are only used externally, wh
internal administration various processing methods ar
scribed. Theminimum requirement is that the fruits are s
in water and subsequently sun-dried. Different proc
methods are used for producing different therapeutic e
according to TCM concepts [31]. From a scientific perspe
processing may lead to significant qualitative and qua
tive changes in the metabolite pattern. This is of part
importance for pharmacologically/toxicologically c
compounds in TCM drugs, such as DHE. Therefor
determined theDHE content in different commercial batc
dried E. rutaecarpa fruits, and in a series of comme
available processed TCM products, and we then calculate
intake of DHE in recommended daily doses for these pro
(Table 1). DHE was detected in all herbal drug sample
processed TCM products, but quantitative differences
observed. The daily intake in DHE with the crude herba
is significantly higher (12 to 43 mg) than with proc
Evodia-containing preparations (6.7 to 7.3 mg consid
manufacturers' recommendations). However, the amou
DHE consumed in the latter type of products could s
toxicologically relevant. If the DHE intake should indeed
out to be toxicologically critical, the alkaloid would have
removed from Evodia products, even if the pharmacol
activity of the herbal drug would be linked to the compou
selective removal of quaternary indoloquinazoline alk
with the cation-exchange resin Lewatit® MonoPlus SP 1
demonstrated with our experiments (Fig. 2), could be a
approach for their removal from Evodia extracts w
altering the fingerprint of the non-alkaloidal portion.
4. Conclusions
An efficient two-step protocol for the gram-scale iso
of DHE from a crude E. rutaecarpa extract has been deve
.
its [22,31]) Processed TCM product3 DHE content in 1 g of formulation/Wu zhu yu 7.3 mg/7.3 mg
Wu zhu yu zhi 6.5 mg/nd
Wu zhu yu tang 3.2 mg/nd
Wen jing tang 1.1 mg/nd
Si shen wan 0.5 mg/6.7 mg
the mean from three injections.
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The approach is based on a combination of cation-exchange
chromatography and preparative RP-HPLC. Gram amounts of
DHE could be purified for quality control purposes and further
evaluation of its in vivo pharmacological and toxicological
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available Evodia products provided valuable information
the exposure to this alkaloid. These data are of consid
relevance from a clinical point of view, e.g., for evaluatin
potential of DHE for pharmacological/pharmacokinetic
actions with other phytomedicines, dietary supplemen
drugs. We developed a procedure for the selective remo
quaternary indoloquinazoline alkaloids from Evodia ex
which could be upscaled for production of DHE-dep
Evodia products.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgments
This project was supported by the Swiss National Sc
Foundation (grant no. 205320_126888), and by the
Curie Action “hergAccess”. The authors are gratef
Chemia Brugg AG (Brugg, Switzerland) for the g
Lewatit® ion-exchange resins. We also thank Dr. M. D
for synthesizing dehydroevodiamine chloride, Dr. M. Ou
the valuable discussions on analytical method validation
Orlando Fertig for the technical assistance.
Appendix A. Supplementary data
Supplementary data to this article can be found onl
http://dx.doi.org/10.1016/j.fitote.2014.02.005.
References
[1] ButterweckV, Nahrstedt A.What is the best strategy for preclinical
of botanicals? A critical perspective. Planta Med 2012;78:747–54.
[2] Martin SM, Kau DA, Wrigley SK. Scale-up of natural product is
In: Sarker SD, Latif Z, Gray AI, editors. Natural product isolation.
Totowa, New Jersey: Humana Press Inc.; 2005. p. 439–61.
[3] Hamburger M, Adler S, Baumann D, Förg A, Weinreich B. Prep
purification of the major anti-inflammatory triterpenoid ester
marigold (Calendula officinalis). Fitoterapia 2003;74:328–38.
[4] Baumann D, Adler S, Hamburger M. A simple isolation method
major catechins in green tea using high-speed countercurren
matography. J Nat Prod 2001;64:353–5.
[5] Zhou TT, Fan GR, Hong ZY, Chai YF, Wu YT. Large-scale isolati
purificationof geniposide from the fruit ofGardenia jasminoidesEllis b
speed counter-current chromatography. J Chromatogr A 2005;1100
[6] Zhou M, Zhuo JX, Wei WX, Zhu JW, Ling XR. Simple and effectiv
scale preparation of geniposide from fruit of Gardenia jasminoid
using a liquid–liquid two-phase extraction. Fitoterapia 2012;83:15
[7] Lee HJ, Lee KH, Park KH, Moon JH. Large scale isolation and puri
of salvianolic acid B in high purity from roots of Dansham
miltiorrhiza Bunge). Food Sci Biotechnol 2010;19:497–502.t
-
r
f
s
f
r
r
t
g
.
.
e
e
-
d
-
.
-
s
.
n
a
extract in support of preclinical in vivo studies for prostate
chemoprevention. Planta Med 2007;73:1495–501.
[10] Chinese Pharmacopoeia Commission. Pharmacopoeia of the P
Republic of China — Volume I. English ed. Beijing: China Medical
Press; 2010.
[11] Tang W, Eisenbrand G. Handbook of Chinese medicinal
chemistry, pharmacology, toxicology. Weinheim: Wiley-VCH; 2
[12] Huang X, Li W, Yang XW. New cytotoxic quinolone alkaloids from
of Evodia rutaecarpa. Fitoterapia 2012;83:709–14.
[13] Wang XX, Zan K, Shi SP, Zeng KW, Jiang Y, Guan Y, et al. Qu
alkaloids with antibacterial and cytotoxic activities from the f
Evodia rutaecarpa. Fitoterapia 2013;89:1–7.
[14] Sugimoto T, Miyase T, Kuroyanagi M, Ueno A. Limonoid
quinolone alkaloids from Evodia rutaecarpa Bentham. Chem
Bull 1988;36:4453–61.
[15] Wang YF, Liu YN, Hu LM, Pan GX, Gao XM. A qualitativ
quantitative assessment of eight constituents in Fructus Evod
HPLC-DAD-ESI-MS/MS. J Liq Chromatogr R T 2011;34:408–20.
[16] Park CH, Kim SH, Choi W, Lee YJ, Kim JS, Kang SS, et al.
anticholinesterase and antiamnesic activities of dehydroevodia
constituent of Evodia rutaecarpa. Planta Med 1996;62:405–9.
[17] Decker M. Novel inhibitors of acetyl- and butyrylcholinesterase d
from the alkaloids dehydroevodiamine and rutaecarpine. Eur
Chem 2005;40:305–13.
[18] Yang MCM, Wu SL, Kuo JS, Chen CF. The hypotensive and ne
chronotropic effects of dehydroevodiamine. Eur J Pha
1990;182:537–42.
[19] Chiou WF, Liao JF, Chen CF. Comparative study on the vasod
effects of three quinazoline alkaloids isolated from Evodia rutae
Nat Prod 1996;59:374–8.
[20] Loh SH, Lee AR, HuangWH, Lin CI. Ionic mechanisms responsible
antiarrhythmic action of dehydroevodiamine in guinea-pig i
cardiomyocytes. Brit J Pharmacol 1992;106:517–23.
[21] Laverty HG, Benson C, Cartwright EJ, Cross MJ, Garland C, Hamm
et al. How can we improve our understanding of cardiovascula
liabilities to develop safermedicines? Brit J Pharmacol 2011;163:6
[22] Stöger EA, Friedl F. Arzneibuch der Chinesischen Medizin. Germ
Stuttgart: Deutscher Apotheker Verlag; 2009.
[23] Zhongzhen Z. An illustrated Chinese Materia medica in Hong
Hong Kong: School of Chinese Medicine, Hong Kong Baptist Uni
2004.
[24] Basalo C, Mohn T, Hamburger M. Are extraction methods in qu
tive assays of pharmacopoeia monographs exhaustive? A com
with pressurized liquid extraction. Planta Med 2006;72:1157–6
[25] Benthin B, Danz H, Hamburger M. Pressurized liquid extrac
medicinal plants. J Chromatogr A 1999;837:211–9.
[26] King CL, Kong YC,WongNS, YeungHW, FongHHS, SankawaU. Ute
effect of Evodia rutaecarpa alkaloids. J Nat Prod 1980;43:577–82.
[27] Lin LC, Li SH, Wu YT, Kuo KL, Tsai TH. Pharmacokinetics and
metabolite identification of dehydroevodiamine in the rat. J Ag
Chem 2012;60:1595–604.
[28] Pachter IJ, Raffauf RF, Ullyot GE, Ribeiro O. The alkaloids of
arborea Engl. J Am Chem Soc 1960;82:5187–93.
[29] Pachter IJ, Mohrbacher RJ, Zacharias DE. Chemistry of hortiami
6-methoxyrhetsinine. J Am Chem Soc 1961;83:635–42.
[30] Zhao ZZ, Liang ZT, Chan K, Lu GH, Lee ELM, Chen HB, et al. A
issue in the standardization of Chinese Materia Medica: proc
Planta Med 2010;76:1975–86.
[31] Bensky D, Clavey S, Stöger E. Chinese herbal medicine: materia m
3rd ed. Seattle: Estland Press, Inc.; 2004.119
Supplementary data 
 
Gram-scale purification of dehydroevodiamine from Evodia rutaecarpa fruits, and a 
procedure for selective removal of quaternary indoloquinazoline alkaloids from Evodia 
extracts 
 
Anja Schramm, Matthias Hamburger* 
 
Division of Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, 4056 Basel, 
Switzerland  
 
* Corresponding author. Tel.: +41 (0)61 267 14 25; fax: +41 (0)61 267 14 74 
E-mail address: matthias.hamburger@unibas.ch (M. Hamburger) 
  
120
Analytical data of dehydroevodiamine (DHE, 1) 
 
 
 
HR-ESI-TOF-MS m/z 302.1291 [M+] (calcd for C19H16N3O: 302.1288) 
 
Table S1. NMR spectroscopic data (MeOH-d4, 500 MHz, δ in ppm). 
Position δH (J in Hz) δCa 
1 8.06, br d (8.4) 117.7 
2 8.11, ddd (8.6, 7.2, 1.5) 136.2 
3 7.79, ddd (8.0, 7.2, 0.9) 128.3 
4 8.44, dd (7.9, 1.5) 127.9 
4a  118.9 
5  158.7 
7 4.61, t (7.1) 41.9 
8 3.42, t (7.1) 18.6 
8a  131.8 
8b  123.9 
9 7.85, br d (8.2) 121.1 
10 7.31, ddd (8.5, 7.1, 1.0) 121.8 
11 7.55, ddd (8.5, 7.2, 1.0) 129.3 
12 7.67, br d (8.5) 113.0 
12a  142.4 
13a  119.9 
13b  150.3 
14a  139.9 
14-NCH3 4.45, s 39.9 
a 13C shifts deduced from HSQC and HMBC experiments.  
δH reference data measured in MeOH-d4 can be found in [1,2]. 
δH and δC reference data measured in DMSO-d6 can be found in [3]. 
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 Figure S1. 1H NMR spectrum of DHE (1) in MeOH-d4 (recorded with water suppression). 
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 Figure S2. 1H NMR spectrum of DHE (1). Expansion of the region 7.2–8.5 ppm.  
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 Figure S3. 1H NMR spectrum of DHE (1). Expansion of the region 3.0–5.0 ppm. Water suppression caused decreased signal intensities for 
δH 4.61 (H-7) and δH 4.45 (14-NCH3).   
124
Analytical data of hortiamine (2) 
 
 
 
HR-ESI-TOF-MS m/z 332.1389 [M+] (calcd for C20H18N3O2: 332.1394) 
 
Table S2. NMR spectroscopic data (MeOH-d4, 500 MHz for δH, 125 MHz for δC, δ in ppm). 
Position δH (J in Hz) δCa δC 
1 8.02, br d (8.6) 117.6 119.3 
2 8.09, ddd (8.4, 7.1, 1.2) 136.4 138.0 
3 7.76, dd (8.1, 7.3) 128.2 129.9 
4 8.41, dd (7.9, 1.2) 127.9 129.6 
4a  118.6 120.5 
5  158.3 159.7 
7 4.58, t (7.0) 42.0 43.6 
8 3.36, t (7.0) 18.7 20.2 
8a  131.1 132.2 
8b  124.2 125.7 
9 7.20, d (2.0) 99.6 100.9 
10  155.8 157.3 
11 7.18, dd (9.0, 2.1) 122.2 123.8 
12 7.55, d (9.0) 114.0 115.6 
12a  138.4 139.7 
13a  119.7 121.2 
13b  150.2 151.5 
14a  140.0 141.5 
14-NCH3 4.42, s 39.8 41.4 
10-OCH3 3.88, s 54.8 56.3 
a 13C shifts deduced from HSQC and HMBC experiments.  
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 Figure S4. 1H NMR spectrum of hortiamine (2) in MeOH-d4 (recorded with water suppression). 
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 Figure S5. 1H NMR spectrum of hortiamine (2). Expansion of the region 7.0–8.5 ppm.  
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 Figure S6. 1H NMR spectrum of hortiamine (2). Expansion of the region 3.0–5.0 ppm. Water suppression caused decreased signal 
intensities for δH 4.58 (H-7) and δH 4.42 (14-NCH3).   
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 Figure S7. DEPT NMR spectrum of hortiamine (2) in MeOH-d4. 
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Additional information on processed Evodia-containing TCM products 
 
 
“Wu zhu yu”  
Supplier: This product was purchased through the Internet.  
Manufacture: Guangdong Yifang Pharmaceutical Co., Ltd., China  
Lot no.: 0908053 
Recommended daily dose: 0.5 g of the granule (equivalent to 3 g of crude herbal drug) twice a 
day 
Ingredient: Evodiae fructus  
 
 
 
“Wu zhu yu zhi”  
Supplier: Plantasia, Oberndorf, Austria 
Manufacture: Tianjiang Pharmaceutical Co., Ltd., China 
Lot no.: 0710519 
Recommended daily dose: no information given  
Ingredient: Evodiae fructus (prepared) 
 
 
 
“Wu zhu yu tang”  
Supplier: Euroherbs BV, EZ Westervoort, The Netherlands 
Manufacture: Kaiser Pharmaceutical 
Lot no.: 423756 
Recommended daily dose: no information given  
Contents per 100 g:  Zingiberis rhizoma recens  33 
   Evodiae fructus   28 
   Jujubae fructus    22 
   Ginseng radix et rhizoma   17 
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“Wen Jing Tang”  
Supplier: Euroherbs BV, EZ Westervoort, The Netherlands 
Manufacture: Kaiser Pharmaceutical 
Lot no.: 433556 
Recommended daily dose: no information given  
Contents per 100 g:  Pinelliae rhizoma   13 
   Ophiopogonis radix   13 
   Evodiae fructus   10 
   Zingiberis rhizoma recens  10 
   Angelicae sinensis radix    7 
   Cnidii fructus       7 
   Paeoniae radix alba     7 
   Ginseng radix et rhizoma    7 
   Cinnamomi ramulus      7 
   Moutan cortex     7 
   Glycyrrhizae radix et rhizoma   6 
   Asini corii colla      6 
 
 
 
“Si Shen Wan”  
Supplier: Eagle Herbs, Santa Monica, CA, USA  
Manufacture: no information given 
Lot no.: no information given 
Recommended daily dose: ½‒1 teaspoon of the granule, up to three times daily 
Ingredients:  Psoraleae fructus 
Myristicae semen 
Schisandrae chinensis fructus  
Evodiae fructus 
Jujubae fructus  
Zingiberis rhizoma recens  
Chebulae fructus 
(quantities of ingredients are not listed) 
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Quantitative determination of DHE  
Intra-day precision (repeatability) and inter-day precision (between-day precision) were 
assessed with calibration samples (Cal), quality control samples (QC), and two Evodia extract 
samples. The intra- and inter-series imprecisions (expressed as CV %) were calculated for 
each level (Cal, QC, and extract sample) as follows: CV % = 100 x (standard deviation / mean 
measured concentration). 
 
1. Intra-day imprecision 
Compound: DHE 
Units:   µg/mL 
Matrix:  DMSO 
 
      
 
Cal1 QC1 QC2 QC3 Cal5 
Theoretical concentration 10.0 µg/mL 20.0 µg/mL 100 µg/mL 160 µg/mL 200 µg/mL 
Run number Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
1 6.93 18.2 104 163 196 
  7.17 18.2 104 162 197 
Intra-run Mean 7.05 18.2 104 163 196 
Intra-run S.D. 0.17 0.06 0.18 0.18 0.64 
Intra-run CV % 2.44 0.32 0.17 0.11 0.33 
 
The intra-day imprecision was between 0.11% and 2.44%.  
 
  
132
2. Inter-day imprecision 
Compound: DHE 
Units:   µg/mL 
Matrix:  DMSO 
 
      
 
Cal1 QC1 QC2 QC3 Cal5 
Theoretical concentration 10.0 µg/mL 20.0 µg/mL 100 µg/mL 160 µg/mL 200 µg/mL 
Run number Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
1 6.93 18.2 104 163 196 
  7.17 18.2 104 162 197 
Mean 7.05 18.2 104 163 196 
S.D. 0.17 0.06 0.18 0.18 0.64 
CV % 2.44 0.32 0.17 0.11 0.33 
Run number Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
2 7.25 18.5 104 161 198 
  7.37 18.2 104 162 195 
Mean 7.31 18.4 104 161 196 
S.D. 0.08 0.18 0.09 0.65 1.75 
CV % 1.15 0.99 0.09 0.40 0.89 
Run number Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
Measured 
conc. 
3 7.39 18.5 * 61 158 195 
  7.35 17.7 104 * 94 197 
Mean 7.37 18.1 83 126 196 
S.D. 0.03 0.61 30.05 45.00 1.57 
CV % 0.41 3.35 36.36 35.79 0.80 
Inter-run Mean 7.24 18.2 97 150 196 
Inter-run S.D. 0.10 0.28 10.11 15.28 1.32 
Inter-run CV % 1.33 1.55 12.21 12.10 0.67 
      * LC injection issue, values used for calculations 
 
The inter-day imprecision was between 0.67% and 12.21%.  
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3. Evodia extract samples 
Compound: DHE 
Units:   µg/mL 
Matrix:  Methanolic extracts were dissolved in DMSO at a concentration of 3.5 mg/mL.  
 
   
 
Extract 1 a Extract 2 b 
Run number Measured conc. Measured conc. 
1 135 87 
  135 86 
Mean 135 86 
S.D. 0.25 0.55 
CV % 0.18 0.64 
Run number Measured conc. Measured conc. 
2 131 88 
  130 89 
Mean 130 88 
S.D. 0.66 0.66 
CV % 0.51 0.75 
Run number Measured conc. Measured conc. 
3 137 84 
  133 85 
Mean 135 84 
S.D. 2.95 0.79 
CV % 2.18 0.94 
Inter-run Mean 133 86 
Inter-run S.D. 1.29 0.67 
Inter-run CV % 0.96 0.77 
 
a Dried E. rutaecarpa fruits were from Lian Chinaherb AG (Wollerau, Switzerland).  
b Dried E. rutaecarpa fruits were from Complemedis AG (Trimbach, Switzerland).  
 
For both Evodia extract samples, the inter-day imprecision was between 0.77% and 0.96%.  
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3.5. Phytochemical profiling of Curcuma kwangsiensis rhizome extract, and 
identification of labdane diterpenoids as positive GABAA receptor 
modulators  
 
Schramm A, Ebrahimi SN, Raith M, Zaugg J, Rueda DC, Hering S, Hamburger M. 
Phytochemistry 2013; 96: 318–329 
 
 
 
Labdane diterpenoids from Curcuma kwangsiensis rhizomes were identified as positive 
α1β2γ2S GABAA receptor modulators with the aid of HPLC-based activity profiling. Eleven 
compounds, including four new natural products, were obtained. Structures were elucidated 
by high resolution mass spectrometry and microprobe NMR. The absolute configuration of 
diterpenoids was assigned by ECD. Modulation of the GABA-induced chloride current was 
assessed in a functional assay on Xenopus oocytes. The highest efficiency was observed for 
zerumin A.  
 
 
 
 
Extraction of plant material, HPLC microfractionation, isolation of compounds, recording 
and interpretation of analytical data for structure elucidation (LC-PDA-ESI-TOF-MS, 
microprobe NMR, optical rotation), electrophysiological studies on pure compounds 
(preparation of Xenopus oocytes, two-microelectrode voltage-clamp measurements, data 
analysis), writing the draft of the manuscript, and preparation of figures (except for Fig. 5, 
7, and 8) were my contributions to this publication.  
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Electronic circular dichroism (ECD)a b s t r a c t
An ethyl acetate extract of Curcuma kwangsiensis S.G. Lee & C.F. Liang (Zingiberaceae) rhizomes (100 lg/
ml) enhanced the GABA-induced chloride current (IGABA) through GABAA receptors of the a1b2c2S subtype
by 79.0 ± 7.0%. Potentiation of IGABA was measured using the two-microelectrode voltage-clamp tech-
nique and Xenopus laevis oocytes. HPLC-based activity profiling of the crude extract led to the identifica-
tion of 11 structurally related labdane diterpenoids, including four new compounds. Structure elucidation
was achieved by comprehensive analysis of on-line (LC-PDA-ESI-TOF-MS) and off-line (microprobe 1D
and 2D NMR) spectroscopic data. The absolute configuration of the compounds was established by com-
parison of experimental and calculated ECD spectra. Labdane diterpenes represent a new class of plant
secondary metabolites eliciting positive GABAA receptor modulation. The highest efficiency was observed
for zerumin A (maximum potentiation of IGABA by 309.4 ± 35.6%, and EC50 of 24.9 ± 8.8 lM).
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Worldwide, anxiety and sleep difficulties, especially insomnia,
are common and highly prevalent healthcare problems (Ringdahl
et al., 2004; Uhde et al., 2009). A crucial target for anxiolytics, sed-
atives, hypnotics, anticonvulsants, and muscle relaxants is the
gamma-aminobutyric acid type A (GABAA) receptor, a ligand-gated
ion channel that mediates inhibitory neurotransmission in the cen-
tral nervous system (CNS). The GABAA receptor has a heteropenta-
meric structure and can be assembled from 19 different subunits
(a1–6, b1–3, c1–3, d, e, p, q1–3, and h). The most abundant GABAA
receptor in the mammalian brain consists of two a1, two b2, and
one c2S subunits (Olsen and Sieghart, 2008). Despite the broad
range of drugs that are clinically in use to treat anxiety and sleep
disorders, there is an increasing demand for herbal preparationswith such properties. Herbal products have become increasingly
important during the last decades, owing to positive consumer
acceptance (Biesalski, 2002). In addition to synthetic drug candi-
dates, a wide range of plant-derived natural products have been
shown to modulate the function of GABAA receptors (Johnston
et al., 2006). Given the continued importance of natural products
in drug discovery and development (Newman and Cragg, 2012),
plant-derived compounds may provide inspiration for new scaf-
folds of GABAA receptor modulators.
In the search for positive GABAA receptor modulators of natural
origin, we screened an in-house plant extract library, comprising
major officinal herbal drugs of the European and Chinese Pharma-
copoeias, for the ability to potentiate GABA-induced chloride
currents. Extracts were tested with an automated two-microelec-
trode voltage clamp assay in Xenopus laevis oocytes expressing re-
combinant a1b2c2S GABAA receptors, at a concentration of 100 lg/
ml. A previously validated HPLC profiling protocol for the discovery
of new GABAA receptor modulating natural products was applied
to identify the active constituents (Kim et al., 2008). Using this
approach, we successfully identified various plant secondary
metabolites including alkaloids (Zaugg et al., 2010), lignans (Zaugg
et al., 2011a), terpenes (Zaugg et al., 2011b,d), coumarins (Zaugg
Fig. 1. Activity profiling of C. kwangsiensis rhizome extract for GABAA receptor
modulating activity. (A) HPLC chromatogram (254 nm) of a semi-preparative
separation of 5 mg extract. (B) Activity profile of collected peak-based microfrac-
tions a–r tested for IGABA modulation. Peak labeling in the HPLC chromatogram
refers to the isolated compounds 1–11.
A. Schramm et al. / Phytochemistry 96 (2013) 318–329 319et al., 2011c), sanggenons (Kim et al., 2012), and flavonoids (Yang
et al., 2011) as positive GABAA receptor modulators.
In the course of our in vitro screening, an ethyl acetate extract
from rhizomes of Curcuma kwangsiensis S.G. Lee & C.F. Liang (Zing-
iberaceae) displayed positive GABAA receptor modulation. While
the activity was only moderate, the extract was selected for further
investigation based on chemotaxonomic considerations and the
fact that none of the typical metabolites of the genus Curcuma
was reported to exhibit GABAA receptor modulating activity. Cur-
cumae rhizoma (Ezhu) is the dried rhizome of C. kwangsiensis
S.G. Lee & C.F. Liang, C. wenyujin Y.H. Chen & C. Ling, or C. phaeocau-
lis Val., and belongs to the best known herbs in traditional Chinese
medicine (TCM). Ezhu is widely used as a digestive and analgesic
agent, and also for the treatment of menstrual disorders (Chinese
Pharmacopoeia Commission, 2010; Tang and Eisenbrand, 2011).
The genus Curcuma counts approximately 100 species, among
which only about one fifth have been studied extensively from a
phytochemical viewpoint. Known compounds from Curcuma spe-
cies belong to three major classes of plant secondary metabolites,
including diphenylalkanoids, phenylpropanoids, and terpenoids
(Nahar and Sarker, 2007). The phytochemistry of C. kwangsiensis
is poorly studied compared to other Curcuma species. The rhizome
is known to contain a number of structurally related diarylhepta-
noids (Li et al., 2011, 2010), and various mono- and sesquiterpenes
which are the main components of the essential oil (Zeng et al.,
2009).
We here describe the identification of GABAA receptor modulat-
ing labdane diterpenes via an HPLC-based discovery platform,
along with the structure elucidation and in vitro pharmacological
evaluation of the isolated compounds. The absolute configuration
of the diterpenoids was established by comparing experimental
and TDDFT simulated electronic circular dichroism (ECD) spectra.2. Results and discussion
2.1. Isolation and structure elucidation
In a screening for new GABAA receptor modulators, an ethyl
acetate extract from C. kwangsiensis rhizomes enhanced IGABA by
79.0 ± 7.0% when tested at 100 lg/ml. To track the active principles
responsible for positive GABAA receptor modulation, the extract
was submitted to a process referred to as HPLC-based activity
profiling. This approach combines physicochemical data recorded
on-line with biological information obtained in parallel from
time-based microfractionation (Potterat and Hamburger, 2006).
An aliquot of the extract (5 mg) was separated by semi-preparative
RP-HPLC, and collected peak-based microfractions were retested in
the oocyte assay. Fig. 1 shows the active time window of the HPLC
chromatogram (254 nm) and the activity of peak-based microfrac-
tions a–r. The activity was dispersed over a broad time window,
suggesting that the activity of the extract was due to several re-
lated compounds. The highest activity was found in microfraction
k (potentiation of IGABA by 164.7 ± 47.6%), while other microfrac-
tions were less or only marginally active. By means of LC-PDA-
ESI-TOF-MS analysis of the extract, in combination with off-line
NMR data recorded after peak-based collection, the compound
eluting at 42.5 min was readily identified as coronarin D (6), a lab-
dane diterpene previously reported from Hedychium coronarium
(Itokawa et al., 1988). Several HPLC peaks in the active time win-
dow exhibited UV and MS spectra similar to those of 6, indicating
structurally related compounds. Targeted preparative purification
by a combination of flash chromatography on silica gel and semi-
preparative RP-HPLC afforded a series of 11 labdane diterpenes
(1–11) (Fig. 2), including four new natural products (2, 4, 9, and
11). Structure elucidation was achieved by comprehensive analysis138of on-line (LC-PDA-ESI-TOF-MS) and off-line (microprobe 1D and
2D NMR) spectroscopic data, and comparison with literature data.
The relative configuration of compounds was established by
NOESY and NOE difference experiments, while the absolute config-
uration was determined by comparison of experimental and calcu-
lated ECD spectra.
The 1H and 13C NMR data of compound 1 (Tables 1 and 2) were
in agreement with the data published for curcuminol D, a diter-
pene isolated from Curcuma wenyujin (Zhang et al., 2008) and
Curcuma zedoaria (Park et al., 2012). However, the relative config-
uration of curcuminol D was established only for the decalin ring
system, whereas the configuration at C-15 remained undefined.
We here report the unequivocal determination of the relative
and absolute configuration of compound 1 based on NMR spectral
assignments and ECD spectroscopy. Assignment of the relative
configuration of the trans-decalin system was supported by NOESY
correlation between H-5 and H-9, and between CH3-20 and H-2b.
Hence, H-5, H-9, and CH3-20 were in an axial position, indicative
for two possible absolute configurations of the decalin ring system
(5R,9R,10R or 5S,9S,10S). In addition, 1D NOE difference experi-
ments were performed to assign the relative configuration at C-
15 (Fig. 3). Presaturation of H-15 resulted in the enhancement of
H-14a, H-16a, and H-16b. Irradiation of H-14b enhanced H-14a,
H-9, and H-16a, while no enhancement of H-15 was observed. A
selective 1D TOCSY experiment was used to unambiguously deter-
mine the multiplicities of H-14a, H-14b, H-16a, and H-16b (Ta-
ble 1). Excitation of H-15 unraveled H-14b as a doublet of
doublet with coupling constants J = 13.7, and 12.6 Hz, indicative
for the trans-orientation of both protons. Consequently, the hydro-
xyl group at C-15 had to be in a-orientation. This was further cor-
roborated by the vicinal coupling constants between H-14a/H-15
(3JH–H = 4.1 Hz), H-16a/H-15 (3JH–H = <4.0 Hz), and H-16b/H-15
(3JH–H = 3.1 Hz) which corresponded to dihedral angles of approx.
50, 50–60, and 60, respectively.
In order to establish the absolute configuration of 1, ECD spectra
were calculated for two stereoisomers (5S,9S,10S,15S and
5S,9S,10S,15R). Conformational analysis using OPLS 2005 molecu-
lar mechanic force field in H2O revealed nine and eight conformers,
Fig. 2. Structures of compounds 1–11.
Table 1
1H NMR spectroscopic data for compounds 1, 2, 4, and 4a (500 MHz, d in ppm, J in Hz).
Position 1 (CDCl3) 2 (CDCl3) 2 (C6D6) 4 (CDCl3) 4a (C6D6)
1a 0.95, ddd (13.3, 13.3, 3.5) 0.99, ddd (12.9, 12.9, 3.5) 0.73, ddd (12.9, 12.9, 3.0) 1.06, ddd (12.8, 12.8, 3.1) 0.85a
1b 1.84, br d (13.6) 1.88, br d (12.6) 1.58, br d (12.6) 1.67a 1.51a
2a 1.47, m 1.50, m 1.37a 1.50, m 1.36a
2b 1.54, m 1.56, m 1.45, m 1.55, m 1.46a
3a 1.14, ddd (13.3, 13.3, 2.4) 1.18, ddd (13.2, 13.2, 3.1) 1.09, ddd (13.4, 13.4, 3.3) 1.18, ddd (13.2, 13.2, 3.5) 1.08, ddd (13.3, 13.3, 3.7)
3b 1.40, br d (13.3) 1.44, br d (13.2) 1.36a 1.39, br d (13.2) 1.31a
4
5 1.29, dd (12.0, 4.1) 1.30, dd (12.1, 4.3) 1.15, dd (12.0, 4.4) 1.11, dd (12.5, 2.1) 0.91, dd (12.6, 2.8)
6a 2.12a 2.12a 1.94, br d (17.7) 1.72a 1.55a
6b 1.91, br d (13.9) 1.93, br d (13.6) 1.75, dd (17.7, 12.0) 1.32, dddd (12.9, 12.9, 12.9, 4.1) 1.20, dddd (12.6, 12.6, 12.6, 4.3)
7a 5.62, br s 5.65, br s 5.56, br s 2.01, ddd (12.7, 12.7, 4.5) 1.86, ddd (12.9, 12.9, 5.1)
7b 2.38a 2.27a
8
9 2.51, br d (12.5) 2.47a 2.28a 1.87, br d (10.4) 1.69, br d (10.7)
10
11a 2.76, dd (19.7, 4.9) 2.64, dd (18.7, 6.2) 2.28a 2.40a 2.28a
11b 2.26a 2.16a 1.84, m 2.24, m 2.16a
12 6.76, br s 7.27, dd (6.2, 6.2) 7.31, dd (6.1, 6.1) 7.03, dd (6.4, 6.4) 7.10, dd (6.2, 6.2)
13
14a 3.06, dd (12.6, 4.1) 3.00, dd (13.6, 4.9) 3.20, dd (13.8, 4.4) 3.36, m 3.43, m
14b 2.22, dd (12.6, 13.7)b 2.47a 2.49, dd (14.1, 13.1)
15 3.68, m 3.85, m 3.91, m
16a 2.36, br d (14.2) 2.49a 2.39, br d (13.9)
16b 2.06, dd (14.2, 3.1)b 2.09a 2.05, dd (13.9, 4.7)
17a 9.29, s 4.82, br s 4.86, d (1.0)
17b 4.38, br s 4.53, d (1.0)
18 0.85, s 0.89, s 0.83a 0.87, s 0.81, s
19 0.87, s 0.91, s 0.83a 0.81, s 0.75, s
20 0.75, s 0.79, s 0.66, s 0.71, s 0.65, s
15-OCH3 3.37, s
16-OCH3 3.39, s
a Multiplicities of overlapped signals are omitted.
b Signals were resolved by 1D selective TOCSY experiment.
320 A. Schramm et al. / Phytochemistry 96 (2013) 318–329respectively, within a 2 kcal/mol energy window from the particu-
lar global minimum. These conformers were subjected to geomet-
rical optimization and energy calculation using density function
theory (DFT) with B3LYP using the 6-31G⁄⁄ basis set in the gas
phase. Vibrational frequency calculations were carried out to con-
firm these minima. No imaginary frequencies were found. Confor-
mational analysis using relative free energies indicated the
presence of five and four stable conformers for 5S,9S,10S,15S and
5S,9S,10S,15R stereoisomers, respectively. The four low-energy13structures of the 5S,9S,10S,15R stereoisomer are represented in
Fig. S34 of the Supplementary data. The experimental ECD spec-
trum of 1 showed three negative cotton effects (CEs) at around
320, 240, and 210 nm (Fig. 5). The calculated ECD spectrum of
the 5S,9S,10S,15R stereoisomer showed good agreement with the
overall pattern of the experimental ECD spectrum. The negative
CE around 320 nm was due to the n?p⁄ transition of the a,b-
unsaturated aldehyde, and the CE around 240 nm to a p?p⁄ tran-
sition. The difference between calculated and experimental spectra9
Table 2
13C NMR spectroscopic data for compounds 1, 2, 4, and 4a (125 MHz, d in ppm).
Position 1a (CDCl3) 2 (CDCl3) 2a (C6D6) 4 (CDCl3) 4aa (C6D6)
1 39.5 39.7 39.4 39.4 38.9
2 18.8 19.1 18.9 19.5 19.3
3 42.0 42.2 42.1 42.2 42.1
4 33.0 32.7 32.8 33.8 33.4
5 50.0 50.4 50.3 55.5 55.1
6 24.2 24.4 24.1 24.3 24.1
7 128.4 128.9 128.1 38.0 37.9
8 131.9 132.9 133.0 148.2 147.4
9 51.5 51.2 nd 56.5 56.3
10 36.5 36.7 36.3 39.7 39.4
11 30.7 30.6 29.5 24.6 24.1
12 157.6 147.6 146.6 150.5 146.5
13 138.9 127.2 127.5 124.3 125.3
14 29.6 32.6 33.0 32.6 32.5
15 69.7 70.4 70.8 177.6 170.6
16 41.1 41.0 42.1 172.7 166.9
17 194.6 173.7 173.1 108.2 107.8
18 33.2 33.3 33.2 33.8 33.4
19 21.7 22.0 21.9 22.0 21.8
20 13.1 13.2 13.6 14.6 14.2
15-OCH3 51.1
16-OCH3 51.1
nd: not detected.
a 13C shifts deduced from HSQC and HMBC experiments.
Fig. 4. Geometrically optimized 3D structure of the most stable conformer of
5S,9S,10S,15R-()-curcuminol H (2). Key NOESY correlations for corroborating the
configuration at C-15 are indicated with arrows.
A. Schramm et al. / Phytochemistry 96 (2013) 318–329 321may have resulted from an overestimation of the UV absorbance in
the calculations, or from minor differences between calculated and
solution conformers (Zaugg et al., 2011a). The calculated ECD spec-
trum of the 5S,9S,10S,15S stereoisomer (Fig. 5) was clearly different
from the experimental data, with two positive CEs at around 300
and 250 nm, and one negative CE at around 230 nm. Thus, we con-
clude that the absolute configuration of compound 1 is
5S,9S,10S,15R.
The molecular formula of compound 2 was established as
C20H30O3 from the pseudomolecular ion peak at m/z 341.2080
[M+Na]+ in the HR-ESI-TOF-MS spectrum. The UV spectrum
showed an absorption maximum at 217 nm and was similar to that
of 1 (kmax 219 nm). Analysis of the 1H NMR data (Table 1) showed
strong similarities with 1, except for the downfield shift of H-12
(dH 7.27, dd, J = 6.2, 6.2 Hz in 2; dH 6.76, br s in 1) and the absence
of an aldehyde proton (dH 9.29, s, H-17 in 1). The COSY and HMBC
correlations were in agreement with those observed for 1 and con-
firmed the presence of an uncommon 6/6/8 carbon ring skeleton.
Remarkable differences in the 13C NMR shifts (Table 2) were ob-
served for C-12 (dC 147.6 in 2; dC 157.6 in 1), C-13 (dC 127.2 in 2;
dC 138.9 in 1), and C-17 (dC 173.7 in 2; dC 194.6 in 1). The carbon
signal at dC 173.7 was assigned to a carboxylic group which caused
a shielding of C-12 and C-13. Thus, the planar structure of 2 dif-
fered from 1 in the oxidation state of C-17. The relative configura-
tion of 2was established with the aid of 3J NMR coupling constantsFig. 3. The most predominant conformers of two possible stereoisomers, 5S,9S,10S,15S
derived from vicinal coupling constants and key NOE correlations (indicated with arrow
140in the 1H NMR spectrum, and by NOESY correlations. Measure-
ments were performed in the anisotropic solvent benzene-d6 to re-
solve overlapping signals appearing in CDCl3 (Table 1). The
observed vicinal coupling constants and estimated dihedral angles
were comparable with those observed for compound 1. Fig. 4
shows the 3D optimized structure of the most stable conformer
of the 5S,9S,10S,15R stereoisomer and key NOESY correlations. H-
15 showed NOESY cross-peaks with H-16a, H-16b, and H-14a,
but not with H-14b. Hence, the hydroxyl group at C-15 was also
in a-position, and the relative configuration of 2 is identical with
that of 1.
The absolute configuration of 2was investigated by comparison
of experimental and calculated ECD spectra. Conformational anal-
ysis, geometry optimization, and calculation of ECD spectra of the
conformers were performed as described above. Conformational
analysis of the 5S,9S,10S,15S and 5S,9S,10S,15R stereoisomers re-
vealed 15 and 17 conformers, respectively, within a 2 kcal/mol en-
ergy window from the particular global minimum. Conformational
analysis using relative free energies indicated the presence of six
and eight stable conformers, respectively. The eight low-energy
structures of the 5S,9S,10S,15R stereoisomer are represented in
Fig. S36 of the Supplementary data. The conformers exhibited dif-
ferences with respect to the orientation of the carboxylic acid moi-
ety and the hydroxyl group. For the 5S,9S,10S,15R stereoisomer, the
ECD spectrum showed two negative CEs around 240 and 210 nm
(Fig. 5). The negative CE at around 240 nm was likely due to a
p?p⁄ transition of the a,b-unsaturated acid chromophore. There
was excellent agreement of the overall patterns of the calculated
and experimental ECD spectra. In contrast, the ECD spectrum cal-
culated for the 5S,9S,10S,15S stereoisomer significantly differed(left) and 5S,9S,10S,15R (right), of ()-curcuminol D (1). The structural information
s) were in accord only with the 5S,9S,10S,15R stereoisomer.
Fig. 5. Comparison of experimental and calculated ECD spectra of 1 (left) and 2 (right). The calculations were performed with TDDFT at the B3LYP/6–31G⁄⁄ level with MeCN
as solvent.
Fig. 6. Structure of dimethyl-(E)-labda-8(17),12-diene-15,16-dioate (4a) with key
HMBC and NOESY correlations.
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at around 240 and 215 nm, respectively. The 5S,9S,10S,15R config-
uration of 2 is further supported by the obvious biogenetic
relationship between 1 and 2. We propose to name the new com-
pound 2 as ()-curcuminol H.
For compound 3, a molecular formula of C20H30O3 was calcu-
lated from its HR-ESI-TOF-MS spectrum. On the basis of spectro-
scopic data, including 1D and 2D NMR data, optical rotation, and
UV absorption maximum, compound 3 was identified as zerumin
A. This diterpenoid has been reported from the seeds of Alpinia
zerumbet (Xu et al., 1996). The relative configuration of 3 was con-
firmed by NOESY data.
Compound 4 has a molecular formula of C20H30O4, as calculated
from the pseudomolecular ion peak at m/z 357.2048 [M+Na]+ in
the HR-ESI-TOF-MS spectrum. Comparison of 1H and 13C NMR
spectra of 4 (Tables 1 and 2) with those of 3 (Table S1 of the Sup-
plementary data) revealed that both compounds were closely re-
lated. Differences were observed for the signals of the side chains
of 3 and 4. The olefinic proton at C-12 in 4 (dH 7.03, dd, J = 6.4,
6.4 Hz) was shifted downfield compared to 3 (dH 6.60, dd, J = 6.0,
6.0 Hz), while the signal of the aldehyde proton (dH 9.29, s, H-16)
in 3 was absent in the 1H NMR spectrum of 4. The 13C signal as-
signed to C-16 (dC 194.1 in 3; dC 172.7 in 4) indicated the presence
of a second carboxylic group in 4. Thus, compound 4was the diacid
congener of zerumin A (3). While for compound 3 the E-geometry
of the double bond of the side chain was verified by HMBC and
NOESY correlations, no unambiguous assignment was possible
for 4 on the basis of both NOESY and NOE difference experiments.
The labdadienedioic acid 4 was previously semi-synthetically ob-
tained as a 3:2 mixture of E/Z isomers, but unfortunately no at-
tempts were made to assign the NMR resonances of the two
isomers (González et al., 2010). The geometry of the double bond
was established with the aid of the dimethyl ester derivative 4a
(Tables 1 and 2, and Fig. 6). The HMBC spectrum confirmed that
the methoxy groups at dH 3.37 and dH 3.39 were located at C-15
and C-16, respectively. The NOESY spectrum showed a diagnostic
cross-peak between H-12/16-OCH3, and indicated a spatial prox-
imity of H-14, H-11a, and H-11b. Hence, the E-configuration of
the double bond between C-12/C-13 was established, which is in
accord with the configuration of the related aldehyde 3.
The ECD spectrum of 4 (Fig. 7B) showed a positive CE around
218 nm and two negative CEs at around 200 and 250 nm. The po-
sitive CE at 218 nm was probably due to a p?p⁄ transition of the
a,b-unsaturated acid moiety, whereas the negative CE at 200 nm
was attributed to a p?p⁄ transition of the olefinic group. A molec-
ular model of 4 was built based on the relative configuration
represented in Fig. 7A, and the 3D structure subjected to14conformational analysis and geometry optimization as described
above. For the 5S,9S,10S stereoisomer, the DFT energy minimized
at B3LYP/6-31G⁄⁄ level of theory yielded 26 relevant conformers
within a 2 kcal/mol range from the global minimum. The conform-
ers could be divided into three core conformers which differed in
the orientation of the side chain. Minor differences of superim-
posed conformers resulted from free rotation of the C-15 carbox-
ylic group (Fig. 7A). The calculated ECD spectrum exhibited two
positive CEs at around 210 and 240 nm, along with a negative CE
at around 200 nm, and was in excellent agreement with the
experimental ECD spectrum (Fig. 7B). The differences between cal-
culated and experimental spectra were likely due to minor confor-
mational differences in solution. Thus, we conclude that the
absolute configuration of compound 4 is 5S,9S,10S. Compounds 4
and 3 differ only in the degree of oxidation at C-16. The experimen-
tal ECD spectra for both compounds were similar (Fig. 7B). The
slight blue shift of the ECD spectrum of 4 could be explained with
the chromophore group at C-16, changing from an a,b-unsaturated
aldehyde in 3 to an a,b-unsaturated carboxylic acid in 4. The sim-
ilarity of the ECD spectra led to the conclusion that the absolute
configuration of 3 is also 5S,9S,10S.
The known labdane diterpenes 5–7 were identified from their
HR-ESI-TOF-MS, 1D and 2D NMR data as (E)-16-hydroxylabda-
8(17),11,13-trien-15,16-olide (Margaros and Vassilikogiannakis,
2007; Mohamad et al., 2005), coronarin D (Itokawa et al., 1988),
and (E)-15-hydroxylabda-8(17),11,13-trien-16,15-olide (Margaros
and Vassilikogiannakis, 2007; Sy and Brown, 1997), respectively.
These compounds contain a cyclic hemiacetal moiety which is1
Fig. 7. (A) Superimposed lowest energy conformers (within a 2 kcal/mol range from the global minimum) of 4. Compound 4 showed three core conformers which differed in
the orientation of the side chain, whereby c1–26 refers to the 26 conformers. (B) Comparison of experimental spectra of compounds 3 and 4, with the calculated ECD
spectrum of 4. The calculation was performed with TDDFT at the B3LYP/6–31G⁄⁄ level with MeCN as solvent. Comparison of 3 and 4 was justified by the close structural
relationship of the compounds.
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ration of these compounds further.
Compound 8 was identified as (E)-labda-8(17),11,13-trien-
16,15-olide from its UV, optical rotation, HR-ESI-TOF-MS, and
NMR spectroscopic data, which were in good agreement with those
reported in the literature (Nakatani et al., 1994). Analysis of vicinal
coupling constants and NOESY experiments confirmed the relative
configuration as established. Since CD data and absolute configura-
tion have not been reported so far, we submitted compound 8 to
ECD analysis. The experimental ECD spectrum of compound 8
showed a negative CE around 205 nm and a positive CE at
219 nm (Fig. 8B). The positive CE at 219 nm was due to a p?p⁄
transition of the diene group. Conformational analysis of the 3D
model of the 5S,9S,10S stereoisomer and energy minimization re-
vealed two stable conformers (Fig. 8A) which differed in the orien-
tation of the lactone ring. The simulated ECD spectrum showed a
negative CE around 205 nm along with a positive CE around
220 nm. The excellent agreement between simulated and experi-
mental ECD spectra established the absolute configuration of com-
pound 8 as 5S,9S,10S.
The HR-ESI-TOF-MS data of compound 9 revealed a molecular
formula of C20H30O2 (found m/z 325.2155 [M+Na]+), implying six
degrees of unsaturation. The HSQC and HMBC spectra confirmed
the presence of five quaternary carbons, four methine, eight meth-
ylene, and three methyl groups. The signal patterns and shift val-
ues of the carbon and proton signals (Table 3) were similar to
those of 4. The 1H NMR spectrum showed three characteristic
downfield-shifted protons, namely an olefinic proton at dH 6.48
(dd, J = 17.7, 11.7 Hz, H-14) and two olefinic methylene protons142at dH 5.63 (dd, J = 17.7, 1.3 Hz, H-15a) and dH 5.41 (br d,
J = 11.7 Hz, H-15b), indicating the presence of a terminal double
bond. The most deshielded carbon signal at dC 172.6 (C-16) was
attributed to a carboxlic acid. The observed long-range HMBC cor-
relations between C-16 and the olefinic protons H-12 (3J) and H-14
(3J) revealed that, when compared to 4, the additional double bond
was located at C-14/C-15. Diagnostic NOESY contacts between H-9
and H-12, as well as between H-14 and both H-11a and H-11b,
indicated an E-configured double bond between C-12/C-13. Thus,
the structure of the new labdane diterpenoid 9 was established
as (E)-labda-8(17),12,14-trien-16-oic acid. Since 9 could only be
purified up to 90% (1H NMR), optical rotation and CD data were
not determined. On-line LC-PDA-ESI-TOF-MS analysis revealed
the presence of a co-eluting impurity with a pseudomolecular
ion peak at m/z 327.2305 [M+Na]+, corresponding to the molecular
formula C20H32O2. Compound 10 co-eluted with 9 and could only
be obtained as a mixture of 9 and 10 in a ratio of 64:36 (1H
NMR). The 13C NMR spectrum of this mixture showed virtually
duplicated carbon signals which could be readily assigned to both
compounds according to their distinct signal intensities. By com-
prehensive analysis of HR-ESI-TOF-MS and 1D and 2D NMR data,
and comparison with published data, compound 10 was identified
as calcaratarin B (Kong et al., 2000).
For compound 11, the HR-ESI-TOF-MS data revealed a molecu-
lar formula of C20H28O2 (found m/z 323.1979 [M+Na]+), accounting
for seven degrees of unsaturation. Both the 1H NMR data and ob-
served COSY correlations indicated that the structure of 11 was
closely related to that of 8. Notable differences were in the pres-
ence of a methyl group (dH 1.49, dC 22.4, C-17) and an olefinic
Fig. 8. (A) Low-energy conformers (within a 2 kcal/mol range from the global
minimum) of 8. Compound 8 showed two stable conformers. The predominance of
conformer 8-a (95.6%) was corroborated by a NOESY correlation between H-12 and
H-14 (data not shown). (B) Comparison of experimental and calculated ECD spectra
of 8. The calculation was performed with TDDFT at the B3LYP/6–31G⁄⁄ level with
MeCN as solvent.
Table 3
1H and 13C NMR spectroscopic data for compounds 9 and 11 (CDCl3, 500 MHz for dH, 125
Position 9
dH (J in Hz) dCa
1a 1.08, ddd (13.0, 13.0, 2.8) 39.3
1b 1.71b
2a 1.51, m 19.3
2b 1.58, m
3a 1.19, ddd (13.3, 13.3, 3.7) 42.0
3b 1.41, br d (13.2)
4 33.5
5 1.13, dd (12.6, 2.5) 55.4
6a 1.72b 24.1
6b 1.33, dddd (12.9, 12.9, 12.9, 4.2)
7a 2.01, ddd (12.9, 12.9, 4.6) 37.9
7b 2.38b
8 148.2
9 1.87, br d (10.4) 56.8
10 38.3
11a 2.52, m 24.6
11b 2.39b
12 6.86, dd (6.7, 6.7) 148.1
13 128.6
14 6.48, dd (17.7, 11.7) 128.8
15a 5.63, dd (17.7, 1.3) 119.8
15b 5.41, br d (11.7)
16 172.4
17a 4.81, s 107.6
17b 4.35, s
18 0.88, s 33.5
19 0.81, s 21.8
20 0.73, s 14.4
a 13C shifts deduced from HSQC and HMBC experiments.
b Multiplicities of overlapped signals are omitted.
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14methine (dH 5.49, dC 122.3, H-7), indicating that the exocyclic dou-
ble bond in 8was replaced in 11 by a methyl group, and the double
bond shifted to C-7/C-8. These findings were confirmed by key
COSY and HMBC correlations (Fig. 9). The relative configuration
was assigned on the basis of NOESY correlations. H-9 showed
cross-peaks with H-1a, H-5, and H-12. The structural similarity
to 8 was further supported by the NOESY correlation between H-
12 and H-14. Thus, the structure of the new labdane diterpenoid
11 was established as (E)-labda-7,11,13-trien-16,15-olide. Since
the compound could only be purified up to 80% (1H NMR), optical
rotation and CD data were not determined.
2.2. GABAA receptor modulation
Modulation of GABA-induced chloride currents (IGABA) were
studied in an automated two-microelectrode voltage-clamp assay
with transfected Xenopus leavis oocytes expressing recombinant
a1b2c2S GABAA receptors. Potentiation of IGABA by diterpenes 1–
11 was initially assessed at 100 lM (Table 4). Zerumin A (3) dis-
played the highest efficiency (324.2 ± 46.2%, n = 6), whereas
replacement of the aldehyde group at C-16 by a carboxylic moiety,
as in 4, resulted in a total loss of activity. The eight-membered ring,
as in 1 and 2, appears unfavorable for IGABA potentiation, since both
compounds showed comparatively low efficiencies. Despite the
close structural relationship of 1–11, further structure–activity
considerations regarding IGABA modulation remain rather specula-
tive at present.
Concentration–response experiments were performed for zeru-
min A (3) and the major labdane diterpene, coronarin D (6). Both
compounds enhanced GABA-induced chloride currents in a con-
centration-dependent manner (Fig. 10A–D). In the absence of
GABA, application of saturating concentrations of 3 and 6
(100 lM) induced only small chloride currents (Fig. 11). The weak
direct agonistic activity on a1b2c2S GABAA receptors henceMHz for dC, d in ppm).
11
dC dH (J in Hz) dCa
39.5 0.98, ddd (13.1, 13.1, 3.6) 40.4
1.57, br d (13.1)
19.5 1.38b 18.7
1.49b
42.3 1.16b 42.3
1.40b
33.8 33.1
55.5 1.19, dd (12.1, 4.6) 49.7
24.3 2.00, m 23.7
1.90, m
38.1 5.49, br s 122.3
148.4 132.5
57.0 2.42, d (10.5) 60.8
39.7 36.4
24.8 6.62, dd (15.8, 10.7) 138.5
148.9 6.10, d (15.8) 120.9
128.8 129.5
129.1 7.13, dd (2.0, 2.0) 141.9
120.3 4.77, br s 69.4
172.6 172.2
108.1 1.49b 22.4
33.8 0.85, s 33.2
22.0 0.88, s 21.8
14.7 0.86, s 14.9
3
Fig. 9. Key COSY and HMBC correlations observed for (E)-labda-7,11,13-trien-
16,15-olide (11).
Table 4
Mean potentiation of IGABA through a1b2c2S GABAA receptors (GABA EC3–10) by
compounds 1–11 (100 lM).
Compound Potentiation of IGABA (%) na
1 54.7 ± 7.8 4
2 2.5 ± 4.8 5
3 324.2 ± 46.2 6
4 12.1 ± 5.9 5
5 209.5 ± 10.4 4
6 199.7 ± 42.0 5
7 116.7 ± 23.0 4
8 53.6 ± 11.7 4
9/10b 68.6 ± 14.6 3
11 81.2 ± 17.2 3
Diazepam (10 lM)c 191.9 ± 9.5 10
a n: number of experiments.
b Inseparable mixture of 9 and 10.
c Positive control.
Fig. 11. Representative currents illustrating weak direct activation of a1b2c2S
GABAA receptors by (A) zerumin A (3) and (B) coronarin D (6). The current
amplitudes induced by a saturating concentration (100 lM) of 3 and 6 did not
exceed the current amplitudes elicited by GABA control samples (EC3–10).
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ing mechanism of action. The observed EC50 values of
24.9 ± 8.8 lM for 3 and 35.7 ± 8.8 lM for 6 (Table 5) are ofFig. 10. Concentration–response curves for IGABA enhancement by (A) zerumin A (3) and
presence of GABA (EC3–10, single bar, control), and during co-application (double bar) of G
144comparable potencies to known plant-derived modulators, such
as piperine (EC50 = 52.4 ± 9.4 lM), zuihonin A (EC50 = 21.8 ± 7.5 -
lM), sandaracopimaric acid (EC50 = 33.3 ± 8.7 lM) (Zaugg et al.,
2010, 2011a, 2011d), or honokiol (EC50 = 36.2 ± 14.7 lM) (Taferner
et al., 2011). However, their efficiencies (309.4 ± 35.6% for 3 and
211.0 ± 26.0% for 6) were not significantly higher than those of
the clinically used benzodiazepines midazolam and triazolam
(maximum potentiation of the GABA-induced chloride current of
342 ± 64% and 253 ± 12%, respectively) (Khom et al., 2006).
To the best of our knowledge, oral biovailability and CNS pene-
tration of labdane diterpenes have not been studied up to now. Gi-
ven the high lipophilicity of these compounds (clogP values of
compounds are given in Table S2 of the Supplementary data),
absorption in the small intestine and passage through the blood–
brain barrier appears possible (Lipinski et al., 1997; Pajouhesh
and Lenz, 2005). Another important attribute is the number of
H-bond acceptors in the compounds, and the ratio of H-bond
acceptors/donors. These physicochemical features are not only rel-
evant for tissue permeability and, thus, bioavailability of a com-
pound (Lipinski et al., 1997), but also for the binding mode of a
molecule to its site of action. Similar to 3, compounds 5, 6, and 7
potentiated IGABA by more than 100%, all containing H-bond accep-
tors/donors in the ratio 3:1. Further investigations are needed to
substantiate the therapeutic potential of labdane diterpenes as(C) coronarin D (6). Representative currents through a1b2c2S GABAA receptors in the
ABA (EC3–10) and different concentrations of compounds 3 (B) and 6 (D) are shown.
Table 5
Summary of potencies (EC50) and efficiencies (maximum potentiation of IGABA) of
compounds 3 and 6.
Compound EC50
(lM)
Max. Potentiation of IGABA
(%)
Hill coefficient
(nH)
na
3 24.9 ± 8.8 309.4 ± 35.6 2.2 ± 1.0 4
6 35.7 ± 8.8 211.0 ± 26.0 1.4 ± 0.3 5
a n: number of experiments.
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tem. Several constituents from the genus Curcuma have been re-
ported to possess pharmacological properties with a possible link
to the GABAergic system. Curcumin showed in vivo effects against
seizures and cognitive impairment (Mehla et al., 2010), as well as
anxiolytic-like activity (Chimakurthy and Talasila, 2010). Very
recently, the anticonvulsant-like effect of bisabolene sesquiterpe-
noids from Curcuma longa rhizome was demonstrated in zebrafish
and mouse models (Orellana-Paucar et al., 2012).
It is noteworthy that the Chinese Pharmacopoeia does not list
any potentially GABA-related indication for Curcumae rhizome
(Ezhu). However, the closely related herbal drug Curcumae radix
(Yujin; dried root tuber of C. kwangsiensis S.G. Lee & C.F. Liang, C.
wenyujin Y.H. Chen & C. Ling, C. phaeocaulis Val., or C. longa L.) is
used, among others, as an anti-epileptic and sedative agent (Chi-
nese Pharmacopoeia Commission, 2010; Tang and Eisenbrand,
2011).3. Conclusions
With the aid of an HPLC-based activity profiling approach, lab-
dane diterpenoids were identified as a new class of plant secondary
metabolites eliciting positive GABAA receptor modulation. From a
phytochemical point of view, this is the first report of diterpenoids
1–11 in the TCM herb C. kwangsiensis. A total of four labdane diter-
penoids were thereby isolated for the first time. Further pharmaco-
logical studies are needed, at least for the most active diterpene
zerumin A (3), to assess its GABAA receptor subtype-selectivity,
binding properties, and possible in vivo effects.4. Experimental
4.1. General experimental procedures
Solvents used for extraction and flash column chromatography
were of analytical grade. HPLC-grade solvents (Scharlau, Barcelona,
Spain) were used for HPLC separations. HPLC-grade water was ob-
tained by an EASY-pure II water purification system. Formic acid
(98.0–100.0%), dimethylsulfoxide (DMSO), and glacial acetic acid
were purchased from Sigma–Aldrich. Flash chromatography was
performed on a Sepacore

chromatography system (Büchi Labor-
technik, Flawil, Switzerland) consisting of two C 605 pump
modules, a C 620 control unit, and a C 660 fraction collector. Pre-
packed silica gel 60 cartridges (40  150 mm, 40–63 lm, Büchi)
were used for all separations. Liquid injection was performed by
means of a 6-way valve with a 20 ml loop. The flow rate was
15 ml/min, and 1 min fractions were collected, unless otherwise
stated. Analytical TLC analysis was carried out with silica gel 60
F254 pre-coated Al sheets (Merck, Darmstadt, Germany). Detection
was at 254 nm, and after spraying with vanillin-sulphuric acid re-
agent and heating for 5–10 min at 110 C. Analytical and semi-pre-
parative HPLC separations were carried out on SunFire C18 columns
(3  150 mm, 3.5 lm and 10  150 mm, 5 lm, respectively) using
H2O + 0.1% formic acid (solvent A) and MeCN + 0.1% formic acid
(solvent B) as mobile phase. HR-ESI-TOF-MS data were recorded
on a micrOTOF ESI-MS spectrometer (Bruker Daltonics) coupled14via a 1:10 splitter to an Agilent 1100 system consisting of an auto-
sampler, degasser, binary pump, column oven, and PDA detector.
Separation was achieved with a gradient of 55% to 80% B in
35 min at a flow rate of 0.5 ml/min. A solution of formic acid
0.1% in 2-propanol/water (1:1) containing 5 mM NaOH was used
for mass calibration. Semi-preparative HPLC was performed on
an Agilent 1100 system consisting of an autosampler, quaternary
pump with degasser module, column thermostat, and PDA detec-
tor. Data acquisition and processing was controlled by HyStar 3.2
software. NMR spectra were recorded in CDCl3 or benzene-d6 on
a Bruker Avance III spectrometer (Bruker Daltonics) operating at
500 MHz and 125 MHz for 1H and 13C, respectively. A 1 mm TXI
microprobe was used for 1D and 2D NMR experiments (1H, NOE
difference, COSY, HSQC, HMBC, 2D-NOESY), whereas 13C spectra
were recorded with a 5 mm BBO-probe. Topspin 2.1 software
was used for spectra analysis and processing. UV spectra were re-
corded on an Agilent 8453 UV–visible spectrophotometer. Optical
rotation was measured with a Perkin Elmer 341 polarimeter using
a 10 cm microcell and CHCl3 as solvent. CD spectra were recorded
in MeCN on an AVIV CD spectrometer (model 62A DS) and ana-
lyzed with AVIV 60DS V4.1 software.
4.2. Plant material
The rhizomes of C. kwangsiensiswere collected by D. Yang in the
area of Guang Xi, China in 2005 and identified by one of the
authors (M.H.). A voucher specimen (nr. 293) has been deposited
at the Division of Pharmaceutical Biology, University of Basel,
Switzerland.
4.3. Extraction
The rhizome material was powdered in a ZM 1 ultracentrifugal
mill (sieve size 2.0 mm; Retsch, Haan, Germany) cooled with liquid
nitrogen. The library extract (ethyl acetate extract) used for screen-
ing and HPLC-based activity profiling was prepared with an
ASE 200 instrument connected to a solvent controller (Dionex,
Sunnyvale, USA). The conditions were as follows: temperature
70 C; pressure 120 bar; three extraction cycles of 5 min each,
11 ml steel cartridges. For compound purification, the powdered
rhizome material (385 g) was percolated exhaustively at room
temperature with ethyl acetate. Solvent evaporation under re-
duced pressure afforded a dark brown viscous residue (3.8 g).
4.4. HPLC-based activity profiling
Microfractionation for activity profiling was performed accord-
ing to a validated protocol (Kim et al., 2008). Briefly, an aliquot
(5 mg) of the crude extract was separated by semi-preparative
RP-HPLC, and peak-based microfractions were collected manually
into glass tubes. A gradient of 30% to 90% B in 60 min was used.
The flow rate was 5 ml/min and 100 ll of extract (50 mg/ml in
DMSO/methanol [1:3 v/v]) were injected. Microfractions were
evaporated with a Genevac EZ-2 Plus vacuum evaporator. For phar-
macological testing, the dried fractions were re-dissolved in 30 ll
of DMSO, and then diluted with 2.97 ml of bath solution containing
GABA EC3–10.
4.5. Isolation
Preliminary separation was performed by flash chromatogra-
phy. A portion of the extract (1 g) was adsorbed to silica gel 60
(40–63 lm, 3 g) and packed into a PrepElut cartridge. This car-
tridge was then connected to the top of the separation cartridge.
A n-hexane/ethyl acetate gradient (100:0 to 0:100 in 4 h, followed
by 0:100 for 30 min) was used for separation. Fractions (15 ml5
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tate [1:1 v/v]) into ten fractions (A–J). Fractions used for compound
isolation were separated by semi-preparative RP-HPLC with differ-
ent gradients of H2O + 0.1% formic acid (solvent A) and
MeCN + 0.1% formic acid (solvent B). The flow rate was set at
4 ml/min. Final purification of fractions G (86.4 mg) and H
(52.0 mg) with a gradient of 50% to 70% B in 25 min afforded 2
(2.2 mg, tR 15.6 min) and 4 (1.8 mg, tR 18.9 min), respectively.
Compound 5 (0.5 mg, tR19.7 min) was isolated from fraction E
(60.7 mg) using a gradient of 60% to 75% B in 30 min. Fractions C
(48.1 mg) and D (68.4 mg) were combined and separated by flash
chromatography on silica gel, using a gradient of chloroform/ethyl
acetate (100:0 to 90:10 in 2 h). Three fractions (CD1–CD3) were
combined on the basis of TLC patterns (chloroform/ethyl acetate
[95:5 v/v]). Separation of fraction CD1 (5.6 mg) with a gradient of
65% to 90% B in 35 min, yielded 8 (2.7 mg, tR 24.1 min) and 11
(0.4 mg, tR 25.7 min), while fraction CD3 (18.0 mg) under the same
conditions afforded 9 and 10 as an inseparable mixture (1.0 mg, tR
23.8 min). Flash chromatography on silica gel of a portion
(108.3 mg) of fraction F (200.1 mg), using a chloroform/acetone
gradient (100:0 to 95:5 in 1 h, followed by 95:5 to 50:50 in 1 h;
fraction volume: 10 ml) afforded six subfractions (F1–F6). Final
purification of fractions was achieved with a gradient of 60% to
75% B in 30 min. Compound 6 (2.2 mg, tR 22.0 min) and 7
(0.3 mg, tR 24.5 min) were obtained from fraction F3 (10.9 mg),
while fraction F4 (20.1 mg) gave additional 6 (6.3 mg). Fraction
F1 (48.1 mg) afforded compound 1 (2.1 mg, tR 15.9 min), and frac-
tion F5 (15.2 mg) yielded compound 3 (1.0 mg, tR 19.0 min). To ob-
tain sufficient amounts for structure elucidation and
pharmacological testing, the isolation procedure was repeated
once with the same extract amount. Purities of isolated com-
pounds were determined by 1H NMR. Purities of compounds 1–8
were >95%. Compound 9 was obtained as a mixture with 10 in
the ratio 64:36. Purity of 11 was 80%.4.6. Methylation of 4
To a solution of 4 (1 mg, dissolved in chloroform/methanol
[3:2 v/v]), a 2 M solution of trimethylsilyldiazomethane in diethyl
ether (Sigma) was added dropwise under stirring until a yellow
coloration of the reaction mixture appeared. The mixture was fur-
ther stirred for 1 h at room temperature. Then, glacial acetic acid
was added dropwise until complete disappearance of the yellow
color. Evaporation to dryness afforded the dimethyl ester 4a: HR-
ESI-TOF-MS m/z 385.2361 [M+Na]+ (calcd for C22H34NaO4:
385.2349); 1H and 13C NMR data, see Tables 1 and 2.4.7. Characterization of isolates
4.7.1. 5S,9S,10S,15R-()-curcuminol D (1)
White needles; [a]23D: 22.4 (CHCl3, c = 0.10); CD (MeCN,
c = 1.82  104 M, 1 cm pathlength): [h]211 12 018, [h]236
23 810, [h]283 116, [h]326 2 048; UV (MeCN) kmax (log e) 219
(4.20); 1H and 13C NMR data, see Tables 1 and 2; HR-ESI-TOF-MS
m/z 325.2118 [M+Na]+ (calcd for C20H30NaO2: 325.2138).4.7.2. 5S,9S,10S,15R-()-curcuminol H (2)
Colorless oil; [a]23D: 11.8 (CHCl3, c = 0.10); CD (MeCN,
c = 1.41  104 M, 1 cm pathlength): [h]200 9 377, [h]208
15 495, [h]222 8 969, [h]231 12 178, [h]287 + 156; UV (MeCN)
kmax (log e) 217 (4.01); 1H and 13C NMR data, see Tables 1 and 2;
HR-ESI-TOF-MS m/z 341.2080 [M + Na]+ (calcd for C20H30NaO3:
341.2087).1464.7.3. 5S,9S,10S-(+)-zerumin A (3)
[a]23D: +12.4 (CHCl3, c = 0.08); CD (MeCN, c = 1.55  104 M,
1 cm pathlength): [h]200 30 033, [h]220 + 5 799, [h]231 + 10 664,
[h]236 + 10 529; UV (MeCN) kmax (log e) 230 (4.14); HR-ESI-TOF-
MS m/z 317.2118 [MH] (calcd for C20H29O3: 317.2122).
4.7.4. 5S,9S,10S-(+)-(E)-labda-8(17),12-diene-15,16-dioic acid (4)
Colorless oil; [a]23D: +2.0 (CHCl3, c = 0.10); CD (MeCN,
c = 1.53  104 M, 1 cm pathlength): [h]200 30 571,
[h]217 + 10 398, [h]251 1 828; UV (MeCN) kmax (log e) 217 (4.01),
1H and 13C NMR data, see Tables 1 and 2; HR-ESI-TOF-MS m/z
357.2048 [M+Na]+ (calcd for C20H30NaO4: 357.2036).
4.7.5. 5S,9S,10S-()-(E)-labda-8(17),11,13-trien-16,15-olide (8)
[a]23D: 8.1 (CHCl3, c = 0.15); CD (MeCN, c = 1.65  104 M,
1 cm pathlength): [h]200 22 304, [h]202 20 963, [h]204 18 881,
[h]219 +9 024; UV (MeCN) kmax (log e) 249 (3.85); HR-ESI-TOF-MS
m/z 301.2164 [M+H]+ (calcd for C20H29O2: 301.2162).
4.7.6. (E)-labda-8(17),12,14-trien-16-oic acid (9)
Colorless oil, as mixture with 10; 1H and 13C NMR data see
Table 3; HR-ESI-TOF-MS m/z 325.2155 [M+Na]+ (calcd for C20H30-
NaO2: 325.2138).
4.7.7. (E)-labda-7,11,13-trien-16,15-olide (11)
Colorless oil; 1H and 13C NMR data, see Table 3; HR-ESI-TOF-MS
m/z 323.1979 [M+Na]+ (calcd for C20H28NaO2: 323.1982).
4.8. Conformational analysis, geometrical optimization, and ECD
calculation
Conformational analysis of compounds 1, 2, 4, and 8 were per-
formed with Schrödinger MacroModel 9.1 software (Schrödinger,
LLC, New York) using the OPLS 2005 (Optimized Potential for Li-
quid Simulations) force field in H2O. Conformers occurring within
a 2 kcal/mol energy window from the particular global minimum
were chosen for the gas phase geometrical optimization and en-
ergy calculation using the density function theory (DFT) with the
B3LYP functional and the 6-31G⁄⁄ basis set as implemented in
the gas phase with the Gaussian 09 program package (Frisch
et al., 2009). Vibrational analysis was performed at the same level
to confirm stability of minima. Time-dependent density function
theory TDDFT/B3LYP/6-31G⁄⁄ in MeCN using the ‘‘self-consistent
reaction field’’ method (SCRF) with the conductor-like polarizable
continuum model (CPCM) was employed to calculate excitation
energy (denoted by wavelength in nm) and rotatory strength R
in dipole velocity (Rvel) and dipole length (Rlen) forms. ECD curves
were calculated based on rotatory strengths using half bandwidth
of 0.2 eV with conformers of 1, 2, 4, and 8 using SpecDis version
1.53 (Bruhn et al., 2012). The spectra were constructed based on
the Boltzmann-weighting according to their population
contribution.
4.9. Electrophysiological bioassay: expression of GABAA receptors in
Xenopus oocytes and voltage-clamp experiments4.9.1. Oocyte preparation
Oocytes derived from the South African clawed frog, Xenopus lea-
vis, were prepared as follows: after 15 min exposure of female Xeno-
pus leavis to the anaesthetic (0.2% solution of MS-222; the methane
sulfonate salt of 3-aminobenzoic acid ethyl ester; Sigma), parts of
the ovary tissue were surgically removed. Defolliculation was
achieved by enzymatical treatment with 3 mg/ml collagenase type
1A (Sigma). Stage V–VI oocytes were selected and injected with the
desired subunit-encoding cRNAs. To ensure the incorporation of the
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1:1:10, respectively. Injected oocytes were stored at 18 C in
ND96 bath solution containing 1% penicillin–streptomycin solution
(Sigma). ND96 bath solution contained 96 mM NaCl, 2 mM KCl,
1 mM MgCl26H2O, 1.8 mM CaCl22H2O, and 5 mM HEPES (pH 7.4).4.9.2. Automated two-microelectrode voltage-clamp studies
Currents through GABAA receptors were studied with the two-
microelectrode voltage-clamp technique using a TURBO TEC-03X
amplifier (npi electronic GmbH, Germany). Experiments were per-
formed at a holding potential of 70 mV and at room temperature
(20–24 C). Voltage-recording and current-injecting microelec-
trodes (Harvard Apparatus) were filled with 3 M KCl and had resis-
tances between 1 and 3 MX. The automated fast perfusion system
ScreeningTool (npi electronic GmbH, see Baburin et al., 2006 for
details) was used to apply the test solutions to the oocyte. Modu-
lation of the GABA-induced chloride current (IGABA) was measured
with a GABA concentration eliciting 3 to 10% of the maximum cur-
rent amplitude (EC3–10) and corresponded to 3–10 lM GABA. The
EC3–10 was determined at the beginning of each experiment. Suc-
cessful expression of the c-subunit was confirmed by measuring
IGABA after co-application of GABA EC3–10 and 10 lM diazepam
(Sigma). Diazepamwas used as positive control. Sample stock solu-
tions (prepared in DMSO) were freshly diluted every day with
ND96 bath solution containing GABA EC3–10. To exclude current
inhibition in the presence of DMSO, equal amounts of DMSO (1%)
were present in both control and sample-containing solutions.
Electrophysiological experiments were performed one to three
days after cRNA injection. Oocytes with maximal current ampli-
tudes >4 lA after application of 1 mM GABA were discarded to
avoid voltage-clamp errors. Data acquisition and processing were
performed using pCLAMP 10.0 software and Clampfit 10.2 soft-
ware, respectively.4.9.3. Data analysis
Enhancement of IGABA was defined as (I(GABA+Comp)/IGABA) – 1,
where I(GABA+Comp) is the current response in the presence of the
indicated test material (extract, fraction, or pure compound), and
IGABA is the GABA-induced control current. Concentration–response
curves were generated, and the data analyzed using Origin soft-
ware 7.0 (OriginLab Corporation, Northampton, MA, USA). Data
were fitted to the equation 1/[1 + (EC50/[Comp])nH], where EC50 is
the concentration of the compound that increases the amplitude
of the GABA-evoked current by 50% of the compound-induced
maximum response, and nH is the Hill coefficient. Each data point
represents the mean ± S.E. from at least three oocytes and two oo-
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Table S1. 1H and 13C NMR spectroscopic data for compound 3 (CDCl3, 500 MHz, δ in ppm).  
Position Zerumin A (3)  
 δH (J in Hz) δCa 
1α 1.05, ddd (12.6, 12.6, 3.1) 39.2 
1β 1.71b  
2α 1.48, m 19.2 
2β 1.55, m  
3α 1.17, ddd (13.4, 13.4, 3.7) 42.0 
3β 1.39, br d (13.2)  
4  33.7 
5 1.12, dd (12.6, 1.7) 55.4 
6α 1.73b 24.1 
6β 1.32, dddd (12.8, 12.8, 12.8, 4.1)  
7α 2.00, ddd (13.1, 13.1, 4.7) 37.8 
7β 2.39b  
8  148.0 
9 1.89, br d (10.7) 56.4 
10  39.9 
11a 2.56, m 24.6 
11b 2.39b  
12 6.60, dd (6.0, 6.0) 159.0 
13  136.2 
14 3.25, m  30.6 
15  nd 
16 9.29, s 194.1 
17a 4.81, s 107.8 
17b 4.38, s  
18 0.87, s 33.4 
19 0.80, s 21.7 
20 0.72, s 14.4 
a 13C shifts deduced from HSQC and HMBC experiments.  
b Multiplicities of overlapped signals are omitted.  
nd: not detected.  
(δH and δC reference data can be found in Xu, H. X., Dong, H., Sim, K. Y., 1996. Labdane 
diterpenes from Alpinia zerumbet. Phytochemistry 42, 149-151.) 
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Table S2. Calculated logP values for compounds 1–11.  
Compound clogPa 
1 4.25 ± 0.37 
2 4.19 ± 0.43 
3 4.51 ± 0.69 
4 4.40 ± 0.65 
5 4.34 ± 0.62 
6 4.62 ± 0.56 
7 4.45 ± 0.68 
8 4.94 ± 0.61 
9 5.56 ± 0.91 
10 5.57 ± 0.90 
11 5.04 ± 0.57 
a logP values were calculated using ALOGPA 2.1 software (VCCLAB, Virtual Computational 
Chemistry Laboratory, http://www.vcclab.org, 2005).  
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 Figure S1. 1H NMR spectrum of compound 1 (recorded in CDCl3). 
152
 Figure S2. NOESY NMR spectrum of compound 1 (recorded in CDCl3). 
153
 Figure S3. 1D TOCSY NMR experiment applied to compound 1 (recorded in CDCl3). (B) The critical range of the 1H NMR spectrum and 
(A) the selective excitation of the H-15 resonance are shown.  
154
 Figure S4. 1D NOE experiment applied to compound 1 (recorded in CDCl3). (B) The critical range of the 1H NMR spectrum and (A) the 
NOE difference NMR spectrum are shown. Saturating the H-15 resonance increased the intensities of the signals H-14a, H-16a, and H-16b. 
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 Figure S5. 1D NOE experiment applied to compound 1 (recorded in CDCl3). (B) The critical range of the 1H NMR spectrum and (A) the 
NOE difference NMR spectrum are shown. Saturating the H-14b resonance increased the intensities of the signals H-14a, H-9, and H-16a. 
The H-11b resonance was partially saturated by the irradiating frequency, and thus, resulted in a positive NOE for the H-11a signal.  
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 Figure S6. 1H NMR spectrum of compound 2 (recorded in CDCl3).  
157
 Figure S7. 13C NMR spectrum of compound 2 (recorded in CDCl3).  
158
 Figure S8. DEPT NMR spectrum of compound 2 (recorded in CDCl3). 
159
 Figure S9. COSY NMR spectrum of compound 2 (recorded in CDCl3).  
160
 Figure S10. HSQC NMR spectrum of compound 2 (recorded in CDCl3).  
161
 Figure S11. Overlay of HSQC and HMBC NMR spectra of compound 2 (recorded in CDCl3).  
162
 Figure S12. 1H NMR spectrum of compound 2 (recorded in C6D6).  
163
 Figure S13. NOESY NMR spectrum of compound 2 (recorded in C6D6).  
164
 Figure S14. 1H NMR spectrum of compound 4 (recorded in CDCl3).  
165
 Figure S15. 13C NMR spectrum of compound 4 (recorded in CDCl3).  
166
 Figure S16. DEPT NMR spectrum of compound 4 (recorded in CDCl3).  
167
 Figure S17. 1H NMR spectrum of compound 4a (recorded in C6D6).  
168
 Figure S18. Overlay of HSQC and HMBC NMR spectra of compound 4a (recorded in C6D6).  
169
 Figure S19. NOESY NMR spectrum of compound 4a (recorded in C6D6).  
170
 Figure S20. 1D NOE experiment applied to compound 4a (recorded in C6D6). (B) The 1H NMR spectrum and (A) the NOE difference NMR 
spectrum are shown. Saturating the H-12 resonance increased the intensities of the signals H-17b, H-11a, H-11b, and H-9.  
171
 Figure S21. 1D NOE experiment applied to compound 4a (recorded in C6D6). (B) The 1H NMR spectrum and (A) the NOE difference NMR 
spectrum are shown. Saturating the H-14 resonance increased the intensities of the signals H-11a and H-11b.  
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 Figure S22. 1H NMR spectrum of compound 9 (with 10% impurity of 10, recorded in CDCl3).  
173
 Figure S23. COSY NMR spectrum of compound 9 (with 10% impurity of 10, recorded in CDCl3).  
174
 Figure S24. HSQC NMR spectrum of compound 9 (with 10% impurity of 10, recorded in CDCl3).  
175
 Figure S25. Overlay of HSQC and HMBC NMR spectra of compound 9 (with 10% impurity of 10, recorded in CDCl3).  
176
 Figure S26. NOESY NMR spectrum of compound 9 (with 10% impurity of 10, recorded in CDCl3). 
177
 Figure S27. 1H NMR spectrum of the mixture 9/10 (existing in a ratio of 64:36, recorded in CDCl3). 
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 Figure S28. 13C NMR spectrum of the mixture 9/10 (existing in a ratio of 64:36, recorded in CDCl3). 
179
 Figure S29. DEPT NMR spectrum of the mixture 9/10 (existing in a ratio of 64:36, recorded in CDCl3).  
180
 Figure S30. 1H NMR spectrum of compound 11 (with 20% impurity, recorded in CDCl3).  
181
 Figure S31. HSQC NMR spectrum of compound 11 (with 20% impurity, recorded in CDCl3).  
182
 Figure S32. Overlay of HSQC and HMBC NMR spectra of compound 11 (with 20% impurity, recorded in CDCl3). 
183
 Figure S33. NOESY NMR spectrum of compound 11 (with 20% impurity, recorded in CDCl3). 
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 Figure S34. Minimized conformers of (5S,9S,10S,15R)-1 in the gas phase using DFT at the B3LYP/6-
31G** level. Four conformers (1-a–d) occurred within a 2 kcal/mol range from the global minima. 
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 Figure S35. Comparison of the computed ECD spectra for the four lowest energy conformers of 
(5S,9S,10S,15R)-1. The calculations were performed with TDDFT at the B3LYP/6-31G(d,p) level using 
the CPCM solvent continuum model with MeCN as the solvent. 
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 Figure S36. Minimized conformers of (5S,9S,10S,15R)-2 in the gas phase using DFT at the B3LYP/6-
31G** level. Eight predominant conformers (2-a–h) were found within a 2 kcal/mol range from the 
global minima. 
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 Figure S37. Comparison of the computed ECD spectra for the eight lowest energy conformers of 
(5S,9S,10S,15R)-2. The calculations were performed with TDDFT at the B3LYP/6-31G(d,p) level using 
the CPCM solvent continuum model with MeCN as the solvent. 
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 Figure S38. Comparison of the computed ECD spectra for the 26 lowest energy conformers of 
(5S,9S,10S)-4. The calculations were performed with TDDFT at the B3LYP/6-31G(d,p) level using the 
CPCM solvent continuum model with MeCN as the solvent. 
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 Figure S39. Comparison of the computed ECD spectra for the two low-energy conformers of 
(5S,9S,10S)-8. The calculations were performed with TDDFT at the B3LYP/6-31G(d,p) level using the 
CPCM solvent continuum model with MeCN as the solvent. 
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4. Conclusions and outlook 
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In the course of an interdisciplinary hERG in vitro screening, major European medicinal 
plants as well as frequently consumed spices, vegetables, and fruits were found to be associated 
with a low risk for hERG inhibition. Subsequent screening of a plant-derived alkaloid library led, 
however, to the identification of potent hERG blockers, including (+)-N-methyllaurotetanine (1), 
(+)-boldine (2), (+)-bulbocapnine (3), (+)-chelidonine (4), (+)-corynoline (5), and protopine (6) 
(Figure 10). Pronounced hERG in vitro inhibition is a major cardiac safety liability, but cannot be
 
 
Figure 10. Structures of plant-derived hERG channel blockers. 
 
 
directly translated to an increased risk of QT prolongation and TdP arrhythmia. Follow-up 
investigations should primarily focus on in vitro electrophysiological studies to determine whether 
the identified hERG blocking alkaloids also inhibit other cardiac ion currents and affect the 
ventricular action potential duration. If the results point towards potential cardiotoxic risks, an 
assessment of the cardiac safety in correlation with pharmacokinetic data is certainly warranted. 
The pro-arrhythmic liability of a single hERG blocker needs to be evaluated in a predisposed 
model that utilizes either the occurrence of early afterdepolarizations (EADs) or TdP arrhythmia 
as study endpoint. In parallel, one should determine the compound’s pharmacokinetic profile and 
identify its main metabolites. The development of a state-of-the-art bioanalytical method (e.g., an 
UPLC-MS/MS assay) and its full validation according to recommendations of international 
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guidelines is crucial to generate reliable pharmacokinetic data. It has to be further considered that 
most herbal preparations are used in form of infusions or decoctions for oral consumption. 
Potential hERG-related safety aspects should, therefore, be assessed with the expected clinical 
route of administration. A dedicated human trial in healthy volunteers will clarify what kind of 
free plasma concentrations of these alkaloids will be reached after regular dosing of their 
corresponding herbal products. Similar considerations should be also applied to already known 
plant-derived hERG inhibitors. Our literature survey revealed that chelerythrine (7) and 
lobeline (8) (Figure 11) strongly reduce the hERG channel activity in HEK293 cells with 
IC50 values of 0.11 and 0.34 µM, respectively. Our screening of medicinal plants pointed towards 
a need for a more thorough assessment of the hERG liability of traditional Chinese herbal drugs. 
Given the increasing popularity of 
herbal remedies from other traditional 
health systems, also Ayurveda, 
Kampo, and Unani herbal drugs 
should be screened.  
 
 
The availability of gram amounts of pharmacologically/toxicologically critical compounds 
is an essential prerequisite for further risk assessment studies. Dehydroevodiamine (DHE), a 
major bioactive constituent of the traditional Chinese herbal drug Evodiae fructus (Evodia 
rutaecarpa fruits), is currently being investigated in different in vivo models for cardiac safety. 
For this purpose, we developed an efficient two-step protocol for its gram-scale isolation from a 
crude E. rutaecarpa extract. Our purification strategy can be further used as a starting point for a 
future commercialization of DHE as reference compound. Access to DHE in high purity (> 95%) 
is particularly useful for the quality control of Evodia-containing products. 
Figure 11. Structures of chelerythrine (7) and lobeline (8).  
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In the search for positive GABAA receptor modulators of plant origin, we investigated an 
ethyl acetate extract from rhizomes of Curcuma kwangsiensis. An HPLC-based discovery 
platform was used to identify the active constituents in the extract. Targeted isolation afforded a 
series of 11 structurally related labdane diterpenoids, which were then pharmacologically 
characterized at GABAA receptors of the α1β2γ2S subtype. The tested diterpenes have, however, 
limited potential for further development due to their moderate GABAA receptor modulating 
activity. Intensive medicinal chemistry efforts will be necessary to develop a lead candidate with 
higher efficiency. Our study demonstrates that HPLC-based activity profiling, combined with 
database searches, is an effective strategy to characterize bioactive compounds in crude natural 
extracts.  
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Welch grössere Freude gibt es, als die Erde in ihrem Pflanzenkleide zu 
betrachten, gleich einem Gewande von Stickereien, besetzt mit exotischen 
Perlen, geschmückt mit einer Vielfalt seltener und kostbarer Juwelen? 
John Gerard, The Herbal, 1597 
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